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With about 30% of proteins being able to get phosphorylated, reversible phosphoryla-
tion is one of themajor posttranslational modification mechanisms [1]. The phospho-
rylation stateof aprotein isdeterminedbyprotein kinases, attachingphosphategroups
toproteins, andproteinphosphatases, catalyzing the reverse reaction [2]. While the im-
portant role of kinases has been established long ago, phosphatases were erroneously
considered second row enzymes formaintaining a kinase dependent equilibrium until
recently, but are now known to play critical and highly specific roles in many signaling
processes such as growth, proliferation and metabolism [3, 4]. Furthermore have they
been shown to act as positive as well as negative modulators in signaling [5]. Recent
literature suggests that kinases are involved in controlling the amplitude of a signaling
response, whereas phosphatases are controlling rate and duration of a response [6].
Originally, phosphataseswere classified into Ser/Thr-specific, Tyr-specific and dual-
specific phosphatases based on their substrate specificity [7]. However, newer studies
do not support this differentiation based on substrate specificity, because many phos-
phatases show a broader range of accepted substrates than expected. Therefore Sacco
et al. suggested a classification based on amino acid sequence similarity of the cat-
alytic sites with Ser/Thr-specific and Tyr-specific phosphatases being further divided
into different subgroups and dual-specific phosphatases classified in one family to-
gether with Tyr-specific phosphatases [7, 8].
Later investigations of phosphatase substrate selectivity interestingly revealed that
they often do not show significant selectivity in vitro, but clear preference to phos-
phorylate certain substrates in vivo. Whereas one part of this in vivo selectivity can
be related to non-catalytic phosphatase domains, regulating their activity or enrich-
ing substrate concentration in the environment of the phosphatase by targeting it to a
certain compartment of the cell, there is still a considerable part of the selectivity that
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seems to be related to the catalytic domains of the phosphatases. This indicates that
active site directed selective inhibition should be possible, butmight be dependend on
assay conditions [8].
Although protein-tyrosine phosphorylation only constitutes less than 1% of protein
phosphorylation activity [1], protein tyrosine phosphatases are encoded by the largest
family of phosphatase genes [9], which depicts their importance in phosphorylation
mediated signaling. Protein tyrosine phosphatases share a so-called signature motif,
which is the conserved sequence (H/V)C(X)5R(S/T) in the active site [6]. This motif
includes the cysteine working as the nucleophile of the catalytic substrate reaction as
published by Pannifer et al. (Figure 1.1) [6, 10].
Figure 1.1.: Mechanism of protein-tyrosine phosphorylation. A: Formation of
cysteinyl-phosphate, B: regeneration by hydrolysis. Adapted from Pannifer et al. [10].
1.2. Inhibition of Protein Tyrosine Phosphatase 1B
Themostprominentmemberof thePTP superfamily, PTP1B,waspurifiedover 25 years
ago fromhumanplacenta [11]. It consists of 435 aminoacidswith residues 30-278 sum-
marized as the catalytic domain and 35 C-terminal residues responsible for targeting
the enzyme to the cytosolic face of the endoplasmic reticulum [12]. Duringmany years
of intense studies PTP1B has been validated as a drug target for diabetes and obesity
as well as a promising target for different types of cancer [13, 14, 4]. PTP1B negatively
modulates insulin and leptin signaling [5] and is overexpressed in the mentioned dis-
eases [4]. Figure 1.2 depicts cellular pathways with PTP1B interference.
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Figure 1.2.:PTP1B interfering with insulin, leptin and growth factor signaling. Adapted
from Johnson et al. [15].
PTP1B knockout mice show enhanced insulin sensitivity, low postprandial serum
glucose and insulin levels as well as resistance to obesity under a high-fat diet. Fur-
thermore they seem otherwise healthy with no increased risk of cancer [16, 17]. There-
fore the development of potent drugs promises increased insulin sensitivity without
the weight gain, a side effect occurring with marketed insulin sensitizing drugs.
However, developingPTP1Bmodulators asdrugshasbeenhamperedbyseveral chal-
lenges: One of them is the problem of bioavailability. Since the active site has devel-
oped to bind highly polar and charged phosphate substrates, tightly binding inhibitors
show the same properties which are connected to low membrane permeability and
therefore low ability to reach PTP1B localized at the endoplasmic reticulum in vivo
[5]. Beneath prodrug modifications, it was recently proposed to use a special prop-
erty of the protein to circumvent this issue: Due to its molecular environment, the cat-
alytic cysteine of PTP1B shows a low pKa of around 4.6 [2], which on the one hand en-
hances its nucleophilic properties for catalysis of the dephosphorylation, but on the
other hand makes it prone to oxidation. After oxidation to sulfenic acid the reaction
proceeds producing a 5-membered sulfenamide, connecting Cys215 and Ser216 in the
catalytic site [4]. This cyclization leads to a conformational change protecting the pro-
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tein from irreversible oxidation and facilitating reactivation by reduction. The resulting
protein cavity, however, is less polar than the reduced version, butmore open, and was
suggested as a promising target structure for less polar inhibitors [3].
Unfortunately, the circumstances and the amount of oxidation in vivo are not thor-
oughly discovered. Therefore it remains unclear how relevant targeting this state of
the protein might be for the treatment of the abovementioned diseases. Noteworthily,
this susceptibility to oxidation has caused problems in high-throughput screening, of-
ten including oxidizing or peroxide releasing compounds, which is another obstacle in
inhibitor design for PTP1B [4].
The most challenging part in the development of PTP1B targeting drugs, however,
is related to the high degree of structural conservation throughout the active sites of
PTPs [5]: An especially close relative of PTP1B –TC-PTP –shows an overall identity of
74% in the catalytic domain shared by both proteins and 100% sequence identity of
catalytic site residues (T177-P185, H214-R221, Q266; PTP1B naming). A study by You-
Ten et al.[18] led to the result that TC-PTP knockout mice die within 5 weeks after birth
showing severe defects in T-Cell and B-Cell function. This is supported by the genetic
association of the TC-PTP gene with inflammation and autoimmunity [19]. Therefore
selectivity of PTP1B inhibitors against the highly similar TC-PTP seems strongly ad-
vised to prevent severe side effects in humans. While selectivity was discovered to be
achievable over other PTPs, only few PTP1B inhibitors could be developed to at most
moderate selectivity over TC-PTP [6].
Moreover, complicating structure-based drug design approaches, the flexible WPD
(Trp, Pro, Asp) loop closes upon substrate binding, enabling catalytic activity of the
enzyme. Furthermore, stronger inhibitors seem to bind to the closed conformation of
the active site [15]. While for PTP1Bboth conformationswere resolved in several crystal
structures, there is only one crystal structure publicly available for TC-PTP [20]. This
structure, however, depicts the open WPD loop conformation and therefore the less
relevant structure for inhibitor design. Additionally, this structure is of low quality as
discussed in Section 4.1.3 which restricts its use in detailed structure comparisons.
Despite the mentioned challenges, some progress has been made in the develop-
ment of PTP1B inhibitors which is summarized in several reviews [15, 21, 12]. Major
breakthroughs include: A) Discovery of the difluoromethylene phosphonate group as
phosphotyrosine mimetic, which converted peptidic substrates to inhibitors [22], B)
Identification of a second phosphotyrosine binding site (B-site) close to the catalytic
site with slight differences in amino acid composition in TC-PTP compared to PTP1B
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[23], C) Identification of early bi-pTYR-mimetic peptides not binding to the second
phosphotyrosine binding site in crystal structures, but showing interactionswith Arg47
(C-site), surprisingly still leading to moderate selectivity - about tenfold - against TC-
PTP [24].
Later efforts concentrated on reducing the peptidic character of the inhibitors and
reducing the charge, keeping the bidentate approach to increase selectivity [25, 26, 27,
28, 29]. This lead to carboxylic acid based inhibitors and finally the highly active thia-
diazolidinone and isothiazolidinone derivatives which are stabilized in the active site
by a hydrogen bonding network similar to that of pTYR residues [30, 31, 32, 12]. Figure
1.3 shows the binding site interactions of an thiadiazolidinone-derivative in compari-
son to the interactions of a phenylphosphate ligand. The thiadiazolidinone-derivative
is able to effectively replace almost all hydrogen bonding interactions observed for the
phenylphosphate moiety even replacing the active site water molecule and its medi-
ated interactions. Newer studies state higher selectivity with selectivity ratios up to
45 against TC-PTP, however they lack detailed biological data like inhibition curves or
data from kinetic analyses as well as structural proof of bindingmode in formof crystal
structures [33].
Figure 1.3.: Left: Phenylphosphate ligand and water molecule in the active site cavity
of PTP1B (derived from PDB structure 1PTY); Right: Isothiadiazolidinone-derivative in




2. Aim and Objectives
This study focuses on structurebaseddesignof small, active site, reversible selective in-
hibitors of PTP1B. Themoderate selectivity of known substrates and inhibitors lead us
to assume that selectivity can be achieved and increased through targeted interactions
within the active site. Furthermore, we hypothesize that the overall sequence differ-
ences lead to a specific flexible behavior of PTP1B compared to TC-PTP and that those
differences could lead to differing preferred conformations, which can be exploited
to design selective inhibitors. Additionally, the concept of dynamically mapping con-
formational differences to achieve selectivity could be applied to other projects were
specificly targeting one of two or more closely related proteins is crucial.
Based on the abovementioned assumptions two approaches are chosen to increase
selectivity of PTP1B inhibitors:
I) To detect the key factors of selectivity in and around the active site of PTP1B,
crystal structures of the protein in complex with some of themost selective com-
pounds known so far will be investigated thoroughly, starting with
i) analysis of three-dimensional protein structures with special regard to lig-
and interactions with sites of amino acid sequence differences to TC-PTP,
followed by
ii) investigations of the flexible behavior of those complexes using molecu-
lar dynamics simulations and their comparison to the respective TC-PTP-
ligand complexes obtained by homology modeling based on each investi-
gated PTP1B complex structure.
For the investigationsof theprotein-ligandcomplexes establishedmodelingmeth-
ods like 3Dpharmacophores, surface depictions andmolecular interaction fields
are employed. The investigations of flexible behavior, however, require more
elaboratemethods. For that, dynamic three-dimensionalpharmacophores called
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dynophores [34, 35, 36] as recently established by our group seem suitable. Addi-
tionally, due to thehigh similarityof the twoproteins, it seems reasonable to com-
plement this method concentrating on pharmacophoric features by developing
a method to assess the quality of steric complementarity of protein and ligand
over time. Since this aspect is still neglected in available interaction monitoring
tools, such a tool bears the potential for broader application.
II) The second part explores the flexibility of both proteins without a known selec-
tive inhibitor with respect to possible differences in conformational preferences:
starting with molecular dynamics simulations of both proteins a method will be
developed to classify the occuring conformations into clusters of different bind-
ing site shapes and identify clusters or conformations preferred by PTP1B, but
highly improbable for TC-PTP.
Consequently, the key features of selectivity derived from both approaches will be
integrated into an adapted virtual screening workflow to find commercially available
compounds with high potential to be PTP1B selective inhibitors.
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3. Computational Methods
This work mainly deals with computational methods which can be subsumed under
the term Computer Aided Drug Design. Since computational power is developing fast
and becoming more affordable, computational methods have become an important
part in drug design, savingmoney and time by limiting thenumber of compounds sub-
mitted tomore expensive biological tests [37, 38, 39]. Often differentmethods are com-
bined to reduce the number of false positive predictions [37]. Depending on the avail-
able or utilized data those methods can be divided into ligand- and structure-based
methodologies: ligand-based methods are based on 2D structures of known ligands
and their activities ranging from quantitative structure-activity relationships, as first
developed by Hansch in the 1960s, to three-dimensional pharmacophore generation
[40, 41]. Their interpretability is often limited, since predictions are based on two-
dimensional ligand structures, elaborated guesses of three-dimensional bound con-
formations or calculated descriptors based on those structures. Therefore, if available,
inclusion of structural information of the protein into the process is preferred.
This chapter brieflydescribes structure-basedmethods employed in this studydivid-
ing them into the sections ”Structural Data”, ”Conformation Generation” and ”Ligand-
Target Complementarity” followed by a section ”Binding Site Shape Clustering” ex-
plaining themethod to find differences in binding site conformational preferences de-




Small molecules in commercial databases usually contain information of themolecule
together with a two-dimensional representation of the ligand or a string-like encod-
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ing of the ligand in SMILES format, where the same chemical moiety can be repre-
sented in several ways. Different tools implemented in most modeling software suites
as Schrödinger’sMaestro [42]orCCG’sMOE [43] canbeused to convert those structures
into a three-dimensional format as required formostmodeling tasks. Furthermore, the
careful assignment of stereochemistry, tautomeric forms and ionization states is nec-
essary [37, 44].
For preparation of the vendor databases used for screening theChemaxon Standard-
izer toolbox [45] was used, since it allows user-defined conversion rules in addition to
common preset rules for standardization of the molecular input structures and per-
forms well even on huge databases.
3.1.2. Crystal Structures and HomologyModeling
X-ray scattering andNMR spectroscopy allow the determination of three-dimensional
protein structures at almost atomic resolution. However, in commonresolution ranges,
which are much lower than 1A˙, hydrogen atoms cannot be unambiguously assigned
based on the experimental data. Therefore, hydrogen atoms are usually assignedbased
on force-field calculations or common protonation rules. Unfortunately, those meth-
ods are not capable to correctly assign unusual protonation states due to surrounding
amino acids as the negative charge of the catalytic cysteine in PTP1B, which therefore
require manual intervention.
Many of the experimentally derived three-dimensional protein structures are de-
posited in thepublicly availableProteinDataBank [46] togetherwith informationabout
their origin and quality. The selection of crystal structure complexes for PTP1B was
driven by the selectivity factor of the complexed ligand and additionally influenced by
the resolution of the structures as a simple quality criterion as well as the occurrence
of mutations in or close to the binding site that could disturb the investigation of inter-
actions.
If no crystal structure is available, homology modeling can be used to build a three-
dimensional structural model from the protein sequence and an experimentally deter-
mined three-dimensional structure of a closely related protein. This technique is based
on the observation that in protein families, structure is usually better conserved than
sequence [47]. The homology modeling process usually starts with the search for a re-
lated protein with known 3D structure, followed by the alignment of both sequences,
the assignment of the respective coordinates from the template to the target and fi-
nally a model refinement step with subsequent evaluation of the model [37]. Homol-
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ogy modeling has been shown to yield useful models for structure based drug design,
if the pairwise alignment of target and template exceeds 50% [48]. Common protein
structure modeling tools like Modeller [49], PHYRE2 [50] and SWISS-MODEL [51] of-
fer special features like multi-template modelling in addition to automatic template
search [52].
For the single template modeling of the known closely related structure of TC-PTP
based on PTP1B structures (sequence identity 57%), the modeling tool integrated into
the software package MOE [43] was chosen, since it offers detailed control over the
modeling process and additionally allows to take into account a ligand bound to the
template structure in the modeling process.
3.2. Conformation Generation
3.2.1. Protein-LigandDocking
In structure baseddrug design, conformation generation of a ligand often is performed
in the form of protein-ligand docking to only obtain ligand conformations that fit the
binding pocket of the protein. Available programs address this problem with different
methodologies. Differences mainly lie in the way they handle ligand flexibility which
can roughly be divided into systematic and randomor stochastic approaches [53]. Sys-
tematic methods can further be divided into conformational search based, fragmen-
tation based and database based methods [53]. The most thorough, but also com-
putationally most expensive variant of the different systematic approaches is confor-
mational search, where all rotatable ligand bonds are systematically rotated in small
steps to evaluate all possible combinations [53]. Fragmentation methods try to cir-
cumvent the combinatorial explosion implicated by using conformational search for
ligands with a high number of rotatable bonds by docking one or several parts of the
ligand and then joining or incrementally growing the solution to a docking pose of
the whole ligand [53]. Database basedmethods seperate the problem of conformation
generation from the binding site fitting step, by precalculating a number of conforma-
tions per ligand and then rigidly docking those precalculated conformations [53]. The
second group of methods to explore ligand conformatinal space employs random or
stochastic methods: here Monte Carlo methods and genetic algorithms are the most
popular subgroups [53]. Monte Carlo methods select poses based on a probability
function, while genetic algorithms start with a population of ligands and by sequen-
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tially changing and combining parameters of the population members using a fitness
function converge towards a final pose [53, 54]. A prominent program employing a ge-
netic algorithm is the software Gold [54].
The programs also differ in the type of simulationmethods they usewhich can apply
principles ofmolecular dynamics or energyminimization [55]. Possible conformations
of the ligandare assessedwith scoring functions, which canbe theoryderivedor empir-
ical [56]. Often a simpler function is used for prescoring during the conformation gen-
eration process, whereas a more elaborated function is used afterwards to yield more
reliable results for affinity prediction [55]. Currently available scoring functions have
their limitations, for example are most scoring functions focusing on energetic rather
than entropic contributions to binding, which might lead to high ranking errors, if the
binding of a concerned ligand is predominantly entropy driven [55]. Therefore, dock-
ing programs are able to explore the conformational space of ligands sufficiently well
to find binding poses very similar to that found in a crystal structure protein-ligand
complex, but in many cases they are not able to correctly place that pose at the top of
their ranking [57]. Inclusion of target specific information into the ranking process has
been shown to increase prediction quality [57].
A fewprograms additionally offer the introduction of somedegree of conformational
flexibility to the target. This can be achieved by either using different input target con-
formations, knownas ensemble docking, or sampling of sidechain conformations, ran-
domly or based on rotamer libraries [55]. However, those artificial changes of a protein
need to be handledwith care, since introducing protein flexibility to docking can come
with the cost of increased false positive rates due to less restrictive binding sites, espe-
cially if the cost of the protein movements to these conformations from a low energy
conformation is not accounted for [58].
Common docking programs [56] are AutoDock [59, 60], DOCK [61], FlexX [62], Glide
[63] and GOLD [54]. For this study, GOLD was chosen, since in a comparative study of
docking programs including PTP1B as a target, GOLD performed especially well to re-
cover a high amount of actives with top ranked scores, which seemed not only related
to the high negative charges of the known actives for this target [64]. Subsequent en-
ergy minimization of the resulting poses together with surrounding amino acids was
performed. Careful attention was paid to the fact that energy minimization can intro-
ducehardly recognizable strain inorder tooptimizedirected interactions and therefore
create the illusion of good binding [65].
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3.2.2. Molecular Dynamics Simulations
Amore elaborate way than rotamer changes to sample protein flexibility aremolecular
dynamics simulations [66]. Those are simulations of the motions of a macromolecule
in atomic detail with the aim of assessing its accessible conformational space. This can
be done by numerical solution of the classical equations of motion, which is therefore
restricted in accuracy by the available computational power as well as the quality of
available force-fields and includes the following components [67, 68]:
I: System Set-Up. The input structure is inspected and errors are corrected, the
ionization state of themacromolecule is calculated, counter ions and solvent are
included.
II: Force Fields. Forces are calculated for every atom with the help of force-field
equations. Those equations contain parameters for bond stretching, bending
and rotations as well as for non-bonded interatomic interactions like van der
Waals contacts and electrostatic potentials.
III: Laws of MotionUsing the previously calculated forces accelerations and ve-
locities are computed using Newton’s law of motion. Initial velocities are usually
assigned randomly based on the overall energy of the system and therefore repli-
cas of the simulation using different initial velocities help to sample the effects of
different starting points.
IV: Trajectory Simulation. With the obtained velocities atom coordinates can
be updated. However, since the calculations include numerical integration, this
needs to be done for a time step of shorter than the fastest movements in the
molecule and is usually preset between 1 and 2 fs. With the repetition of steps II
to IV snapshots of atom coordinates can be saved over a period of time to form
the trajectory.
Common software for molecular dynamics simulations includes AMBER [69], GRO-
MACS [70], Desmond [71] andNAMD [72] andOpenMM [73]. Simulations by those pro-
grams are to a great extent depending on the applied force-field and themodel chosen
to represent the solvating water. However, no force-field could be shown to be consis-
tentlymore feasible for drugdesign approaches than theothers and simulations onone
starting structure with different force-fields often show consistent results [74]. For this
study the freely available Desmond software with OPLS-AA force-field was chosen due
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to its user-friendliness being integrated into the Maestro software suite and its ability
to assign ligand parameters [71].
Initial analysis stepsusually involve calculationof rootmeansquaredeviation (RMSD)







with n: number of atoms compared and di : distance of one atom i in one frame com-
pared to a reference frame.
RMDS calculation requires a preceding alignment step of each frame to a reference
structure - usually the starting structure of the simulation - in order to eliminate the
effects of translational and rotational movements of the whole protein during simula-
tion. Plotting of the RMSD of the Cα atoms of a protein over the time of a molecular
dynamics simulation allows conclusions about the stability of a protein structure.
TheRMSFdescribes theatom-wisedeviation toa reference structure -usually amean
structural state of the protein over the simulation or the starting structure of the simu-
lation - averaged over the simulation steps. This allows to identify and compare stable
and unstable regions of a protein over a simulation.
3.3. Ligand-Target Complementarity
Affinity of a ligand to a target is heavily affected by its favorable and repelling interac-
tions. Therefore, investigating these interactions can lead to important insights for the
design of new ligands. The main principles found in almost all high-affinity protein
ligand complexes are high steric complementarity, high complementarity of surface
properties like polarity or hydrophobicity and an energetically favorable ligand con-
formation [75]. However, some of those criteria are easier to assess then others. For
example the entropy contribution to binding free energy is usually not observable in
static structures [76]. Furthermore, a protein-ligand pair can display more than one
stable bound conformation [76]. Additionally, flexible protein parts tend to prefermore
flexible ligandmoieties, another aspect hard to observe in static structures [65].
Several concepts havebeenapplied to visualize favorableprotein-ligand interactions
or promising interaction sites at a protein surface. The ones that play an in important
role in this study, namely (1) molecular interaction fields, (2) 3D pharmacophores and
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dynophores as well as (3) shape complementarity calculations will be described below.
3.3.1. Molecular Interaction Fields
Molecular interaction fields (MIFs) depict the spatial distribution of the interaction po-
tential between a target structure and a probe [77, 44]. That means for a given probe,
like a secondary amine nitrogen, this probe is placed at every point of a regular grid
in and around the target structure where its energy of interactions is calculated taking
into account for example the hydrogen bonding energy, van der Waals forces as well
as charge interaction energies. This data can then be depicted in form of an interac-
tion map at a chosen interaction energy threshold for a specified probe. Which terms
of interaction energy and which parameters of the probe are included into the calcu-
lations depends on the implementation of this method, of which the most elaborate
one is found in the software GRID [78, 79]. Since this method was only used to support
the screening model developed based on the binding site shape clustering explained
below, the readily available implementation of the MOE software was considered of
sufficient accuracy.
The application of molecular interaction fields was selected to support screening in
this work, since the developed shape pattern alone would not have been restrictive
enough for virtual screening. Additionally, the shapepatternwasdesigned to introduce
selectivity, which cannot be achieved without activity. Consequently, it was aimed to
introduce activity based on the information on favorable protein-probe interactions.
To combine both the selectivity and the activity model, the format of a 3D pharmaco-
phore (described in the following section) was chosen, since 3D pharmacophores are
particularly efficient for virtual screening [80, 81]. This, however, requires the transla-
tion ofmolecular interaction field potentials into pharmacophoric features, whichwas
achieved by calculating the local minima of the computed interaction fields for differ-
ent probes reflecting hydrogen bond donor, hydrogen bond acceptor andhydrophobic
behavior.
3.3.2. 3D Pharmacophores and Dynophores
3D pharmacophores are abstractions of interactions into different types like hydrogen
bonding interactions, hydrophobic contacts and aromatic interactions together with
their spatial arrangement. In a stricter sense like specified in the IUPAC definition,
the term 3D pharmacophore only describes those kinds of three-dimensional interac-
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tion patterns for which their containing features are ”necessary to ensure the optimal
supramolecular interactions with a specific biological target structure and to trigger
(or to block) its biological response” [82]. In order to ensure that an interaction pat-
tern corresponds to that definition, validation of the model is performed by assuring a
good compromise of retrieval rates of known active and potentially inactive molecules
[75, 83]. Nevertheless, a pharmacophoric feature foundwith all known ligandsdoes not
mean it is necessary to achieve high affinity binding as well as good pharmacophoric
fit can still lead to low affinity due to e.g. steric clashes [75]. Due to their high level of
abstraction, pharmacophores are especially feasible for scaffold hopping [84].
Commonprograms for3Dpharmacophoregenerationandvirtual screeningareCAT-
ALYST [85], Phase [86], MOE [43], LIGANDSCOUT [80] and FLAP [87]. They show subtle
distinctions in feature definition and placement, as well asmore significant differences
in the matching algorithm used for screening, which affects accuracy of the results as
well as screening velocity [88, 84]. In this study theMIF-based interactionpatternswere
encoded into LigandScout pharmacophore format, since it is easily interpretable and
manipulatable and allows fast and accurate screening.
Recently, the concept of 3D pharmacophores derived from a protein structure and
a bound ligand was transferred to molecular dynamics simulations of protein-ligand
complexes [34, 35, 36]. This allows the analysis of protein-ligand binding for many dif-
ferent conformations and therefore amoredetailed inspectionof the stability andqual-
ity of interactions together with the variability of interaction partners on the protein
site. For this purpose, the Dynophore application was used for analysis of molecular
dynamics simulations of higher selective ligands in PTP1B in comparison to simula-
tions of the same ligands in homology models of TC-PTP.
3.3.3. Shape Complementarity
Theabovementioned tools for analyzing ligand-target complementarity only cover one
of the three principles of high affinity binding, the high complementarity of surface
properties. Unfortunately, steric complementarity is not sufficiently accounted for in
establishedmethods formonitoring protein-ligand interactions. 3Dpharmacophores,
however, often allow specification of excluded volumes, which enable the user to add
spacial restrictions to the interaction pattern and can introduce steric complementar-
ity of the hits to the target [84]. But especially for shape complementarity, assessment
on a single snapshot seems of limited use, due to for example the previouslymentioned
tendency of flexible protein parts to prefer more flexible ligand moieties. Therefore
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a tool was created and implemented in R that can quantify shape complementarity
throughout a wholemolecular dynamics trajectory, trace back the complementarity to
certainparts of the ligandandallows the statistical analysis of differences for one ligand
in different protein surroundings [89]. Nevertheless, a particularly good shape fit can
be less energetically favorable, if the ligand is forced into this conformation due to the
lack of better alternatives. In order to detect especially unfavorable ligand conforma-
tions, the ligand strain energy was calculated in addition to the shape fit and they were
assessed together. Strain energy is an estimate of the difference between the energy of
the ligand in the bound state compared to that in the nearest local energy minimum
conformation. The strain energy can be calculated as a MOE 3D descriptor. However,
due to the many simplifications and assumptions integrated in this calculation, the
generated values need to be handled with caution. They are therefore not accurate
enough to be integrated in calculations of ligand binding energy, but still can give im-
portant hints on the twist or strain of a ligand.
3.4. Binding Site Shape Clustering
The method of binding site shape clustering developed in this study to exploit differ-
ences in conformational flexibility of two closely related proteins is based on the con-
cept of conformational selection theory. It is assumed that conformational changes
in the target happen before association with a ligand and that the ligand chooses an
appropriate conformation for binding out of the available ensemble of target confor-
mations. Protein-ligand binding therefore gets likelier with increased presence of suit-
able protein conformations in the ensemble of target conformations as well as with
increased presence of suitable ligand conformations in the ligand conformational en-
semble. This is in line with the abovementioned increased probability to find energet-
ically favorable ligand conformations in high-affinity protein-ligand complexes. Con-
formational selection theory therefore stands in contrast to the concept of induced fit
assuming initial ligand binding to a suboptimal protein conformation followed by an
adaption of the protein to the bound ligand. Recent studies describe increasing evi-
dence for the existence of ligand binding conformations without ligand presence and
assume a dominant role of conformational selection, although the coexistence of both
mechanism cannot be ruled out [90, 91].
The screening process implemented in this study additionally considers ligand rigid-
ity as favorable. Chang et al. state that a ligand binding to a protein loses conforma-
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tional flexibility resulting in anentropy loss opposingbinding [92]. Some sources there-
fore assume that binding of an inflexible ligand is less entropically unfavorable, since
rotational freedom of the ligand was already restricted before binding [93]. However,
experimental evidence for this assumption is scarce, which may be due to the lack ap-
propriate methods for determination of entropic contributions to binding in such de-
tail. Chang et al. additionally stress the downside of rigid ligands: they require an exact
fit of the protein to the ligand and therefore high resolution structures and accurate
predictions in the modelling process, since the ligand’s ability to adapt to the binding
site is limited [92].
Based on those assumptions, the method of binding site shape clustering was de-
veloped: To compare protein conformations with focus on the catalytic binding site
surroundings, the open source tool POVME2 [94, 95], originally created to measure
and compare pocket volumes, is used to depict the shape of the binding site for every
molecular dynamics frame based on equidistant points. Since the tool is used to com-
pare the shapes of the resulting pointmaps, a preceding alignment step of themolecu-
lar dynamics frames is required. This alignment influences the shapepointmaps, since
the placement of the initial map points in space stays the same for every frame, only
those points of a bigger map that are very close to or inside the protein are deleted.
The resulting shape point maps are then translated into bit strings encoding pres-
ence or absence of each point of the starting point map in the binding site shape point
map for eachmolecular dynamics frame respectively using the software R. Ifmolecular
dynamics trajectories of two similar proteins are aligned and binding site shape point
maps are calculated with the same starting point map, the bit strings of both proteins
can be compared. To identify themost prominent conformational states of the binding
sites throughout the molecular dynamics simulations, cluster analysis of the bit string
data was performed. Clustering methods have become a popular means to deal with
the high amount of data from molecular dynamics simulations in different contexts
[96, 97, 98].
Cluster analysis seeks to createhomogeneousgroupsofobjectswith low inter-cluster
homogeneity in a set of data based on the states or values of their attributes. Cluster-
ing therefore is a valuable tool to structure data, although it has to be considered that
the resulting clusters do not necessarily have a useful interpretation for the analyzed
aspects of the data. Additionally, very different groups can be found for the same set of
data using different clustering algorithms [99]. Since the final cluster size or number of
clusters to obtain was unclear, a hierarchical clustering algorithmwas chosen [99]. The
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term hierarchical clustering coversmethods that divide data into a hierarchy of groups
with levels of subgroups and therefore allows for the decision of cluster size to be post-
poned until after clustering. Hierarchical clustering methods can further be divided
into agglomerativemethods, startingwith singletons andmerging clusters until all data
is combined in one cluster, and divisive methods, starting with the whole dataset and
subsequently dividing this set into smaller groups [99]. The chosen clustering method
falls within the category of hierarchical agglomerative clustering methods, because it
starts with each entry being its own cluster and consequently merges clusters in a way
that the increase in dissimilarity sum stays minimal [100].
As clustering algorithm, the function ward.D from the package hclust was used as
implemented in R which is a generalization of Ward’s clustering algorithm [100]. The
Ward algorithm was developed for data that allows calculation of Euclidean distances
and then depicts minimization of the variance of the data in a cluster. Finch showed
that calculating appropriate distance measures for dichotomous data and submitting
the calculated distance matrices to Ward’s clustering can lead to good results repre-
senting the natural groups of the data. However, it has to be considered that the origi-
nal interpretation of minimizing variance is lost, if other than Euclidean distances are
used as input [101]. For calculating the similarity/dissimilarity of two objects the sim-
ple matching coefficient was used here, which is defined as the number of matching
attributes divided by the number of total attributes [102]. This differs for example from
the Russel-Rao Index where only the simultaneous presence, of a state is considered
as matching, but not the simultaneous absence. It was reasoned here that absence of
a point in the map should be weighted the same as its presence, since the total map
size stays the same during the calculations and considering both simultaneous ap-
pearances asmatching is therefore not resulting in different weighting of "off" or back-
ground attributes for different frames as had to be considered if the startingmapwould
have been small in some cases and big in others. Nonetheless, the absence of a point
which is never "on" and therefore never considered part of the binding site is rated as a
similarity with this measure. This was considered negligible since this number should
be small due to the restricted binding site definition.
After clustering, the cluster stage (total number of clusters) useful for analysis is cho-
sen with a variation of the elbow method [103]. The clusters of the selected stage are
further processed: In order to differentiate between conformations possible for both
proteins and those only possible for one of them, an affiliation ratio representing the
number of frames from PTP1B divided by the total number of frames in that cluster
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was assigned to each of them. Additionally, occupancies are calculated for each point
of the starting pointmap throughout all frames, representing howoften a specific point
ismarked as present (1) in the binding site divided by the total number of frames in that
cluster.
Differences of the clusters are then computed to find the PTP1B affiliated cluster that
is most different to all TC-PTP affiliated clusters. After selection of this cluster poten-
tially representing a PTP1B exclusive conformation, the points with significant differ-
ences in occupancy in this cluster compared to all TC-PTP clusters are extracted and
analyzed. They are further used to extract a diverse selection of frames matching this
selectivity map, which can then be used for virtual screening as described in the previ-
ous sections.
All steps processing the POVME2 output were collected in R scripts to ensure easy
adaption and repeating of the steps on different samples.
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4. Results
4.1. Part I: Protein-Ligand Interaction Analysis
4.1.1. Sequence Comparison of PTP1B and TC-PTP
Sequence alignment with Clustal Omega [104] calculates a total sequence identity of
about57%. Thebinding sitesofbothprotein tyrosinephosphatases, however, arehighly
conserved: 55 residues were considered as binding site residues and compared. Ac-
cording to Li et al. they were grouped into different subsites named site A (catalytic
site) to site D [105]. The catalytic site shows a sequence identity between both proteins
of over 95%, while all subsites together still show a sequence identity of 80%. Table 4.1
highlights differences in amino acid sequence for the binding site subsites of PTP1B
compared to TC-PTP.
















Table 4.1.: Sequence comparison of active site surrounding residues (PTP1B number-
ing). Differences are highlighted in red.
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Figure 4.1.: PTP1B (from crystal structure 1PTY) with sequence differences to TC-PTP
and binding site subsites.
As becomes obvious from the sequence comparison, the subsites surrounding the
catalytic cavity, named B, C and D, contain several differences in sequence in PTP1B
compared to TC-PTP. To assess their relevance for ligand binding, they were also high-
lighted ina three-dimensionaldepictionof thePTP1Bprotein structure (seeFigure 4.1).
Unfortunately, most of those differences seem of minor relevance for the design of
selective inhibitors: A264 and the respective proline found in TC-PTP are turned away
from the cavity and could therefore only influence the space available for the ligand
in the binding site. Due to their similar size, however, this difference is insignificant.
F256 and its corresponding tyrosine sidechain are similar in size and faced inside the
protein, therefore theadditionalhydroxyl group inTC-PTPcannotbe involved in ligand
binding. Due to the orientation away from the pocket towards the solvent an exchange
to a valine for Leu119 also seems unlikely to influence the binding cavity, the same
holds for Gly117 and its corresponding glutamic acid residue. However, due to their
differences in size andpolarity, changes in the flexible behavior of theD site loop inTC-
PTP can be expected. The remaining differences are mainly concentrated in the B site
of the binding area and although some residues like histidine 25 are faced away from
the binding pocket, the high amount of differences in this area is likely to result in at
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least subtle differences of the pocket’s shape and electrostatic properties. Furthermore,
Lys41 in the C site could lead to a different conformation of the adjacent C site (YRD)
loop through charge interactions not possible for the corresponding valine in TC-PTP.
4.1.2. PTP1B Crystal Structure Analysis
With the aim of getting insight into structural features for selectivity of PTP1B ligands
against TC-PTP, crystal structures of PTP1Bwere analyzed with emphasis on structures















2F70 IC50 33500 203500 6.1 [106]
2F6T IC50 42500 169000 4.0 [106]
1XBO IC50 920 19200 20.9 [107]
1QXK Ki 9000 182000 20.2 [107]
1Q6T IC50 5 36 7.2 [107]
1Q1M Ki 6900 164000 23.8 [107]
1PYN Ki 3200 24780 7.7 [107]
1PH0 Ki 120 470 3.9 [107]
1NZ7 Ki 76 380 5.0 [108]
1NNY Ki 22 49 2.2 [107]
unselective
2B07 Ki 370 380 1.0 [109]
1Q6P IC50 3 3 1.0 [107]
1NL9 Ki 1100 1100 1.0 [107]
1ECV Ki 14000 14000 1.0 [107]
Table 4.2.: PTP1B crystal structures selected for analysis with ligand activities in PTP1B
and TC-PTP and the resulting selectivity factor.
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Systematic investigationofPTP1Bcrystal structureswas startedwith145crystal struc-
tures of human PTP1B listed in the Uniprot database for human PTP1B (P18031) at the
time of this study (last checked March 2018), 7 of which were excluded from analysis
due to low resolution (>2.70 Å) [110, 46]. Additional 59 structures were excluded due
to covalent modifications in or close to the active site. From the remaining 79 crystal
structure complexes 14 complexes were chosen, for which activity data of the ligands
towards both PTP1B and TC-PTP were available and where the ligands showed either
selective behavior against TC-PTP (selectivity factor > 2) - true for 10 of the structures
- or unselective behavior (selectivity factor between 0.95 and 1.05). Table 4.2 lists the
selected structures with their ligand activities in PTP1B and TC-PTP and the resulting
activity factor. Interaction counts for polar interactions, counting hydrogen bonds as
well as ionic interactions as 1 and water mediated hydrogen bonds as 0.5, are depicted
as heat map in Figure 4.2(left). On the one hand, unselective ligands show a tendency
for fewer B site interactions to Gln262, Arg24 and Arg254. On the other hand, polar
interactions to the sidechain of Asp48 and Asp181 seem favorable to introduce selec-
tivity. In the investigated complexes selective ligands additionally show a tendency to-
wards fewer interactions to the backbone of Phe182. For complexes 1Q6T and 1Q6P
crystal packing seems to influence the interactions of the ligand to the protein. Con-
clusions from interaction counts for those structures therefore show a higher level of
uncertainty.
The counts of hydrophobic parts of the ligand interacting with hydrophobic areas on
the protein surface depicted in Figure 4.2(right) show no clear tendency of the interac-
tions to increase or decrease selectivity of the ligands. However, during the investiga-
tion of the crystal structures the missing ability of this method to distinguish between
bigger and smaller lipophilic areas of interaction was noticed.
4.1.3. TC-PTP Crystal Structure Analysis andHomologyModeling
Only one TC-PTP crystal structure was available in the PDB at the time of this study
(PDB code: 1L8K, resolution 2.56 Å; last checked March/2018). Figure 4.3 shows this
TC-PTP structure superposed to the PTP1B structure 1PTY depicting only the back-
bones of the two protein structures. Themain differences concerning the ligand bind-
ing site are found in the conformation of the catalytic cavity loop depicted in violet.
This loop is found inanopenposition in theTC-PTPstructure. This openconformation
is also possible for PTP1B, but the loop closes for both proteins upon substrate bind-






















































































Figure 4.2.: Interaction plots for protein-ligand binding in selected PTP1B complexes.
Left: polar interactions shaded by interaction count, right: hydrophobic interactions
(black = presence of interaction).
β -sheet structure in PTP1B, but not in TC-PTP. However, comparison of several PTP1B
structures revealed conformational variations for this loop, which shows disordered
behavior in the original publication of the TC-PTP crystal structure [20]. The publica-
tion further suggests an unusual conformation introduced by crystal packing for this
loop.
Since this assessment led to the conclusion that the available TC-PTP crystal struc-
ture was not feasible for detailed structure comparisons regarding selective PTP1B lig-
ands, homology models were created for TC-PTP-ligand complexes based on each of
the threemost selective PTP1B crystal structures 1QXK, 1Q1Mand 1XBO. From the en-
semble of structures produced during homology modeling, conformations were cho-
sen that showhigh resemblance to the respective PTP1B structures regarding sidechain
and ligand conformations. Figure 4.4 shows one of the TC-PTP homology models in
comparison to the PTP1B template.
4.1.4. Molecular Dynamics Simulations
Homology modeling for TC-PTP resulted in three-dimensional structures very similar
to the PTP1B templates. In order to elucidate whether the complexes show differences
in their flexible behavior or if even equilibration of the TC-PTPmodelswould lead away
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Figure 4.3.: PTP1B (PDB code 1PTY) in light grey superposed to TC-PTP (PDB code
1L8K) in dark grey. Major conformational differences highlighted in violet and cyan.
from the PTP1B equivalent ligand binding conformation, molecular dynamics simula-
tions were performed and analyzed. For each of the three most selective PTP1B com-
plexes and the respective homology models three simulations with varying seeds were
performed to be able to distinguish effects due to the initially assigned velocities from
system typical behavior during analysis.
For the 1XBO complex and the respective TC-PTP homology model complex, anal-
ysis of the Cα-RMSD plots after backbone alignment (Figure 4.5) showed stable sys-
tem behavior with similarly fast equilibration of the PTP1B and TC-PTP systems after
less than 5 ns and only minor deviations up to 2.1 Å from the starting conformation.
Simulation 1 of the homology model shows a slight RMSD drift towards the end of the
simulation time. Overall, the RMSDplots show a tendency of the homologymodels for
slightly higher RMSDvalues, which is in good agreement with the expectations consid-
ering that TC-PTP was forced into a PTP1B conformation during homology modeling.
Similar behavior is found for the 1Q1M complex and the respective TC-PTP homology
model complex (Figure 4.6). However, the differences between PTP1B and TC-PTP are
smaller, suggesting that the homology model based on 1Q1M is slightly closer to a na-
tive TC-PTP structure.
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Figure 4.4.: Homology model of TC-PTP (light) based on the PTP1B complex 1Q1M
(dark).
The simulations of the 1QXK complex and the respective TC-PTP homology model
complex showslightly increasedRMSDvalues compared to the simulations of theother
complexes with maximum RMSD values below 2.0 Å (Figure 4.7). The plot shows that
all structures finally move away from an initial RMSD plateau after at maximum 10 ns.
Apart from simulation 2, the homology model simulations of 1QXK show more stable
behavior than the respective PTP1B simulations, although with higher initial RMSD
values for the homology model. Simulation 2, however, seems to finally join the equi-
libriumof the other replica after about 15 ns, despite the increased initial RMSD values.
Additionally, RMSF values were calculated and plotted (Figures 4.8 to 4.13) to deter-
mine flexible and inflexible regions and compare those areas for both proteins: All sim-
ulations show a high correlation of stable and unstable regions between the different
complexes, but also between PTP1B and TC-PTP simulations. This distribution of flex-
ible and inflexible regions is in good agreement with the secondary structure elements
of the proteins. Unsurprisingly, the C and N terminal regions show slight increase of
flexibility. For the 1QXK simulations (Figures 4.12 and 4.13) the C terminal end shows
highly increased flexibility with RMSF values greater up to more than 7 Å. The biggest
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Figure 4.5.: RMSD plots of the molecular dynamics simulations performed on the
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Figure 4.6.: RMSD plots of the molecular dynamics simulations performed on the
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Figure 4.7.: RMSD plots of the molecular dynamics simulations performed on the
1QXKcrystal structure complex (left) and the respectiveTC-PTPhomologymodel com-
plex (right).
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teine and the α helix connected to this loop. Interestingly, the WPD loop, known for
its high flexibility during the ligand binding process, shows only limited flexibility be-
low 2 Å for all simulations. The B site residues from 254 to 262 as well as the YRD loop
(47-51) show slightly increased flexibility compared to the catalytic loop for all simu-
lations. Additional to those similarities, some cases of behavior specific for PTP1B or
TC-PTP can be observed from the RMSF plots: The 1XBO and 1QXK simulations are
showing higher flexibility for the TC-PTP simulations regarding the D site (116-121)
and the neighboring region (122-140). Additionally, for all complexes, the TC-PTP sim-
ulations show higher flexibility in the residues 30-40, a loop like structure lying directly
behind the YRD loop viewed from the catalytic cavity.
4.1.5. Dynophore Analysis
In addition to the abovementioned parameters, dynamic pharmacophores were cal-
culated and analyzed to gain insight into protein-ligand interactions to further char-
acterize the selective complexes and their stability over time. For this analysis, frame
1000was considered as starting point of the dynophore analysis, since all systemswere
considered equilibrated based on the RMSD analysis after this point (about 5 ns).
Figure 4.14 shows the three-dimensional depiction of the first simulation based on
the 1XBO complex. The three-dimensional depiction of a dynophore is influenced by
the alignment of the single frames, in this case the Cα-atoms of the stable active site
loop amino acids Cys215-Arg221 were chosen. Since no differences are obvious be-
tween PTP1B and TC-PTP on visual inspection of the dynophores, the underlying in-
teractions were statistically analyzed: To elucidate the differences between PTP1B and
TC-PTP ligandbinding features, two-dimensional plots of the ligands together with the
detected hydrogen bond acceptors (HBA), hydrogen bonddonors (HBD), hydrophobic
(HYD), aromatic (AR) and negative ionizable (NI) features were created. For each fea-
ture mean occurrences over three molecular dynamics simulations together with the
95% confidence intervals were plotted as bar charts juxtaposing PTP1B and TC-PTP.
For all three selective complexes, differences between PTP1B and TC-PTP are small
compared to the confidence intervals. However, for all simulations, mean occurence
values of theB site hydrogenbondacceptors (HBA5, HBA6andHBA7) tend tobehigher
in PTP1B simulations compared to themean values of the corresponding TC-PTP sim-


































Figure 4.9.: RMSF plot of the molecular dynamics simulations performed on the TC-
















Figure 4.10.: RMSF plot of the molecular dynamics simulations performed on the
















Figure 4.11.: RMSF plot of the molecular dynamics simulations performed on the TC-































Figure 4.13.: RMSF plot of the molecular dynamics simulations performed on the TC-
PTP homology model complex based on 1QXK.
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Figure 4.14.: Three-dimenional depiction of the dynophore created based on one of
the performed molecular dynamics simulations of the 1XBO complex. Dots represent
pharmacophoric features of interactions detected for a molecular dynamics frame.
Red: hydrogen bond acceptor or negative ionizable interaction, green: hydrogen bond
donor, blue: aromatic interaction, yellow: hydrophobic interaction.
Interestingly, there is one interaction in the catalytic cavity - HBA3 - which shows com-
parably high occurrence in PTP1B compared to TC-PTP for the simulations of 1XBO
and 1Q1M.
Apart from those similarities, the dynophore interactions also reveal binding inter-
actions characteristic for each single protein: The simulations based on the 1XBO com-
plex show the fewest, but most stable interactions. The dominant interaction partner
in the only occasionally occurring HBD2 interaction are different watermolecules sug-
gesting minor importance for the protein ligand interaction energy. Closer analysis of
the interaction partners on protein side for all interactions reveals a tendency of the
PTP1B interaction HYD1 to interact not only withMet258, but also Ile219, whereas the
latter interaction is not found for the TC-PTP simulations. Instead, in the TC-PTP sim-
ulations the Met interaction is extended to the HYD2 feature. The high occurrence of
the HBA4 interaction was found to be caused by a trapped water molecule transferred
from the crystal structure. The 1Q1M simulations show more interactions, some of
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them, especially the aromatic interactions, are of very low occurrence. As for the 1XBO
simulations, the A site interactions (NI, HBA1 and HBA2) as well as the hydrophobic
features are of high occurrence, suggesting very stable hydrogen bonds with active site
amino acids and good placement of the ligand in the channel, connecting A and B site
of the binding pocket with increased flexibility for all simulations in the B site (HYD1).
Apart from lower occurrence of the hydrophobic features on the slightly longer chain in
the center of the ligand, 1QXK simulations show similar behaviour as described for the
1Q1M complex. However the 1QXK ligand is the only one of the three analyzed ligands
showing C site interactions. Interestingly, the C site interactions HBD3 and HBD4 of
this ligand are among the interactions with highest preference for PTP1B. Additionally,
the 1QXK ligand shows several interactions (HBA2, HBA3, HBA4, HBD1 and AR1), all
located in the active site binding part of the ligand, wheremean occurences in TC-PTP
exceed those in PTP1B.
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Figure 4.15.: Top: Ligand interactions occurring over the molecular dynamics simula-
tions of the 1XBO complex structures. Bottom: Mean percent of occurrence for the de-
picted interactions over the three replica ofMDsimulations of each PTP1B andTC-PTP
as classified by the dynophore app in LigandScout. Error bars depict 95% confidence
intervals.
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Figure 4.16.: Top: Ligand interactions occurring over the molecular dynamics simula-
tions of the 1Q1Mcomplex structures. Bottom: Mean percent of occurrence for the de-
picted interactions over the three replica ofMD simulations of each PTP1BandTC-PTP
as classified by the dynophore app in LigandScout. Error bars depict 95% confidence
intervals.
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Figure 4.17.: Top: Ligand interactions occurring over the molecular dynamics simula-
tions of the 1QXK complex structures. Bottom: Mean percent of occurrence for the de-
picted interactions over the three replica ofMDsimulations of each PTP1B andTC-PTP
as classified by the dynophore app in LigandScout. Error bars depict 95% confidence
intervals.
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4.1.6. Shape Complementarity Analysis
For each of the previously described MD runs, the shape complementarity of the pro-
tein binding site and the bound ligand was calculated as described in detail in the next
paragraphs: Basis for the shapecomplementarity arepointmapsas createdby theopen
source tool POVME2 [94, 95]. Figure 4.18 shows the size and location of the starting
grids for the different PTP1B structures in the respective protein structure. To manage
computing times, the starting maps were chosen to enclose only the included ligand
and the surrounding binding site. This leads to slightly deviating protein areas consid-
ered for the shape fit calculations. Their total sizes are similar with 45415 points for
1XBO and 41248 points for 1QXK.
Figure 4.18.:Maps of starting points for shape map calculation for 1XBO and the cor-
responding TC-PTP homologymodel (left) and 1QXK and the corrensponding TC-PTP
homology model (right). Protein backbones are included for size orientation, ligands
in space filling representation for binding site location.
Figure 4.19-A shows a schematic 2D depiction of a grid of points spanning the bind-
ing area of a protein as created by the POVME2 tool together with a bound ligand. For
every frame of an alignedmolecular dynamics trajectory, subsets of this same grid can
be created. On theonehand, twomapswith all points of distance to ligandheavy atoms
of at least 1.59 Å and 0.59 Å were extracted (see Figure 4.19-C and D, respectively). The
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thresholds were chosen to obtain a point surface of two to three data points of 0.5 Å
distance around the ligand. The points are placed around a distance of one van der
Waals radius of a hydrogen atom (1.09 Å) to the ligand heavy atoms. Additionally, the
POVME2 toolwasmodified to create a subset of the starting grid of the points inside the
protein surface as depicted in Figure 4.19-B. The modified python script can be found
in section A.1 of the Appendix. Further processing of the point maps was performed
using the software R. The script appended in section A.2 is used to calculate a ligand
surface map as the difference of both maps (Figure 4.19-E). This surface map is then
used to calculate the overlap of the proteinmap and the ligand surfacemap (E) for each
frame and converts it to a ratio of the number of overlapping points divided by the total
number of ligand surface points for this frame as a parameter of shape complementar-
ity. Employing a nearest neighbor algorithm as implemented as function nn2 from the
RANN [111] package in R [89] it also assigns nearest ligand heavy atoms to each ligand
surface map point (step E). This enables to calculate an atom related overlap ratio as
illustrated in Figure 4.19-G in order to trace back especially good or bad protein-ligand
complementarity to a certain part of the ligand.
Plotting of the resulting shape fit ratio of the 1XBO derived complexes together with
the calculated strain energy of the ligand reveals interesting tendencies (Figure 4.20):
While the strain energy distributions are almost equal for PTP1B and TC-PTP, the
shape fit distributions differ for the two proteins. Mean andmedian shape fit ratios are
higher for PTP1B (0.653 and 0.654, respectively) compared to the TC-PTP values (0.628
and 0.630). Additionally, the shape fit distribution is broader for TC-PTP: the standard
deviation is calculated to 0.033 compared to 0.025 for PTP1B. To test whether those ob-
served differences are statistically significant, a Mann-Whitney-U-Test was performed
on the data resulting in a p-value below 2.2e-16 for a null hypothesis that the two dis-
tributions are equal. Therefore the difference is statistically highly significant. Despite
this significant difference in shape fit, there seems to be no difference in ligand strain
for both proteins. This could suggest that the ligand does not adopt significantly dif-
ferent conformations, but only the protein shows different flexibility to adapt to those
conformations. Hence, ligand RMSF values where calculated over the simulation to
further investigate this aspect.
Figure 4.21 shows the selective ligand present in all 1XBO derived simulations to-
gether with the atom numbering used in the RMSF (Figure 4.22) and atom-wise shape
fit plots (Figures 4.23 to 4.26). The per atom shape fit plots reveal five atoms (C2, C3,
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Figure 4.19.: Schematic representation of the shape complementarity workflow.
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Further, four atoms (C15, C16, C35, O1) show a slightly better shape fit for the lig-
and in PTP1B. It is noteworthy that all of the identified atoms except for C35 are lo-
cated in the catalytic pocket of the protein during simulation and not in the B site as
expected. The differences in total ligand shapefit therefore mainly seem related to the
catalytic cavity (A site), which is almost identical in amino acid sequence for both pro-
teins. Interestingly, the ligand RMSF plot shows very similar RMSF values of the B site
atoms (C32-39 andO11, O13, O14) for both proteins, whereas some atoms (C14-16 and
O2) although buried in the active site cavity during simulation for both proteins, show
the biggest differences with higher stability in PTP1B. Shape complementarity and lig-
and RMSF together therefore suggest increased protein-ligand shape fit with resulting
higher ligand stability in the active site cavity for PTP1B.
Shapefit calculationswerealsoperformed for thePTP1BanTC-PTPcomplexesbased
on crystal structure 1QXK (see Figure 4.27). The shape fit distributions reveal the same
tendency as for the 1XBO derived complexes: Mean and median shape fit ratios are
higher for PTP1B (0.528 and 0.526, respectively) compared to the TC-PTP values (0.506
and 0.502) and the distribution is broader for TC-PTP with standard deviation of 0.033
forPTP1Band0.046 forTC-PTP.Equivalent to the1XBOsimulations theMann-Whitney-
U-Testwas performed and resulted in a p-value below 2.2e-16 for a null hypothesis that
the twodistributions are equal. Thedifference inmeanof the twodistributions is there-
fore statistically highly significant. Different to the 1XBO simulations, the 1QXK simu-
lations additionally show a difference in the calculated ligand strain distributions. For
3521 of the 12633 frames of PTP1B the ligand strain is below 53, while only 181 frames
of TC-PTP show such a low ligand strain. Interestingly, the 2D plot reveals that the low
ligand strain values of the PTP1B frames do not correlate with especially low shape fit
ratios.
Analogously to thecalculationson1XBOderived simulations, ligandRMSFandatom-
wise shapefit were calculated for the 1QXKbased simulations to further investigate the
relationship between ligandflexibility and shape fit. Figure 4.28 shows the selective lig-
and present in all 1QXK derived simulations together with the atomnumbering used in
the RMSF (Figure 4.29) and atom-wise shape fit plots (Figures 4.30 to 4.34). Unexpect-
edly, the atoms C2, C3, C24, O5, O6 and O7 show a tendency for increased shape fit in
TC-PTP despite the overall observation of better shape fit of the ligand to PTP1B. These
atoms all belong to the part of the ligand which is bound to the catalytic cavity. The
opposite tendency is found for atoms C15, C23, C38, C39, N1, N2, O1, O11 and O12.
Five of those atoms (C38, C39, O1, O11 andO12) belong to the ligand part bound to the
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second phosphotyrosine binding site. The part of the ligand containing N1, N2 and
C23 is bound to the YRD-loop at site C of the binding area. The biggest shift in shape fit
ratio is found for two of those atoms bound to the C site (C23 and N2). The biggest dif-
ferences in ligand RMSF are found for the B site ligand atoms C32 to C39 and O1, O11,
O12 and O13 while A and C site bound atoms show comparably low RMSF differences
in PTP1B compared to TC-PTP. Ligand atoms in the TC-PTP based simulations always
show similar or increased flexibility than the same ligand atoms are showing in PTP1B
simulations. Combined results of the shape fit calculations together with ligand strain
and ligand RMSF could indicate that for this case the B and C site parts are the ones
responsible for selectivity. As in the B site part the reduced shape fit in TC-PTP seems
to be connected to increased flexibility of the ligand, for the C site part of the ligand this
is not observed. However, it is possible that the number of frames with especially low
ligand strain in PTP1B is induced by a special conformation of the YRD-loop which
is not possible for TC-PTP and which enables good binding to N1 and N2 via hydro-
gen bonding, while other conformations possible for both PTP1B and TC-PTP lead to

























0 5 10 15
density
Figure 4.20.: Shapefit ratio and ligand strain energy for all three simulations of both
PTP1B and TC-PTP based on the PTP1B crystal structure 1XBO.
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Figure 4.21.: Selective ligand present in the simulations based on crystal structure


















































Figure 4.22.: Atom wise ligand RMSF for the PTP1B and TC-PTP simulations based on
crystal structure 1XBO.
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Figure 4.23.: Density plots for atom-wise shape fit ratio in PDB complex 1XBO; pink:
PTP1B, green: TC-PTP.
45
Figure 4.24.: Density plots for atom-wise shape fit ratio in PDB complex 1XBO; pink:
PTP1B, green: TC-PTP.
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Figure 4.25.: Density plots for atom-wise shape fit ratio in PDB complex 1XBO; pink:
PTP1B, green: TC-PTP.
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Figure 4.27.: Shapefit ratio and ligand strain energy for all three simulations of both
PTP1B and TC-PTP based on the PTP1B crystal structure 1QXK.
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Figure 4.28.: Selective ligand present in the simulations based on crystal structure




















































Figure 4.29.: Atom wise ligand RMSF for the PTP1B and TC-PTP simulations based on
crystal structure 1QXK.
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Figure 4.30.: Density plots for atom-wise shape fit ratio in PDB complex 1QXK; pink:
PTP1B, green: TC-PTP.
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Figure 4.31.: Density plots for atom-wise shape fit ratio in PDB complex 1QXK; pink:
PTP1B, green: TC-PTP.
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Figure 4.32.: Density plots for atom-wise shape fit ratio in PDB complex 1QXK; pink:
PTP1B, green: TC-PTP.
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Figure 4.33.: Density plots for atom-wise shape fit ratio in PDB complex 1QXK; pink:
PTP1B, green: TC-PTP.
54
Figure 4.34.: Density plots for atom-wise shape fit ratio in PDB complex 1QXK; pink:
PTP1B, green: TC-PTP.
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4.2. Part II: Binding Site Shape Clustering and Screening
4.2.1. Generation of Input Data
Due to the observation that stronger inhibitors of PTP1B are found to preferably bind
to the closed conformation of the active site cavity this approach strives to discover
PTP1B selective compounds targeting the closed active site conformation. In order
to prevent the occurrence of loop opening events during the simulations and poten-
tially connected conformational changes in other parts of the protein, the protein was
guided to keep the closed conformation with a phosphotyrosine residue bound to the
catalytic cavity. As starting system for PTP1B, PDB structure 1PTY was chosen, which
contains phosphotyrosine residues in the catalytic cavity and the second phosphoty-
rosine binding site. The second phosphotyrosine was removed prior to the molecular
dynamics simulations, with the aim not to unnecessarily bias the rest of the binding
cavity. Since a closed cavity complex was not available for TC-PTP, a homology model
was build based on the PTP1B complex 1PTY. To yield a structure equivalent to the
PTP1B structure for simulation, the coordinates of the catalytic phosphotyrosine and
the adjacent catalytic watermoleculewere transposed to theTC-PTPhomologymodel.
Molecular dynamics simulationswere performed on both complexes in triplicates over
50 ns each. Analogously as for the previously described molecular dynamics simula-
tions Cα-RMSD and RMSF plots were created and analyzed.
Similar to the previously described complexes, the simulations of the 1PTY derived
complexes show stable system behavior with RMSD values below 2.4 Å. RMSD plots in
Figure 4.35 show that the PTP1B simulations reach equilibrium after about 5 ns, while
the TC-PTP structures still seem not to have finished the rearrangement after 10 to 15
ns. Further they show a slightly higher overall RMSD than the PTP1B simulations. Both
observations are in good agreement with our expectations due to the fact that ligand
coordinates were transposed from the PTP1B structure without energy minimization.
The time point of 15 ns was therefore considered as starting point of the simulations
for further analysis.
Starting from the determined point of equilibration, point maps depicting the bind-
ing site shape were generated for each frame with the tool POVME2 [94, 95]. Again
the Cα-atoms of the stable active site loop amino acids Cys215-Arg221 were chosen
for alignment of all frames. The TC-PTP trajectories were aligned on the first frame of
the PTP1B trajectories to enable direct comparison of the resulting data due to use of
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Figure 4.35.: RMSD plots of the molecular dynamics simulations performed on the
1PTY crystal structure with a cropped phosphotyrosine in the catalytic pocket (top)
and the corresponding TC-PTP homology model complex (bottom).
gether with the protein surface of the starting frame is depicted in Figure 4.37(left). The
starting point map spans the whole binding area of PTP1B with all subsites (compare
Figure 4.1). However, the outside of the lid closing the catalytic pocket is only partially
covered. Considerations on the influence of this fact regarding the outcome of the clus-
tering workflow are included in the following chapter.
4.2.2. Bootstrapping and Clustering
Since theamountof storagecapacity required for clustering thewholedataset exceeded
theavailable resources, bootstrappingwasused tocreate three smaller samplesof 14598
(one third of the considered frames) frames each [112]. Calculations were then per-
formed on all three samples. Clustering results for each sample were further processed
with an R script, which can be found in section A.3 to guide the selection of the appro-
priate clustering level for further analysis. The approach developed here is similar to
the elbow method to find the optimal number of clusters for a dataset [103]. Like the
elbowmethod, it strives to assess how intra-cluster variance changes for each step and
especially afterwhich step it doesnot increase significantly anymore. Due to thenature
of clustering algorithms, clusters will get more uniform the smaller they get, but too
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small clusters will result in overfitting or unnatural segregation. In this analysis, only
clusters that could clearly be assigned to one of the two proteins PTP1Bor TC-PTPwere
considered, since bigger mixed clusters were consideredmore likely to be less uniform
and also less important in order to find differences between the proteins. As clearly
assignable to one protein, all clusters were considered that contain over 92.5% PTP1B
or TC-PTP frames.
In order to get a parameter for intra-cluster variance, for the clustering steps 1 to 50,
for each cluster the ratio of occupancy of every point of the starting point map was
calculated. From those occupancies, the ratio of the always present points (occupancy
> 95%) and always absent points (occupancy< 5%) from the whole starting point map
was computed, which represents a measure of the uniformness of each cluster. This
uniformness parameter was then plotted for the considered clusters (see Figure 4.36)
together with the mean value over all clusters with curves delimiting the ±1 standard
deviation area around the mean.
All plots show a steep increase of the intra-cluster uniformness in the first clustering
steps. However, after clustering step 8 for sample three or clustering step 9 for sample
one and two, the intra-cluster uniformness is only slightly increasing over the next 40
clustering steps. This bend in the curve signalizes that after clustering step 8 or 9, re-
spectively, the clustering quality does not increase significantly and that this bend is
most likely to represent the natural clustering structure of the data well. To continue
the work with similar cluster sizes, a common clustering step - step 9 - was chosen for
further analysis for all three samples.
Tables 4.3, 4.4 and 4.5 show the results of the clustering at step 9 for the three samples
together with the assignment of each cluster to one of the two proteins according to
the ratio of frames belonging to each protein. Surprisingly, all clusters at the chosen
clustering step match the chosen threshold criterion and can therefore be assigned to
one protein. For all samples, the clustering shows a distribution with nice cluster sizes
of over800 framesper cluster andminimal ratiosof over94%of framesbelonging toone
protein. This suggests that there are indeeddifferences in thebinding site shapeof both
proteins and that the chosen clustering method seems able to detect these differences
well.
Based on this cluster assignment to the two proteins, calculations were performed
on all samples in order to find the PTP1B assigned cluster of each sample that is most
different to all TC-PTP assigned clusters. With this aim, for each PTP1B cluster the







































































Figure 4.36.: Intra-cluster uniformness over clustering step number for all three sam-
ples. Mean value over all clusters per step as pink line; pink area represents±1 standard
deviation area around the mean.
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calculated and summed up. Squared differences were chosen to give less emphasis to
smaller occupancy differences that might not be statistically significant. The PTP1B
cluster with the highest sum was considered to be the most different to all TC-PTP









1835 1835 100.0 0 0.0 PTP1B
1044 1044 100.0 0 0.0 PTP1B
2963 93 3.1 2870 96.9 TC-PTP
2049 2049 100.0 0 0.0 PTP1B *
2302 2302 100.0 0 0.0 PTP1B
1163 0 0.0 1163 100.0 TC-PTP
977 1 0.1 976 99.9 TC-PTP
989 0 0.0 989 100.0 TC-PTP
1276 0 0.0 1276 100.0 TC-PTP
Table 4.3.: Clustering of sample 1 at the chosen clustering step. Asterisk marks PTP1B









2986 1 0.0 2985 100.0 TC-PTP
1775 1775 100.0 0 0.0 PTP1B*
2550 2410 94.5 140 5.5 PTP1B
1885 1885 100.0 0 0.0 PTP1B
939 0 0.0 939 100.0 TC-PTP
970 0 0.0 970 100.0 TC-PTP
1206 1206 100.0 0 0.0 PTP1B
1468 0 0.0 1468 100.0 TC-PTP
819 0 0.0 819 100.0 TC-PTP
Table 4.4.: Clustering of sample 2 at the chosen clustering step. Asterisk marks PTP1B








2042 2042 100.0 0 0.0 PTP1B*
2886 96 3.3 2790 96.7 TC-PTP
929 0 0.0 929 100.0 TC-PTP
2484 2363 95.1 121 4.9 PTP1B
1505 0 0.0 1505 100.0 TC-PTP
940 0 0.0 940 100.0 TC-PTP
1666 1666 100.0 0 0.0 PTP1B
1139 1139 100.0 0 0.0 PTP1B
1007 0 0.0 1007 100.0 TC-PTP
Table 4.5.: Clustering of sample 3 at the chosen clustering step. Asterisk marks PTP1B
cluster most different to the TC-PTP assigned clusters.
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Figure4.37.:Left: Pointmap spanning thebinding areaof PTP1Busedasbasis toderive
protein shape information for clustering together with surface of the first PTP1B frame.
Right: Subsection of the points related to selectivity.
4.2.3. Selectivity and Interaction Patterns
Consecutively, all grid points were stored that show at least 70% occupancy difference
of the selected PTP1B cluster to all TC-PTP clusters simultaneously. For sample 1 this
list comprises 124 points that are part of the available space for ligand binding in TC-
PTP, but not in PTP1B. Points that are part of the binding site for PTP1B, but not TC-
PTP were not found. Sample 2 shows a similar result with 121 points available for lig-
and binding in TC-PTP, but not PTP1B and no common points for all clusters with the
opposite behavior. Similarly, sample 3 shows 116 points available for ligand binding
in TC-PTP, but not PTP1B and no common points for all clusters with the opposite be-
havior. Interestingly, of the points that are part of the available space for ligand binding
for TC-PTP, but not PTP1B, the three samples share 110 points, therefore showing sig-
nificant overlap of the results. Those shared points are depicted in Figure 4.37(right).
The points concentrate on site C of the PTP1B binding area and the upper lid of site A.
At the lid of site A, differences in the torsional freedom of the Phe182 sidechain seem
responsible for the observed binding site preferences. The points found in the C site
span the areaof the sidechains of Arg47 andAsp48, whereTC-PTP seems toprefermore
outward faced conformations.
Screeningof all 43754 framesconsidered in thecluster analysis (21877 for eachPTP1B
and TC-PTP) with the 110 points correlated with selectivity and also with the subset of















































Figure 4.38.: Ratio of frames matching at least x percent of the selectivity map. Left:
For the subset of 64 points around Arg47. Right: For the whole map of 110 points.
betweenPTP1BandTC-PTP frames, but also to select PTP1B frames for the consequent
virtual screening workflow. The results are plotted in Figure 4.38. The selectivity map
containing all 110 points is fulfilled by 905 PTP1B frames, but no TC-PTP frame. The
best fitting frame of all TC-PTP frames matches 73 of the 110 points. The subset of the
selectivitymapcontaining the 64points aroundArg47 is fulfilledby1491PTP1B frames,
but no TC-PTP frame. The best fitting frame of all TC-PTP frames matches 59 of those
64 points. However, many of the TC-PTP frames - 13542 -match none of the 64 points.
Further it can be deduced from Figure 4.38 that the TC-PTP frames matching higher
numbers of the selectivity map points are rare for both the full map and the subset of
64 points.
From the 905 PTP1B framesmatching all of the 110 points of the selectivity map, five








With the aim to find ligands showing selective inhibition of PTP1B, a virtual screen-
ing workflowwas developed using the previously described selectivity map. In order to
add a filtering step to the screening process to increase the likelihood of activity against
PTP1B an approach based onmolecular interaction fields was chosen to deduce phar-
macophoric features from the chosen protein frames, since a purely shape-based ap-
proach would lead tomany false positive hits with no suitable distribution of pharma-
cophoric features. A schematic representation of the workflow is depicted in Figure
4.39.
In a first step (Fig. 4.39-A),molecular interaction fields were generatedwithMOE us-
ing probes for hydrogen bond donor, hydrogen bond acceptor and hydrophobic inter-
actions. To translate the interaction energy maxima to pharmacophore feature points,
the generated molecular interaction fields were saved in .cns format and further pro-
cessed using an R script created for this purpose. The script reads the interaction fields
and finds interaction energy maxima by comparing the energy at each grid point with
all neighboring points. A binding site center is defined and all points more than 15 Å
away from this center are excluded. Exclusion volumes are added on those points of
the 110 points correlated with selectivity, which are close to the binding site of the con-
sidered frame and not inside the protein surrounded by other exclusion volumes (Fig.
4.39-C). This limitation of the exclusion volumes to the necessary ones saves time dur-
ing screening. Both feature points as well as exclusion volume spheres of each frame
are written to a LigandScout pharmacophore format for visual inspection. Upon visual
inspection features with high overlap were merged and features distant from the cat-
alytic site were removed. Additionally, less restrictive exclusion volumes were added
manually at protein atom positions in binding site regions not covered by the selectiv-
ity map derived exclusion volumes (Fig. 4.39-D).
The finalmodels are named by their molecular dynamics frame of origin. Mod_3290
is depicted in Figure 4.39-E. It comprises one hydrogen bond donor feature and four
hydrogen bond acceptor features of which one shows high overlap with the hydrogen
bond donor feature. The other three hydrogen bond acceptor features are arranged
with low overlap in the catalytic cavity. Further the model contains one hydropho-
bic feature of increased size between the triple of hydrogen bond acceptors and the
overlapping hydrogen bond donor / hydrogen bond acceptor feature. It also contains
over 50 exclusion volumes of different size in total. The other models show a similar
number and arrangement of exclusion volumes and similar feature arrangements as
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depicted in Figure 4.40: Mod_5079 shows a triple of hydrogen bond acceptor features
separated from a fourth hydrogen bond acceptor feature by two hydrophobic features.
In mod_5561 a quadruple of hydrogen bond acceptors is separated from a fifth hydro-
gen bond acceptor by only one hydrophobic feature. Mod_7139 only shows a triple of
hydrogen bond acceptor features and two hydrophobic features. In mod_7181 a triple
of hydrogen bond acceptor features is joined by a hydrogen bond donor and a hydro-
gen bond acceptor feature of high overlap and separated from another hydrogen bond
acceptor feature by a hydrophobic feature.
All pharmacophore models show high similarity of the feature types and their distri-
bution compared to a PTP1B bound phosphotyrosine residue: They all show at least
three overlapping hydrogen bond acceptor features in the catalytic pocket together
with a hydrophobic feature in a distance of 4 to 5 Å to the nested hydrogen bond ac-
ceptor features, which are also found for phosphotyrosine and other PTP1B ligands.
However, they all show additional features close to the YRD loop to ensure interactions
with residues of the C site in a selective binding site conformation.
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Figure 4.39.: Schematic representation of the pharmacophore generation workflow on
the example of frame "1PTYorigFrame3290"; A: Molecular interaction field, B: phar-
macophore translation of selected interaction energy maxima, C: automatically gen-
erated exclusion volumes based on selectivity pattern, D: manually added exclusion
volumes, E: final interaction pattern; color code: green - hydrogen bond donor, MIF
threshold -3.4; red - hydrogen bond acceptor, MIF threshold -3.4; yellow - hydropho-
bic, MIF threshold -1.7.
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Figure 4.40.: Molecular interaction fields and final interaction patterns based on the
selected frames "1PTYorigFrame5079", "1PTYrep2Frame5561", "1PTYorigFrame7139"
and "1PTYrep2Frame7181"; color code: green - hydrogen bond donor, MIF thresh-
old -3.4; red - hydrogen bond acceptor, MIF threshold -3.4; yellow - hydrophobic, MIF
threshold -1.7.
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In thenext step, four databases of commercially available compoundswere prepared
as described in the Experimental Section and screened with the optimized selectivity
and interaction patterns. The numbers of hits for each pharmacophore are summa-
rized in Table 4.6.
Database mod_3290 mod_5079 mod_7139 mod_5561 mod_7181
ChemBridge 3368 610 7356 1759 8
ChemDiv 2834 1107 12859 2352 7
keyorganics 599 197 1821 399 5
VitasM 4203 941 16176 2633 84
Table 4.6.: Virtual screening results (number of hits) of four vendor databases with the
optimized interaction patterns.
Database mod_3290 mod_5079 mod_7139 mod_5561 mod_7181
ChemBridge 326 58 403 108 0
ChemDiv 162 151 541 137 0
keyorganics 67 52 308 26 0
VitasM 359 113 1157 167 1
Table 4.7.: Results (number of hits) of the pharmacophore rescreening of the represen-
tative poses extracted from docking grouped by the four vendor databases.
All hits of the pharmacophore screening were submitted to protein-ligand docking
into the corresponding frame to assess their most likely binding modes and in order to
reassure in the next step the pharmacophore fit of the ligand in a protein bound con-
formation. 25 docking poses per ligand were generated and checked for consistency
utilizing an R script created for that purpose (see Section A.4). The script performs
a density-based clustering of the poses for each ligand and based on the number of
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clusters with sufficient size chooses up to three representatives. Figure 4.41 shows an
example for the result of the density-based clustering for 25 docking poses of a small
molecule in PTP1B. Two clusters are found beneath two single poses. For the identified
clusters representative structures are selected. The results of the automatic processing
nicely agree with intuitively chosen poses.
Hit numbers of the consequent pharmacophore rescreening of the representatives
can be found in Table 4.7.
Figure 4.41.: Results of the density-based clustering in R for 25 docking poses of an ex-
emplary smallmolecule in the PTP1B binding site; yellow and orange poses are chosen
for further analysis, translucent poses are discarded.
The results show that the selection of consistent poses together with the pharma-
cophore rescreening leads to a significant reduction of hits. The number of hits was
further reduced by reassuring that the selected binding poses additionally fit the se-
lected protein frames well: Since the protein could show adaption to the bound lig-
and andmove away from the conformational pattern correlatedwith selectivity, energy
minimization of the poses selected via pharmacophore rescreening together with the
surrounding amino acidswas performed. This stepwas then followed by visual inspec-
tion of the energy minimized conformations with the previously described selectivity
map. Only poses with protein conformations matching at least 100 of the 110 points
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were kept. After careful visual inspection considering both good protein-ligand com-
plementarity as well as rigidity of the ligands to decrease the possibility of them fitting
to other protein conformations and therefore to TC-PTP, the 14 compounds depicted
in Figure 4.42 were chosen for biological testing.
The selected compounds show diverse rigid scaffolds different to those of known
PTP1B inhibitors. Despite the different scaffolds, the compounds show some similar-
ities. For example 9 of the 14 compounds show a trifluoro moiety and three of the 14
compounds are spiro-compounds. Since the ligands were already chosen to be as di-
verse as possible during visual inspection, the similarity of the resulting compounds
suggests either a too restrictive filtering procedure or a lack of chemical diversity in the
screened databases.
Figures 4.43 and 4.44 show docking poses of two of the selected compounds. Com-
pound 0357-0002 shows good shape fit in the catalytic cavity aswell as close to the YRD
loop. It can interact with the protein via four hydrogen bond acceptor interactions and
three charge interactions as well as a big area of hydrophobic interactions between the
catalytic cavity and the YRD loop. The charge interaction to Arg47 has a high potential
of exploiting a PTP1B exclusive conformation of the YRD loop. Additionally, there is a
small empty place in the catalytic cavity close to Gln266 which could allow the accom-
modation of a water molecule as observed during catalysis and add water mediated
interactions of the ligand to Gln266.
Compound 18735792 shows a similar good shape fit as compound 0357-0002. It is
noteworthy that this compound is not negatively charged as most known PTP1B in-
hibitors, but in fact contains a tertiary aminewhich could positively influence the com-
pounds cell permeability. Due to the absenceof anegative charge, the interactionswith
the catalytic cavity are dominated by hydrogen bonds. The docking pose shows four
hydrogen bonding interactions with the catalytic pocket, but they are assumed to be
less strong then the ones detected for compound 0357-0002, due to the small size and
therefor tightly bound lone-pairs of the fluorine atoms. As described for compound
0357-0002, additional water mediated hydrogen bonds of the ether oxygen to Gln266
seem possible. Additional hydrophobic interactions support the protein-ligand inter-
actions in the active site. Further twomore hydrogen bond acceptor and one hydrogen
bonddonor interaction are shaped to the YRD loopwhich increase the likelihood of the
compound to prefer PTP1B selective conformations.
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Figure 4.42.: Commercially available compounds selected for biochemical evaluation.
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Figure 4.43.: Docking pose of compound 0357-0002 in the active site of PTP1B; Top: 3
dimensional depictionof proteinbinding site and ligand shape; Bottom: 2dimensional
liganddepictionwith pharmacophoric interactions to the protein; red circles and lines:
hydrogen bond acceptor, red star: negative ionizable, green: hydrogen bond donor,
yellow: hydrophobic interactions.
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Figure 4.44.: Docking pose of compound 18735792 in the active site of PTP1B; Top: 3
dimensional depictionof proteinbinding site and ligand shape; Bottom: 2dimensional
liganddepictionwith pharmacophoric interactions to the protein; red circles and lines:





5.1. Part I: Protein-Ligand Interaction Analysis
The overall aim of this study was the detection of key features in the surrounding of
the active site of PTP1B that could drive selectivity of PTP1B ligands. It was therefore
assumed that despite the disappointing research experiences found in literature, the
active site of PTP1Bcontains unique features that canbeexploited to achieve selectivity
of small molecule binders against TC-PTP.
The first section of the corresponding analysis deals with comparison of the protein
sequences and of three-dimensional information from crystal structures. The high se-
quence similarity found in the active site area is not a new finding, still this detailed
analysis lays important groundwork for further parts of this study. Additionally, the
considerationof sequencedifferences togetherwith the three-dimensional structure of
PTP1B can explain, why the observed sequence differences in the active site are hard
to target with ligand features. It is worth mentioning that the overall sequence iden-
tity of the two proteins is only 57% and therefore low in comparison to the active site
similarity. This part of the study therefore supports the idea that differences in theover-
all protein structure could influence ligand binding and enable ligand selectivity. This
idea was brought up many years before this study, however, so far no definite proof or
reasonable mechanism was found for this hypothesis. Consequently, binding poses of
co-crystallized selective PTP1B inhibitors were analyzed with different methods. Con-
ventional methods like the comparison of protein-ligand interactions of selective and
unselective PTP1B inhibitors show only subtle tendencies, but no solid explanation
for the observed selectivities. Additional, the results suggest C site interactions, espe-
cially with Asp48, to influence selectivity against TC-PTP. The analysis of interaction
counts also reveals the drawbacks of this method: Two crystal structures (1Q6T and
1Q6P) show crystal packing artifacts, which could introduce structural changes that
distort the result. Further, while counting polar interactions like hydrogen bonds is
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rather intuitive, the quantification of hydrophobic interactions and the corresponding
effects on entropy is challenging. Additionally, ligand binding affinities for different
high affinity complexes have been related to shape complementarity or buried surface,
a factor that is not accounted for by counting protein-ligand interactions. The question
of PTP1B selectivity therefore seems unsolvable taking into account only conventional
methods of analysis on static protein structures. Still conventional methods like ana-
lyzing protein-ligand interactions in static structures have been proven useful in many
cases, therefore the absence of explanations in the case of PTP1B selectivity is an im-
portant result.
Since static protein structures did not reveal promising results, the flexible behavior
of selective inhibitors in both proteins was then analyzed using molecular dynamics
simulations. Contemplating the results of this part, however, it needs to be taken into
account that the molecular dynamics simulations for TC-PTP were run on homology
models using PTP1B template structures. Therefore it may simply not be possible for
the TC-PTP structures to escape the possibly artificial local energy minimum created
by homology modeling.
RMSD and RMSF plots of the conducted simulations did not reveal meaningful dif-
ferences in protein flexibility between the two proteins. However, they all support that
the region of the pTYR loop and the connected α-helix is the most stable part of the
protein. Therefore, for further analyses the molecular dynamics frames were aligned
on this stable region to get a picture about flexibility of the surroundings given a ligand
anchored in the catalytic cavity. Remarkably, the WPD loop known for its high flexibil-
ity shows very low flexibility over the time of the simulations, probably due to fixation
in the closed state by the complexed ligands.
To investigate protein-ligand interactions over themolecular dynamics simulations,
dynophores were used. Similar to the static interaction analysis the variation of the re-
sults was high and allowed no clear deductions regarding differences of both proteins.
However, according to the dynophore analyses, B site interactions seem more stable
for PTP1B which is in agreement with their relevance for selectivity deduced form the
static interaction counts and also found in literature. Unfortunately, for those inter-
actions the variations between simulations of one protein are especially high, which
makes this result highly unreliable. However, this analysis also suggests parts of the A
site and the C site as possible interaction sites to introduce selectivity. In the simula-
tions of PTP1B-complex 1XBO and the corresponding homology model a slight shift
of the ligand between A and B site in TC-PTP compared to PTP1B could be observed
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which seems to be connected to different hydrophobic interactions in the region con-
necting both sites. Unfortunately, the dynophore results share the drawback of static
interaction counts that hydrophobic interactions are hard to quantify and shape com-
plementarity is not sufficiently accounted for.
Consequently, we developed a new method to assess protein-ligand shape comple-
mentarity on frames of amolecular dynamics trajectory. Surprisingly, the results on the
test case 1XBO indicate that flexible shape complementarity might be the previously
undiscovered key feature of PTP1B selectivity. Interestingly, this method suggests the
A site interactions to play amain role in the selectivity of the 1XBO ligand, which agrees
with the result of the dynophore analysis that suggests HBA3 to be selectivity relevant.
Additionally, thedetecteddifference inHYD1 interactions fromthedynophore analysis
matches the only detected atom outside the A site, C35. Further, the strain energy plot
did not indicate significant differences in ligand conformations. It stands out that the
atoms with highest differences in ligand RMSF values match the atoms with shape fit
differences. The increased activity of the ligand in PTP1B could therefore be explained
by tighter binding due to better shape complementarity of the protein to the ligand in
the catalytic cavity. Also for the second test case, 1QXK, the newmethod indicated that
shape fit and here additionally ligand strain could be responsible for the observed se-
lectivity of the ligand. Surprisingly, for the 1QXK ligand, despite an overall better shape
fit toPTP1B, the active site part of the ligand shows increased shapefit to TC-PTP,which
fits the tendency observed in the dynophore statistics where HBA3, HBA4 and HBD1
show higher mean occurences in TC-PTP. Here, B and C site interactions seem respon-
sible for the selectivity and connected to especially good shape fit. As for the B site,
this good shape fit is correlated with reduced flexibility of the ligand in this area like
observed for 1XBO. For the C site, however, the increased shape fit does not correlate
with a difference in ligand flexibility. One possible explanation for that could be the as-
sociation of good shape fit in this area with the high number of frames with low ligand
strain in PTP1B: a PTP1B exclusive protein conformation of the YRD-loop could enable
ligand relaxation compared to other protein conformations which possibly introduce
ligand strain in order to enable hydrogen bonding at N1(HBD4) and N2(HBD3). This
hypothesis is supported by the result of the dynophore analysis indicating higher oc-
curences of the relevant hydrogen bonds in PTP1B as well as the results of Binding Site
Shape Clustering section.
Since the novel method of protein-ligand shape complementarity yielded interest-
ing results for the PTP1B/TC-PTP testcases in this study, investigations on additional
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testcases would be highly interesting to discover the applicability of the protein-ligand
shape complementarity method for other other projects and proteins. Unfortunately,
since this method is in the current implementation highly time and resources con-
suming, we had to refrain from investigating further test cases. In order to assess its
relevance on further test cases reimplementation therefore might be a rational step.
Additionally, supplementary studies on the impact of results on input settings of the
method like the size and shape of the starting point map and the spacing of the grid
points would be desirable to optimize themethod for general use. Overall, thismethod
represents a novel opportunity to look at protein-ligand interactions from a different
viewpoint and could help to explain ligand activity differences in so far undisclosed
cases.
5.2. Part II: Binding Site Shape Clustering and Screening
The second part of this study deals with the question if the differences discovered in
protein-ligandcomplementarity canbe targeted tofindor create inhibitorsof increased
selectivity. Hence, it is assumed that the differences in shape complementarity origi-
nate in differing conformational preferences of the two proteins.
Consequently, molecular dynamics simulations of protein structures for both PTP1B
and TC-PTP with only a ligand anchor to keep the WPD loop closed were performed
and analyzed. Keeping the WPD loop closed was considered appropiate due to most
higher active inhibitor binding poses showing a closed WPD loop. Furthermore, this
approach aims to separate the movements connected to the WPD loop opening and
closure frommovements relevant for selectivity of active site inhibitors. However, there
is no guarantee that this restraint on the WPD loop is not suppressing relevant move-
ments or introducing unnatural behavior, especially in TC-PTP, into which the anchor
ligand was just placed instead of using protein-ligand docking. Additionally, the se-
lection of the starting structure of PTP1B and the created homology model for TC-PTP
could impact the outcome of the analysis, as could parameters like size and position
of the starting point map as well as grid spacing or the choice of the clustering algo-
rithm. Especially, due to the insufficient placement of grid points on the WPD loop,
loop movements could not be properly detected in this analysis. However, due to the
anchor ligand they were assumed to be negligible. Again, investigation of all influenc-
ing factors was out of the scope of this thesis and leaves room for further investigations
of this novel method.
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Overall, themethodyields interesting resultswith rationally guided selectionof input
parameters, showing differing conformational preferences for the two proteins:
Firstly, clustering of the three bootstrapping samples leads to a good agreement of
the single results regarding number and size of the detected clusters with nice sepa-
ration between PTP1B and TC-PTP clusters. Secondly, the grid points selected to be
selectivity relevant by the method show a high amount of overlap between the results
of the bootstrapping samples.
Translation of this information into a selectivity pointmap allows visualization of the
result and exploitation for filtering of molecular dynamics frames. This way it could be
verified that filtering with themap selects PTP1B frames (905 frames selected), but not
a single TC-PTP frame. Additionally, PTP1B framesmatching the selectivity map could
be chosen as representative frames for the consequent virtual screening workflow.
Interestingly, the points detected as relevant for selectivity concentrate around only
two protein sites: the first site is located around the side chain of Phe182. The detected
differences here seem to correlate only with rotations of the phenyl ring of this amino
acid. A detection of an area in the A site with this method corroborates the results
of the first part of this study, which indicates this site as selectivity relevant for some
of the analyzed ligands. However, these differences could be induced by the artificial
placement of the phenylphosphatemoiety in the active site for loop closure during ho-
mology modeling. The second part of the selectivity map is located around Arg47 and
Asp48 in theC site of the binding area. Here the YRD loop seemsmore flexible in PTP1B
and therefore able to adapt a conformation more bent towards the catalytic cavity. As-
tonishingly, also the static protein-ligand interaction analysis as well as the dynophore
analysis of ligand 1QXKpointed to this site to be relevant for selectivity. Surprisingly, no
points in the B sitewere detected to be relevant for selectivity. This could correlate with
the high intra-protein variance discovered in the dynophore analysis. Additionally, the
alignment on stable A site atoms could lead to higher variation in more distant points.
Both factors could disturb a pattern of occupancy differences and render it undiscov-
erable by the clustering method.
The final part of this study aims at exploiting conformational differences of PTP1B
andTC-PTP tofind selectivePTP1B inhibitors. Of the 905 framesmatching the selectiv-
ity map, 5 were chosen for the virtual screening workflow. The number was limited by
the available computing time for screening, therefore diverse frames were picked from
the set. Possiblymore elaborate pickingmethods like choosing frameswithmany close
neighbors could increase the chance to find relevant protein conformations.
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In the attempt to not only include spatial, but also pharmacophoric information to
the screening to increase the likelihood of activity at the protein, molecular interaction
fields were used to create interaction patterns screenable with LigandScout. Different
to classical 3D pharmacophores, these interaction patterns are not based on one or
more ligands. This has advantages and disadvantages: On the one hand, purely pro-
tein structure based interaction patterns allow inclusion of interactions with high like-
lihood of positive impact on activity independent on whether or not they are already
present in known ligands. On the other hand, a good interaction energy score at a cer-
tain grid point does not necessarily imply relevance of this interaction for activity. In
fact, the good score might be related to the energy function or the interaction point
could be too small or restricted in its angle to be met by a real ligand. However, this
protein structure based selection of interaction points is a common approach, which
was implemented in a similar fashion inDiscovery Studio/Catalyst and themost recent
LigandScout version [113, 80, 81].
The results of this method are corroborated by the high resemblance of the interac-
tion patterns to 3Dpharmacophores of knownPTP1B ligandswith at least three nested
hydrogen bond acceptor features in the catalytic cavity and a close-by hydrophobic
feature below the WPD loop. Due to the additional C site interactions optimized to
fit only selective PTP1B conformations, there is no appropriate data set for validation
of the interaction patterns. Validating the interaction patterns on PTP1B inhibitors by
omitting their C site featureswould also be of limited relevance, since the remaining in-
teraction patterns would only contain a few number of features andmost likely be very
unspecific. Their high similarity to pharmacophores of known ligands in the active site
therefore depicts the only validation method.
The applied combination of screening with the chosen interaction patterns, protein-
liganddocking, pose-consistencyfilteringand interactionpattern rescreeningwas cho-
sen to reduce false positives among the screening hits. As mentioned in the "Compu-
tational Methods" section combinations of filtering and or screening methods are not
uncommon to decrease false positive rates is virtual screening. However, most stud-
ies rely on docking scores rather than pose-consistency filtering. Pose-consistency fil-
tering was developed and used in this study, since docking scores were found to be
unreliable inmany cases, especially if they were not adapted and validated on the rele-
vant target. Although pose-consistency is depending on the created docking poses and
therefore also on the scoring function, it gives a more qualitative decision criterion for
pose selection which is not dependent on the total score and factors like ligand size.
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The combination of conformational rigidity, good shape fit of the ligand to the selec-
tive protein frame and matching of the interaction patterns depicts a very restrictive
filter for small molecules. Therefore it seems reasonable that the resulting compounds
from vendor databases show a lack of diversity and partially unsatisfactory agreement
with the requirements like the trifluoro-group as triple hydrogen bond acceptor fea-
tures. Since all of the mentioned aspects ensure integral properties of the desired lig-
ands, the only option to find more customized ligands would be de novo synthesis.
However, this was out of the scope of this study, but would be a desirable step after an
initial biochemical validation of the workflow. Further, fluorinated motifs have been
discovered to adopt diverse protein binding features and could therefore be an inter-
esting alternative to known phosphotyrosine mimetics [114].
In total the second part supports the hypothesis discovered in the first part of the
study, suggesting that differences in conformational flexibility of both proteins exist. In




6. Conclusion and Outlook
Despite decades of research, the key principles of PTP1B selectivity against TC-PTP are
still unknown and highly selective PTP1B inhibitors have not been published. Since
selective inhibition of PTP1B could be a valuable contribution in the fight against de-
seases like Type 2 diabetes and obesity, this study strived to detect and exploit key fea-
tures of PTP1B selectivity. This aimwas persued in twodifferent approaches: a detailed
analysis of partially selective PTP1B inhibitors in their protein bound conformations in
Part I and a consequent predictive method based on clustering of binding site shapes
derived frommolecular dynamics simulations in Part II.
Since classical interaction analysis approaches did not lead to concise results regard-
ing influencing factors of PTP1Bselectivity, a novelmethod tomeasureflexibleprotein-
ligand shape complementarity was developed and implemented. Validation on two
partially selective ligands led to interesting findings, indicating protein-ligand shape
complementarity and resulting increased ligand stability in different areas of the bind-
ing site to be responsible for the selectivity of the investigated ligands. Additionally, for
one of the ligands the results point towards an increased possibility of PTP1B to adapt
to the ligand with the YRD loop.
Those conclusions were corroborated by the second part of the study: The novel
method of binding site shape clustering developed here also implicated a part of the
catalytic cavity as anareaofdifferingproteinflexibility inPTP1BandTC-PTPand there-
fore relevant for selectivity. However, due to the limited space in the catalytic cavity
and the highly similar interaction feature patterns in both proteins, the optimization
of ligands towards a PTP1B preferred conformation at this site would be extremely dif-
ficult. Interestingly, this method further strongly suggested the C-site of the protein
binding site to show different conformational preferences in both proteins. Opposed
to the differences in the catalytic cavity, these differences show increased potential for
exploitation with small ligands. Consequently, themethod was extended to exploit the
detected selectivity shape features for virtual screening. With this approach, commer-
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cially available compounds with high potential to be selective PTP1B inhibitors could
be identified.
Beneath the interesting results on the test case of PTP1B, the two novel methods
developed in this study represent valuable new tools that could be of use for differ-
ent applications: The shape complementarity tool complements the shortcomings of
classical protein-ligand interaction analysis tools by focusingon ligandconformational
preferences and shape fit, which have been shown to be integral parts of ligand affinity
and could therefore help to explain and exploit activity differences especially in simi-
lar protein-ligand complexes. The binding site shape clustering tool addresses the is-
sue of different conformational preferences of similar proteins for exploitation in drug
development projects. It could therefore guide development of selective ligands even
in cases where interaction patterns of the proteins are highly similar. However, both
methods are only valuable in combination with interaction feature basedmethods like
pharmacophores or molecular interaction fields to ensure an overall sufficient com-
plementarity of a ligand to the target.
Overall, the results of both parts of this study concur nicely in indicating shape com-
plementarity as an important feature to increase PTP1B selectivity. Additionally, the
novel Binding Site Shape Clustering method developed in this study made it possible
to exploit this discovery for virtual screening andboth aspects together could positively
impact future drug design projects, where selectivity plays an important role.
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7. Experimental Section
Since this thesis focuses on computational methods, this part primarily contains de-
tails and settings of the conducted computational steps that would disturb the expla-
nations in the "Computational Methods" section.
7.1. Part I: Protein-Ligand Interaction Analysis
7.1.1. Sequence Comparison of PTP1B and TC-PTP
Protein sequences for PTP1B (P18031) and Isoform 1 of TC-PTP (P17706-1) were ex-
tracted from Uniprot [110] and aligned with default settings for proteins using Clustal
Omega [115]. PDB [46] complex 1PTY [116]was chosen as representative for analysis of
binding site residues.
7.1.2. PTP1B Crystal Structure Analysis
The Uniprot referenced PDB structures for PTP1B were sorted by resolution and com-
plexes with worse or equal resolution than 2.70 Å were excluded. Structures with co-
valent active site or nearby (Cα in 15 Å sphere around GLN262-CD) modifications like
mutations, intermediates ormissing loops were excluded, since they could disrupt the
natural protein conformation and due to the high similarity of the two proteins sub-
tle changes could distort features of selectivity. Also excluded were structures with
residuemodifications connected tomodified activity (see e.g. [117] or [118]) and struc-
tures with no ligand or only allosteric ligand. For the selected structures, the Chembl
database [107] and, if not available there, the original publication were checked for lig-
andactivities of the co-crystallized ligandagainst PTP1BandTC-PTP. If available, activ-
ities of the ligand against both proteins from the samegroup and assay andunder com-
parable conditions were preferred. Selectivity factors were calculated and the 10 most
selective structures were chosen additionally to 4 non-selective complexes. Analysis
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of the selected complexes was performed usingMOE(2015.10) [43] and LigandScout(4)
[80, 81]. Interaction frequencies were plotted with R [89].
7.1.3. TC-PTP Crystal Structure Analysis andHomologyModeling
Backbone alignment for visual inspection of PTP1B structure 1PTY and TC-PTP struc-
ture 1L8K was performed in MOE(2015.10) [43]. Homology modeling was also per-
formed using MOE(2015.10) [43]: The TC-PTP sequence was aligned to the sequence
of the PTP1B template being one of the crystal structure complexes 1QXK [119], 1Q1M
[120] and 1XBO [121]. C- and N-terminal outgap modeling was disabled, automatic
disulfide bond detection was enabled and atoms of the co-crystallized ligand were se-
lected as environment for induced fit. The basicmodeling stepwas chosen to create 25
main chain models with 10 side chain samples each at 300 K. Amber99 was chosen as
forcefield . Model refinement was performed inmode "Fine" with RMS Gradient set to
1.0. The resulting 250 models were analyzed regarding their protein and ligand RMSD
to the modeling template.
7.1.4. Molecular Dynamics Simulations
Basic protein preparation was performed inMOE(2015.10)[43]: sidechain protonation
was performed with the Protonate 3D tool at pH=7. The cysteine residue in the cat-
alytic center was deprotonated manually. All molecular dynamics simulations were
performed with the software Desmond 3.1 [71]. Systems were set up in an orthorhom-
bic box with SPCwater and neutralized with Na+ ions. NaCl was added to a concentra-
tion of 0.15 M. Simulations were performed with NPT ensemble at 300 K and 1.01325
bar under periodic boundary conditions. A short relaxation time was followed by a 25
ns production run. For relaxation the Desmond standard NPT relaxation protocol was
used. Energies were recorded every 1.2 ps and the trajectory was saved every 4.8 ps. As
forcefield OPLS2005 was chosen. Calculations were run in triplicates on 24 CPUs each
on the Soroban computing cluster of FU Berlin. Trajectories were analyzed using VMD
[122] and the R package "bio3d" [89, 123].
7.1.5. Dynophore Analysis
The dynophore analysis is based on the dynophore tool for statistical analysis of Lig-
andScout 3D pharmacophores, whichwas recently developed in our group byGerhard
86
Wolber and Dominique Sydow [34, 35, 80, 81]. Additional statistical analyses of the re-
sults were carried out in R [89].
The dynophore application creates a 3D pharmacophore for each frame of a molec-
ular dynamics trajectory. Pharmacophore features with the same feature type and in-
teracting atoms on the ligand are binned into superfeatures. Superfeatures are then
statistically analyzed for example regarding its occurrence over the molecular dynam-
ics simulation and the distances of the interacting atoms on protein and ligand side.
7.1.6. Shape Complementarity Analysis
Themodification of the POVME tool [94, 95], whichwas used in this study can be found
in section A.1 of the Appendix. For generation of the POVME point maps grid spacing
of 0.5 Å was used. The distance cutoff for ligand heavy atoms to points of the created
maps was set to 0.59 Å for the inner map and 1.59 Å for the outer map. The distance
cutoff for protein heavy atoms to the created point maps was kept at 0.59 Å.
7.2. Part II: Binding Site Shape Clustering and Screening
7.2.1. Generation of Input Data
Homology modeling was performed using MOE(2015.10) [43]: The TC-PTP sequence
was aligned to the sequence of the PTP1B template 1PTY [116]. The ligandwas reduced
to its phenylphosphate moiety and not used for adaptive homology modeling. The
basic modeling step was chosen to create 25 main chain models with 10 side chain
samples each at 300 K. As forcefield Amber99 was chosen. Model refinement was per-
formed in mode "Fine" with RMS Gradient set to 1.0. The resulting 250 models were
analyzedandfiltered regarding the similarity to thePTP1B template in thebindingarea.
After selection of the final model, the phenylphosphate moiety and the adjacent cat-
alytic water molecule were transposed to the TC-PTP homology model.
Molecular dynamics simulations were prepared and conducted as described in the
subsectionMolecular Dynamics in Part I of themethods section. Simulations were run
in triplicates over 50 ns each after a short relaxation run.
For the creation of point maps using the modified POVME script (section A.1 of the
Appendix) a starting point map of 10427 points spanning the whole binding area was
created. Grid spacing was set to 1.0 Å and the distance cutoff of protein atoms to points
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of the created maps was fixed to 1.09 Å. A contiguous pocket seed sphere was placed in
the center of the catalytic cavity.
7.2.2. Selectivity and Interaction Patterns
Molecular interaction fields were created using MOE2015.10 [43]. Three probes were
selected for interaction field generation: "N1" (amide NH group) for hydrogen bond
donor interactions, "N:" (nitrogen atom with lone pair) for hydrogen bond acceptor
interactions, "DRY" for hydrophobic interactions.
7.2.3. Virtual Screening
For virtual screening databases of the vendors ChemBridge, ChemDiv, VitasM and key-
Organics were chosen. Vendor databases were downloaded in the version of July 2016.
Thedatabaseswere prepared removing salt and solventmolecules fromcompound en-
tries. Then standardization of the structures was performed using the group protocol
for the ChemAxon Standardizer software [45]: amidine and guanidine structures were
harmonized, different acidic structures were deprotonated and basic structures were
protonated. 25 conformations per ligand were generated with LigandScout 4 [80, 81].
After the preparation the databases contained the following numbers of molecules:
ChemBridge - 1,141,083; ChemDiv - 1,455,331;VitasM-1,384,271; keyOrganics - 79,617.
Screeningof thedatabases and rescreeningof selecteddockingposeswith themolec-
ular interaction field derived interaction patterns was conducted with LigandScout 4
[80, 81]. Protein-ligand docking of the resulting hits into the corresponding molecular
dynamics frames was performed with GOLD version 5.2.2 [54]. The phenylphosphate
moiety and all solvent molecules were removed prior to docking. The binding site was
restricted to a sphere of 12 Å radius around the sulfur atom of CYS215. 25 poses per
ligand were generated. Scoring of the docking poses was performed using the scoring
function PLP with rescoring using Goldscore.
Density based clustering on the RMSD matrix of each molecule’s 25 docking poses




Protein Tyrosine Phosphatase 1B (PTP1B) is a validated drug target for the treatment of
diabetes type 2 and obesity. Until now, development of suitable modulators has been
hampered by the polarity of the binding site and related bioavailability issues of the
molecules. The design of selective inhibitors of PTP1B against the closely related T-Cell
protein tyrosine phosphatase (TC-PTP), which was associated to severe side effects in
animal studies, proved even more challenging. Over the years progress was made, but
known PTP1B inhibitors only achieved at maximummoderate selectivity over TC-PTP.
This study aims to break the traditional boundaries of PTP1B selectivity by deliber-
ately exploiting structural differences of both proteins. Due to their high similarity this
requires thorough analysis of their static structures as well as their flexible behavior.
The goal was therefore pursued with two different approaches:
In Part I of the study a detailed analysis of protein complexes with selective ligands
wasperformed including their flexible behavior as determined frommolecular dynam-
ics simulations. Since common analysis methods were not able to explain the selectiv-
ity of the investigated ligands, a newmethod was developed which is able to assess pa-
rameters of ligand affinity that are not covered by currently available methods: steric
complementarity of the ligand to the protein together with ligand strain. The devel-
oped tool allows to assess those properties on high numbers of molecular dynamics
frames to calculate ligand shape fit in a flexible context. It further enables to trace back
the ligand atoms or parts responsible for good or bad shape fit.
In Part II of this study the flexible behavior of the apoproteins was studied. Since sur-
face properties are highly similar in both proteins, the analysis focused on binding site
shapes. For this, a novel approach was chosen that translates binding site shapes from
molecular dynamics simulations into point maps and subsequently uses clustering
and difference calculations to find a PTP1B conformationmost unlike to all discovered
TC-PTP conformations. Theworkflow includes calculation of a selectivitymap consist-
ing of points in the binding site where highest and most relevant differences in PTP1B
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and TC-PTP conformations occur. This map can be visualized and used for screening
of selective PTP1B frames, which can then be used for protein structure based virtual
screening for potentially selective PTP1B inhibitors.
Results of Part I indicate shape fit as the previously undiscovered reason for selec-
tivity of some known PTP1B inhibitors. They further suggest that selectivity can be
achieved by interactions in the catalytic cavity as well as in previously suggested ar-
eas (the B and C site) of the binding site. Additionally, the discovered reduced lig-
and strain in PTP1B for one of the analyzed ligands, while almost maintaining same
occurences of protein-ligand interaction features, lead to the assumption that PTP1B
possesses a higher ability to conformationally adapt to the ligand than TC-PTP. This as-
sumption is corroborated by the results of Part II: The selectivity map indicates the cat-
alytic cavity and the YRD-loop (C site) as areas of different flexible behavior. Especially
the YRD-loop shows increased flexibility in PTP1B compared to TC-PTP. Additionally,
ligands that have a high likelihood of exploiting the discovered conformational differ-
ences while still showing sufficient activity in PTP1B could be found in databases of
commercially available molecules.
Overall, the two innovative approaches to discover key factors of PTP1B selectivity
did not only lead to interesting findings, but could also be adapted to promote other
drug design projects where selectivity is crucial but hard to achieve.
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9. Zusammenfassung
Das Enzym Protein Tyrosin Phosphatase 1B (PTP1B) ist ein validiertes Wirkstoffziel
für die Behandlung von Diabetes Typ 2 und Übergewicht. Die Entwicklung passender
Modulatoren wurde immer wieder durch die Polarität der Bindetasche und damit ver-
bundene Bioverfügbarkeitsprobleme derMoleküle zurückgeworfen. Noch schwieriger
ist es aber, die Moleküle so zu modifizieren, dass sie Selektivität gegenüber dem nahe
verwandten Enzym T-Zell Protein Tyrosin Phosphatase (TC-PTP) erhalten, was auf-
grunddermit diesemProtein assoziierten starkenunerwünschtenWirkungennotwen-
dig erscheint. Trotz einigerFortschritte inden letzten JahrenerreichenbekanntePTP1B-
Inhibitoren bis jetzt maximal moderate Selektivität gegenüber TC-PTP.
Diese Arbeit hat es sich zum Ziel gemacht die durch bisherige Forschung gesetzten
Grenzender PTP1B-Selektivität zu durchbrechen, indemsystematisch strukturelleUn-
terschiede der beiden Proteine ausgenutzt werden. Aufgrund ihrer sehr großen Ähn-
lichkeit erfordert dies eine genaueAnalyse der statischenProteinstrukturen sowie ihres
dynamischen Verhaltens. Um dieses Ziel zu erreichen, wurden zwei Ansätze gewählt:
In Teil I der Arbeit wurde eine detaillierte Analyse von Protein-Komplexen mit se-
lektiven Liganden und deren dynamischen Verhaltens mithilfe von Moleküldynamik-
simulationen durchgeführt. Da verfügbare Analysemethoden nicht in der Lage waren
die beobachtete Selektivität zu erklären, wurde eine neueMethode entwickelt, welche
es ermöglicht zusätzliche Faktoren für Ligandenaffinität zu erfassen: sterische Kom-
plementarität und konformationelle Energie des Liganden. Die entwickelte Methode
ermöglicht es diese Faktoren an einer großen Anzahl von Moleküldynamik-Schritten
zu erfassen, umVerteilungen für die sterische Komplementarität am flexiblen Protein-
Liganden-Komplex zu erhalten. Zusätzlich können die Anteile eines jeden Ligandena-
toms an der Gesamtkomplementarität berechnet und dargestellt werden.
In Teil II der Arbeit wurde das flexible Verhalten der Apoproteine näher untersucht.
Da die Oberflächeneigenschaften beider Proteine kaumUnterschiede zeigen, konzen-
trierte sich diese Analyse auf die Form der Bindetaschen. Dafür wurde ein neuartiger
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Ansatz gewählt, der die Form der Bindetasche aus Moleküldynamiksimulationen ex-
trahiert und in Punktwolken übersetzt. Diese werden anschließend geclustert, worauf-
hin mithilfe von Distanzberechnungen PTP1B-Konformationen ermittelt werden, die
den größtmöglichen Unterschied zu allen ermittelten TC-PTP-Konformationen auf-
weisen. Der dafür verwendete Workflow berechnet zusätzlich einen Selektivitätsfilter
bestehend aus denjenigen Punkten der Punktwolke, die die größten beziehungsweise
relevantestenUnterschiede indenPTP1B-undTC-PTP-Konformationenzeigen. Dieser
Filter dient einerseits dazu die Selektivitätsrelevanten Bindetaschenareale zu visuali-
sieren, kann aber auch zumFiltern nach selektiven PTP1B-Konformationen ausMole-
küldynamiksimulationen dienen, welche anschließend zum strukturbasierten virtuel-
len Screening nach potentiell selektiven PTP1B-Inhibitoren genutzt werden können.
Die Ergebnisse vonTeil I deutendarauf hin, dass die sterische Komplementarität den
bisher unbekannten Grund für die Selektivität einiger bekannter PTP1B-Inhibitoren
darstellen könnte. Außerdem geht aus den Analysen hervor, dass Selektivität womög-
lichauchdurch InteraktionenmitderkatalytischenTaschehervorgerufenwerdenkann,
neben Interaktionenmit schon in früherenStudienvorgeschlagenenArealenderBinde-
tasche (B- undC-Seite). Zusätzlich zeigt einerder selektivenLigandeneine teilweise re-
duzierte konformationelle innere Enenergie, obwohl kaum Unterschiede im Vorkom-
men der Häufigkeiten der Protein-Liganden-Bindungen zu erkennen sind. Hier kann
die Vermutung aufgestellt werden, dass dies durch eine erhöhte Fähigkeit von PTP1B
im Vergleich zu TC-PTP verursacht wird seine Konformation an den Liganden anzu-
passen. Diese Vermutung wird durch die Ergebnisse aus Teil II der Arbeit gestützt: Der
Selektivitätsfilter weist einerseits auf die katalytische Bindetasche, andererseits auf den
YRD-loop (C-Seite) alsArealeunterschiedlicherFlexibilität hin. InsbesonderederYRD-
loop zeigt erhöhte Flexibilität in PTP1B im Vergleich zu TC-PTP. Zusätzlich konnten in
diesem Teil der Arbeit Liganden in Datenbanken käuflich erwerbbarer Moleküle ge-
funden werden, welche nach unserem Modell eine große Wahrscheinlichkeit haben
die ermittelten konformationellenUnterschiede bei zusätzlich guter Aktivität in PTP1B
gezielt auszunutzen.
Insgesamt führten die zwei innovativen Ansätze zur Ermittlung von Schlüsselfak-
toren der PTP1B-Selektivität nicht nur zu äußerst interessanten Ergebnissen, sondern
könnten auch angepasst werden um Wirkstoffdesignprojekte voranzutreiben, bei de-
nen Selektivität von großer Wichtigkeit, aber schwer zu erreichen ist.
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A.1. Modified Version of the POVME2 Tool
Highlighted lines were added to the original script.
1 # POVME 2 . 0 . 1 i s r e l ea sed under the GNU General Public License (
see http : / /www. gnu . org / l i c e n s e s / gpl . html ) .
2 # I f you have any quest ions , comments , or suggest ions , please
don ’ t h e s i t a t e to contact me,
3 # Jacob Durrant , at jdurrant [ at ] ucsd [ dot ] edu .
4 #
5 # I f you use POVME in your work , please c i t e Durrant , J . D. , C .
A . de Ol ivei ra , e t al .
6 # (2011) . "POVME: An algorithm for measuring binding−pocket
volumes . " J Mol Graph















21 try : from cStringIO import StringIO
22 except : from StringIO import StringIO
23
24 from scipy . spa t i a l . distance import cd i s t
25 from scipy . spa t i a l . distance import pdis t
26 from scipy . spa t i a l . distance import squareform
27
28 version = " 2 . 0 . 1 "
29
30 def log ( astr , parameters ) :
31 ’ ’ ’ Output POVME statements , e i t h e r to the screen or to a f i l e
32
33 Arguments :
34 a s t r −− The s t r i n g to output .
35 parameters −− The user−defined parameters .
36
37 ’ ’ ’
38
39 # Pr int the output to the screen .
40 print as t r
41
42 # Save i t to the output f i l e as wel l .
43 try :
44 i f parameters [ ’ CompressOutput ’ ] == True : f = gzip .open (
parameters [ ’ OutputFilenamePrefix ’ ] + ’ output . t x t . gz ’ , ’ ab ’ )
45 else : f = open ( parameters [ ’ OutputFilenamePrefix ’ ] + ’ output . t x t ’
, ’ a ’ )
46
47 f . wri te ( a s t r + "\n" )
48 f . c lose ( )
49 except : pass
50
51 c lass Multithreading ( ) :
52 " " "A c l a s s fo r running ca l cu la t i on s on multiple proce s so r s " " "
53
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54 re su l t s = [ ]
55
56 def __ in i t _ _ ( s e l f , inputs , num_processors , t a sk_c l a s s ) :
57 " " " Launches a ca l cu la t ion on multiple proce s so r s
58
59 Arguments :
60 inputs −− A l i s t , containing a l l the input required fo r the
ca l cu la t ion
61 num_processors −− An integer , the requested number of p roce s so r s
to use
62 t a sk_ c l a s s −− An cla ss , the c l a s s governing what ca l cu la t i on s
w i l l be run on a given thread
63
64 Returns :
65 Nothing , though the ob j e c t s s e l f . r e s u l t s l i s t i s populated with
the ca l cu la t ion r e su l t s
66
67 " " "
68
69 s e l f . r e su l t s = [ ]
70
71 i f num_processors != 1 and ( platform . system ( ) . upper ( ) [ : 3 ] == "
WIN" or "NT" in platform . system ( ) . upper ( ) ) : # I f i t ’ s windows
, you can only use one proces sor .
72 print "WARNING: Use of mult iple processors i s not supported in
Windows . Proceeding with one processor . . . "
73 num_processors = 1
74
75 i f num_processors == 1 : # so ju s t running on 1 processor ,
perhaps under windows
76 s ing le_thread = t a sk_c l a s s ( )
77 s ing le_thread . total_num_tasks = len ( inputs )
78
79 s ing le_thread . r e su l t s = [ ]
80 for item in inputs : s ing le_thread . value_func ( item , None)
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81
82 s e l f . r e su l t s = s ing le_thread . r e su l t s
83
84 else : # so i t ac tua l l y i s running on multiple proce s so r s
85
86 cpu_count = 1
87 cpu_count = multiprocessing . cpu_count ( )
88
89 # f i r s t , i f num_processors <= 0 , determine the number of
p roce s so r s to use programatical ly
90 i f num_processors <= 0 : num_processors = cpu_count
91
92 # reduce the number of p roce s so r s i f too many have been
spe c i f i ed
93 i f len ( inputs ) < num_processors : num_processors = len ( inputs )
94
95 i f len ( inputs ) == 0 : # i f there are no inputs , there ’ s nothing
to do .
96 s e l f . r e su l t s = [ ]
97 return
98
99 # now, div ide the inputs into the appropriate number of
p roce s so r s
100 inputs_divided = {}
101 for t in range ( num_processors ) : inputs_divided [ t ] = [ ]
102
103 for t in range (0 , len ( inputs ) , num_processors ) :
104 for t2 in range ( num_processors ) :
105 index = t + t2
106 i f index < len ( inputs ) : inputs_divided [ t2 ] . append( inputs [ index ] )
107
108 # now, run each d iv i s i on on i t s own proces sor
109 running = multiprocessing . Value ( ’ i ’ , num_processors )
110 mutex = multiprocessing . Lock ( )
111
110
112 arrays = [ ]
113 threads = [ ]
114 for i in range ( num_processors ) :
115 athread = t a sk_c l a s s ( )
116 athread . total_num_tasks = len ( inputs )
117
118 threads . append( athread )
119 arrays . append( mult iprocessing . Array ( ’ i ’ , [0 , 1 ] ) )
120
121 results_queue = multiprocessing .Queue ( ) # to keep track of the
r e s u l t s
122
123 processes = [ ]
124 for i in range ( num_processors ) :
125 p = multiprocessing . Process ( t a rge t=threads [ i ] . runit , args=(
running , mutex , results_queue , inputs_divided [ i ] ) )
126 p . s t a r t ( )
127 processes . append(p)
128
129 while running . value > 0 : is_running = 0 # wait fo r every thing to
f i n i sh
130
131 # compile a l l r e s u l t s into one l i s t
132 for thread in threads :
133 chunk = results_queue . get ( )
134 s e l f . r e su l t s . extend (chunk )
135
136 c lass MultithreadingTaskGeneral :
137 " " "A parent c l a s s of o ther s that governs what ca l cu la t i on s are
run on each thread " " "
138
139 re su l t s = [ ]
140
141 def run i t ( s e l f , running , mutex , results_queue , items ) :




145 running −− A mult iprocess ing . Value ob j e c t
146 mutex −− A mult iprocess ing . Lock ob j e c t
147 resul t s_queue −− A mult iprocess ing . Queue ( ) ob j e c t f o r s t o r ing
the ca l cu la t ion output
148 i tems −− A l i s t , the input data required fo r the ca l cu la t ion
149
150 " " "
151
152 for item in items : s e l f . value_func ( item , results_queue )
153
154 mutex . acquire ( )
155 running . value −= 1
156 mutex . re lease ( )
157 results_queue . put ( s e l f . r e su l t s )
158
159 def value_func ( se l f , item , results_queue ) : # so overwri t ing th i s
function
160 " " " The de f in i t i on that ac tua l l y does the work .
161
162 Arguments :
163 item −− A l i s t or tuple , the input data required fo r the
ca l cu la t ion
164 resul t s_queue −− A mult iprocess ing . Queue ( ) ob j e c t f o r s t o r ing
the ca l cu la t ion output
165
166 " " "
167
168 # input1 = item [ 0 ]
169 # input2 = item [ 1 ]
170 # input3 = item [ 2 ]
171 # input4 = item [ 3 ]
172 # input5 = item [ 4 ]
173 # input6 = item [ 5 ]
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174
175 # use inputs to come up with a r e su l t , some_result
176




181 c lass ConvexHull ( ) :
182 " " "A c l a s s to handle convex−hul l ca l cu la t i on s " " "
183
184 def get_seg_dict_num( se l f , seg_dict , seg_index ) :
185 " " " s eg_d i c t i s a d i c t ionary ob j e c t that contains information
about segments within the convex hul l . The keys are 2x3
tuples , which represent two ends of a segment in space . The
values of s eg_d i c t are the number of times a segment has been
part of a t r iang l e , e i t h e r 1 or 2 . ( Zero times would mean
that the segment doesn ’ t e x i s t in the d i c t ionary y e t ) . This
function looks up and returns the value of a seg_index from
seg_d i c t
186
187 Arguments :
188 s eg_d i c t −− the d i c t ionary of segment 2x3 tuples as keys ,
i n t e g e r s as values
189 seg_index −− the key of the d i c t ionary member we are going to
r e t r i e v e
190
191 Returns :
192 i f seg_index e x i s t s in the keys of seg_d i c t , return the value .
Otherwise , return 0
193
194 " " "
195
196 i f seg_index [ 0 ] [ 0 ] > seg_index [ 1 ] [ 0 ] : # we want the index with
the g r ea t e r x−value , so we don ’ t ge t i d en t i c a l segments in
the d i c t ionary more than once
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197 index = seg_index
198 else :
199 index = seg_index [ : : − 1 ]
200
201 i f index in seg_dict :




206 def increment_seg_dict ( s e l f , seg_dict , seg_index ) :
207 " " " s eg_d i c t i s a d i c t ionary ob j e c t that contains information
about segments within the convex hul l . The keys are 2x3
tuples , which represent two ends of a segment in space . The
values of s eg_d i c t are the number of times a segment has been
part of a t r iang l e , e i t h e r 1 or 2 . ( Zero times would mean
that the segment doesn ’ t e x i s t in the d i c t ionary y e t ) . This
function increments the values within seg_d i c t , or i n i t i a t e s
them i f they dont e x i s t y e t .
208
209 Arguments :
210 s eg_d i c t −− the d i c t ionary of segment 2x3 tuples as keys ,
i n t e g e r s as values




214 None : the values of s eg_d i c t are r ece ived and modified by
r e f e r ence
215 " " "
216
217 i f seg_index [ 0 ] [ 0 ] > seg_index [ 1 ] [ 0 ] : # we want the index with
the g r ea t e r x−value , so we don ’ t ge t i d en t i c a l segments in
the d i c t ionary more than once
218 index = seg_index
219 else :
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220 index = seg_index [ : : − 1 ]
221
222 #" putt ing index : " , index , " into s eg_d i c t because " , index [ 0 ] [ 0 ] ,
">" , index [ 1 ] [ 0 ]
223
224 i f index in seg_dict : # i f the entry already e x i s t s in s eg_d i c t
225 seg_dict [ index ] += 1 # increment
226 else :
227 seg_dict [ index ] = 1 # i n i t i a t e with a value of 1 because i t now
e x i s t s on a t r i ang l e
228 return
229
230 def gift_wrapping_3d ( se l f , raw_points ) :
231 " " " G i f t wrapping fo r 3d convex hul l
232
233 Arguments :
234 raw_points −− A nx3 array of points , where each row corresponds
to an x , y , z point coordinate
235
236 Returns :
237 A convex hul l represented by a l i s t of t r i ang l e s . Each t r i ang l e
i s a 3x3 array , where each row i s an x , y , z coordinate in
space . The 3 rows descr ibe the loca t ion of the 3 corners of
the t r i ang l e . Each of the 3 points are arranged so that a
c ro s s product w i l l point outwards from the hul l
238
239
240 " " "
241
242 n = numpy. shape ( raw_points ) [ 0 ] # number of points
243 point1 = raw_points [ 0 ] # take the f i r s t point
244 xax i s = numpy. array ( [ 1 , 0 , 0 ] ) # c r ea t e a r e f vec tor pointing
along x axi s
245 maxx = raw_points [ 0 ] [ 0 ] # i n i t i a t e h ighes t x value
246 points = [ ] # a l i s t of tupl es fo r easy d i c t ionary lookup
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247 seg_dict = {} # a dic t ionary that contains the number of
t r i ang l e s a seg i s in
248
249 begintime = time . time ( )
250 for i in range (n) : # f ind the n with the l a r g e s t x value
251 point = tuple ( raw_points [ i ] )
252 points . append( point )
253 i f point [ 0 ] > maxx :
254 maxx = point [ 0 ]
255 point1 = raw_points [ i ]
256 #pr int " f ind max x : " , time . time ( ) − begintime
257
258 best_dot = −1.0 # i n i t i a t e dot r e l a t i v e to x−axi s
259 point2 = numpy. array ( raw_points [ 1 ] ) # i n i t i a t e bes t segment
260
261 # f ind f i r s t / bes t segment
262 begintime = time . time ( )
263 for i in range (n) :
264 point i = raw_points [ i ]
265 i f numpy. array_equal ( pointi , point1 ) : continue
266 d i f f _ vec = point i − point1
267 d i f f _ l en = numpy. l i n a l g . norm( d i f f _ vec )
268
269 tes t_dot = numpy. dot ( d i f f _ vec / d i f f _ l en , xax i s )
270 i f tes t_dot > best_dot :
271 best_dot = tes t_dot
272 point2 = point i
273
274 #pr int " f ind f i r s t segment : " , time . time ( ) − begintime
275 point1 = tuple ( point1 )
276 point2 = tuple ( point2 )
277 ref_vec = xax i s
278
279 # now find the bes t t r i ang l e
280 t r i ang l e s = [ ]
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281
282 s e g _ l i s t = set ( [ ( point1 , point2 ) , ] )
283 norm_dict = { ( point1 , point2 ) : xax i s }
284 s e l f . increment_seg_dict ( seg_dict , ( point1 , point2 ) )
285
286 counter = 0
287 f i r s t _ t ime = True
288
289 begintime = time . time ( )
290 section1 = 0 .0
291 section2 = 0 .0
292 section3 = 0 .0
293 while s e g _ l i s t : # as long as there are unexplored edges of
t r i ang l e s in the hul l . . .
294
295 counter += 1
296 seg = s e g _ l i s t . pop ( ) # take a segment out of the s e g _ l i s t
297 tuple1 = seg [ 0 ] # the two ends of the segment
298 tuple2 = seg [ 1 ]
299 point1 = numpy. array ( seg [ 0 ] )
300 point2 = numpy. array ( seg [ 1 ] )
301 r e su l t = s e l f . get_seg_dict_num( seg_dict , ( seg [ 0 ] , seg [ 1 ] ) )
302
303 i f r e su l t >= 2 : # then we already have 2 t r i ang l e s on th i s
segment
304 continue # f o r g e t about drawing a t r i ang l e fo r t h i s seg
305
306 ref_vec = norm_dict [ ( seg [ 0 ] , seg [ 1 ] ) ] # get the norm for a
t r i ang l e that the segment i s part of
307
308 best_dot_cross = −1.0
309 best_point = None
310
311 for i in range (n) : # look at each point
312
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313 point i = raw_points [ i ]
314 # i f numpy . array_equal ( pointi , point1 ) or numpy . array_equal (
pointi , point2 ) : continue # i f we are t r y ing one of the
points that are point1 or point2
315 di f f _vec1 = point2 − point1
316 # d i f f _ l en1 = numpy . l ina l g . norm( d i f f _ v ec1 )
317 di f f _vec2 = point i − point2
318 # d i f f _ l en2 = numpy . l ina l g . norm( d i f f _ v ec2 )
319
320 # t e s t _ c r o s s = numpy. c ro s s ( d i f f _ v ec1 / di f f_ l en1 , d i f f _ v ec2 /
d i f f _ l en2 )
321 # t e s t _ c r o s s = numpy. c ro s s ( d i f f_vec1 , d i f f _ v ec2 )
322 te s t _c ros s = numpy. array ( [ di f f _vec1 [ 1 ] ∗ di f f _vec2 [2 ]− di f f _vec1
[ 2 ] ∗ di f f _vec2 [ 1 ] , d i f f _vec1 [ 2 ] ∗ di f f _vec2 [0 ]− di f f _vec1 [ 0 ] ∗
di f f _vec2 [ 2 ] , d i f f _vec1 [ 0 ] ∗ di f f _vec2 [1 ]− di f f _vec1 [ 1 ] ∗
di f f _vec2 [ 0 ] ] ) # c ro s s product
323
324 te s t _c ros s_ l en = numpy. sqr t ( t e s t _c ros s [ 0 ] ∗ t e s t _c ros s [ 0 ] +
t e s t _c ros s [ 1 ] ∗ t e s t _c ros s [ 1 ] + t e s t _c ros s [ 2 ] ∗ t e s t _c ros s [ 2 ] ) #
numpy . l ina l g . norm( t e s t _ c r o s s ) # ge t the norm of the c ro s s
product
325
326 i f t e s t _c ros s_ l en <= 0 . 0 : continue
327 # t e s t _ c r o s s _ l en_ inv = 1 / t e s t _ c r o s s _ l e n
328 te s t _c ros s = t e s t _c ros s / t e s t _c ros s_ l en
329 dot_cross = numpy. dot ( tes t_cross , re f_vec )
330 #dot_cross = t e s t _ c r o s s [ 0 ] ∗ r e f _v ec [ 0 ] + t e s t _ c r o s s [ 1 ] ∗ r e f _v ec [ 1 ]
+ t e s t _ c r o s s [ 2 ] ∗ r e f _v ec [ 2 ]
331 i f dot_cross > best_dot_cross :
332 best_cross = t e s t _c ros s
333 best_dot_cross = dot_cross
334 best_point = point i




338 point3 = best_point
339
340 i f s e l f . get_seg_dict_num( seg_dict , ( tuple2 , tuple1 ) ) > 2 :
continue
341 i f s e l f . get_seg_dict_num( seg_dict , ( tuple3 , tuple2 ) ) > 2 :
continue
342 i f s e l f . get_seg_dict_num( seg_dict , ( tuple1 , tuple3 ) ) > 2 :
continue
343
344 # now we have a t r i ang l e from point1 −> point2 −> point3
345 # must t e s t each edge
346 i f f i r s t _ t ime :
347 s e l f . increment_seg_dict ( seg_dict , ( tuple2 , tuple1 ) )
348 s e g _ l i s t . add ( ( tuple2 , tuple1 ) )
349 norm_dict [ ( tuple2 , tuple1 ) ] = best_cross
350
351 s e l f . increment_seg_dict ( seg_dict , ( tuple3 , tuple2 ) )
352 s e g _ l i s t . add ( ( tuple3 , tuple2 ) )
353 norm_dict [ ( tuple3 , tuple2 ) ] = best_cross
354
355 s e l f . increment_seg_dict ( seg_dict , ( tuple1 , tuple3 ) )
356 s e g _ l i s t . add ( ( tuple1 , tuple3 ) )
357 norm_dict [ ( tuple1 , tuple3 ) ] = best_cross
358
359 t r i ang l e s . append ( (numpy. array ( tuple1 ) ,numpy. array ( tuple2 ) ,numpy.
array ( tuple3 ) ) )
360
361 f i r s t _ t ime = False
362
363 #pr int " f ind a l l t r i ang l e s : " , time . time ( ) − begintime
364
365 #pr int " sec t ion1 : " , s ec t ion1
366 #pr int " sec t ion2 : " , s ec t ion2
367 #pr int " sec t ion3 : " , s ec t ion3
368 return t r i ang l e s
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369
370 def ak l_ toussa in t ( s e l f , points ) :
371 " " " The Akl−Toussaint Heur i s t i c . Given a s e t of points , t h i s
de f in i t i on wi l l c r ea t e an octahedron whose corners are the
extremes in x , y , and z d i r e c t i on s . Every point within th i s
octahedron wi l l be removed because they are not part of the
convex hul l . This causes any expected running time fo r a
convex hul l algorithm to be reduced to l inea r time .
372
373 Arguments :
374 points −− An nx3 array of x , y , z coordinates
375
376 Returns :
377 Al l members of o r i g ina l s e t of points that f a l l outs ide the Akl−
Toussaint octahedron
378
379 " " "
380
381 x_high = (−1e99 , 0 , 0 ) ; x_low = (1e99 , 0 , 0 ) ; y_high = (0 ,−1e99 , 0 ) ;
y_low = (0 ,1 e99 , 0 ) ; z_high = (0 ,0 ,−1e99 ) ; z_low = (0 ,0 ,1 e99 )
382
383
384 for point in points : # f ind the corners of the octahedron
385 i f point [ 0 ] > x_high [ 0 ] : x_high = point
386 i f point [ 0 ] < x_low [ 0 ] : x_low = point
387 i f point [ 1 ] > y_high [ 1 ] : y_high = point
388 i f point [ 1 ] < y_low [ 1 ] : y_low = point
389 i f point [ 2 ] > z_high [ 2 ] : z_high = point
390 i f point [ 2 ] < z_low [ 2 ] : z_low = point
391
392 octahedron = [ # def ine the t r i ang l e s of the su r fa ce s of the
octahedron
393 numpy. array ( ( x_high , y_high , z_high ) ) ,
394 numpy. array ( ( x_high , z_low , y_high ) ) ,
395 numpy. array ( ( x_high , y_low , z_low ) ) ,
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396 numpy. array ( ( x_high , z_high , y_low ) ) ,
397 numpy. array ( ( x_low , y_low , z_high ) ) ,
398 numpy. array ( ( x_low , z_low , y_low ) ) ,
399 numpy. array ( ( x_low , y_high , z_low ) ) ,
400 numpy. array ( ( x_low , z_high , y_high ) ) ,
401 ]
402 new_points = [ ] # every thing outs ide of the octahedron
403 for point in points : # now check to see i f a point i s ins ide or
outs ide the octahedron
404 outside = s e l f . outs ide_hul l ( point , octahedron , epsi lon=−1.0e−5)
405 i f outside :
406 new_points . append( point )
407
408 return numpy. array ( new_points ) # conver t back to an array
409
410 def outs ide_hul l ( s e l f , our_point , t r i ang l e s , epsi lon=1.0e−5) :
411 " " " Given the hul l as defined by a l i s t of t r i ang l e s , t h i s




414 our_point −− an x , y , z array that i s being t e s t ed to see whether
i t e x i s t s ins ide the hul l or not
415 t r i ang l e s −− a l i s t of t r i ang l e s that def ine the hul l




419 True i f our_point e x i s t s outs ide of the hull , Fa l se otherwise
420
421 " " "
422
423 our_point = numpy. array ( our_point ) # conver t i t to an numpy .
array
424 for t r i ang l e in t r i ang l e s :
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425 re l_po int = our_point − t r i ang l e [ 0 ] # vec tor from t r i ang l e
corner 0 to point
426 vec1 = t r i ang l e [ 1 ] − t r i ang l e [ 0 ] # vec tor from t r i ang l e corner 0
to corner 1
427 vec2 = t r i ang l e [ 2 ] − t r i ang l e [ 1 ] # vec tor from t r i ang l e corner 1
to corner 2
428 our_cross = numpy. cross ( vec1 , vec2 ) # c ro s s product between vec1
and vec2
429 our_dot = numpy. dot ( re l_point , our_cross ) # dot product to
determine whether c ro s s i s point inward or outward
430 i f numpy. dot ( re l_point , our_cross ) > epsi lon : # i f the dot i s





435 def unique_rows ( a ) :
436 " " " I d e n t i f i e s unique points ( rows ) in an array of points .
437
438 Arguments :
439 a −− A nx3 numpy . array represent ing 3D points .
440
441 Returns :
442 A nx2 numpy . array containing the 3D points that are unique .
443
444 " " "
445
446 a [ a == −0.0 ] = 0 .0
447 b = numpy. ascontiguousarray ( a ) . view (numpy. dtype ( (numpy. void , a .
dtype . i temsize ∗ a . shape [ 1 ] ) ) )




452 def create_pdb_l ine ( numpy_array , index , resname , l e t t e r ) :
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453 " " " Create a s t r i n g formatted according to the PDB standard .
454
455 Arguments :
456 numpy_array −− A 1x3 numpy . array represent ing a 3D point .




460 A st r ing , formatted according to the PDB standard .
461
462 " " "
463
464 i f len ( numpy_array ) == 2 : numpy_array = numpy. array ( [ numpy_array
[ 0 ] , numpy_array [ 1 ] , 0 . 0 ] )
465 i f numpy_array . shape == (1 , 3) : numpy_array = numpy_array [ 0 ]
466
467 output = "ATOM "
468 output = output + s t r ( index % 999999) . r j u s t ( 6 ) + l e t t e r . r j u s t ( 5 )
+ resname . r j u s t ( 4 ) + l e t t e r . r j u s t ( 2 ) + s t r ( index % 9999) .
r j u s t ( 4 )
469 output = output + ( "%.3 f " % numpy_array [ 0 ] ) . r j u s t (12 )
470 output = output + ( "%.3 f " % numpy_array [ 1 ] ) . r j u s t ( 8 )
471 output = output + ( "%.3 f " % numpy_array [ 2 ] ) . r j u s t ( 8 )




476 def numpy_to_pdb( narray , l e t t e r , resname=" " ) :
477 " " " Create a s t r i n g formatted according to the PDB standard .
478
479 Arguments :
480 narray −− A nx3 numpy . array represent ing a 3D point .





484 ( Optional ly ) A s t r ing , formatted according to the PDB standard .
485
486 " " "
487
488 i f len ( narray . f l a t t e n ( ) ) == 3 :
489 return create_pdb_l ine ( narray , 1 , "AAA" , l e t t e r ) + "\n"
490 else :
491 i f resname == " " :
492 l e t t e r s = [ "A" , "B" , "C" , "D" , "E" , "F" , "G" , "H" , " I " , " J " , "K"
, "L" , "M" , "N" , "O" , "P" , "Q" , "R" , "S" , "T" , "U" , "V" , "W" ,
"X" , "Y" , "Z" ]
493 resnames = [ ]
494 for l 1 in l e t t e r s :
495 for l 2 in l e t t e r s :
496 for l 3 in l e t t e r s :
497 resnames . append( l1+l 2+ l 3 )
498 resnames . remove ( "XXX" ) # because th i s i s r e served fo r empty
atoms
499 else :
500 resnames = [ resname ]
501
502 t = " "
503 for i , item in enumerate( narray ) : t = t + create_pdb_l ine ( item ,
i +1 , resnames [ i % len ( resnames ) ] , l e t t e r ) + "\n"
504 return t
505
506 def dx_freq ( freq_mat , parameters ) :
507 ’ ’ ’
508 Generates a DX f i l e that r ecords the frequency that a volume
element i s open
509
510 Arguments :
511 freq_mat −− a Nx4 matrix , where the f i r s t 3 columns are the x , y ,
z coords of the point , and the 4th column i s the frequency of
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emptiness fo r that point in space
512
513 ’ ’ ’
514
515 header_template = " " " # Data from POVME 2 . 0 . 1
516 #
517 # FREQUENCY ( un i t l e s s )
518 #
519 ob j e c t 1 c l a s s g r idpos i t i on s counts %d %d %d
520 or ig in %8.6e %8.6e %8.6e
521 del ta %8.6e 0.000000e+00 0.000000e+00
522 del ta 0.000000e+00 %8.6e 0.000000e+00
523 del ta 0.000000e+00 0.000000e+00 %8.6e
524 ob j e c t 2 c l a s s gr idconnect ions counts %d %d %d
525 ob j e c t 3 c l a s s array type double rank 0 items %d data fo l lows
526 " " "
527
528 footer_template = " " "
529 a t t r i bu t e "dep " s t r i n g " pos i t i on s "
530 ob j e c t " regular pos i t i on s regular connections " c l a s s f i e l d
531 component " pos i t i on s " value 1
532 component " connections " value 2
533 component " data " value 3 " " "
534
535 # 1 . Sor t the points into the proper order fo r a dx f i l e
536
537 # already sor t ed c o r r e c t l y
538
539 # 2 . Obtain key information about the gr id
540 N = freq_mat . shape [ 0 ] # number of data points
541
542 minx = min( freq_mat [ : , 0 ] )
543 miny = min( freq_mat [ : , 1 ] )
544 minz = min( freq_mat [ : , 2 ] ) # f ind the upper and lower corners of
the gr id
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545 maxx = max( freq_mat [ : , 0 ] )
546 maxy = max( freq_mat [ : , 1 ] )
547 maxz = max( freq_mat [ : , 2 ] )
548
549 widthx = maxx − minx # f ind the widths of the gr id
550 widthy = maxy − miny
551 widthz = maxz − minz
552
553 xs = numpy. unique ( freq_mat [ : , 0 ] )
554 ys = numpy. unique ( freq_mat [ : , 1 ] )
555 zs = numpy. unique ( freq_mat [ : , 2 ] )
556
557 resx = xs [1 ]− xs [ 0 ]
558 resy = ys [1 ]− ys [ 0 ]
559 resz = zs [1 ]− zs [ 0 ]
560
561 # resx = freq_mat [ ( widthz+1) ∗ ( widthy+1) , 0 ] − freq_mat [0 , 0 ]
562 # r e s y = freq_mat [widthz+1 ,1 ] − freq_mat [0 , 1 ] # f ind the
r e so lu t i on of the gr id
563 # r e s z = freq_mat [1 , 2 ] − freq_mat [0 , 2 ]
564
565 nx = ( widthx ) / resx + 1 # number of gr id points in each
dimension
566 ny = ( widthy ) / resy + 1 # need to add one because the
subt rac t ion l eaves out an en t i r e row
567 nz = ( widthz ) / resz + 1
568
569 # t e s t to make sure a l l i s wel l with the s i z e of the gr id and
i t s dimensions
570 as se r t ( nx ∗ ny ∗ nz ) == N, "Something i s wrong with the
freq_mat array : i t i s not a prismatic shape"
571
572 # 3 . wri te the header and foo t e r
573 i f parameters [ ’ SaveVolumetricDensityMap ’ ] == True :
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574 i f parameters [ ’ CompressOutput ’ ] == True : d x _ f i l e = gzip . open (
parameters [ ’ OutputFilenamePrefix ’ ] + " volumetric_density . dx .
gz" , ’wb ’ )
575 else : d x _ f i l e = open ( parameters [ ’ OutputFilenamePrefix ’ ] + "
volumetric_density . dx" , ’w ’ )
576
577 header = header_template % (nx , ny , nz , minx , miny , minz , resx ,
resy , resz , nx , ny , nz , N) # format the header
578 footer = footer_template # the f oo t e r needs no formatting
579 dx _ f i l e . wri te ( header )
580 newline_counter = 1
581 for i in range (N) : # wri te the data to the DX f i l e
582 dx _ f i l e . wri te ( "%8.6e" % freq_mat [ i , 3 ] )
583 i f newline_counter == 3 :
584 newline_counter = 0
585 dx _ f i l e . wri te ( "\n" )
586 else :
587 dx _ f i l e . wri te ( " " )
588 newline_counter += 1
589 dx _ f i l e . wri te ( footer )
590 dx _ f i l e . c lose
591 return
592
593 c lass MultithreadingCalcVolumeTask ( MultithreadingTaskGeneral ) :
594 ’ ’ ’ A c l a s s fo r ca l cu la t ing the volume . ’ ’ ’
595
596 def value_func ( se l f , item , results_queue ) :
597 " " " Calculate the volume .
598
599 Arguments :
600 item −− A l i s t or tuple , the input data required fo r the
ca l cu la t ion
601 resul t s_queue −− A mult iprocess ing . Queue ( ) ob j e c t f o r s t o r ing
the ca l cu la t ion output
602
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603 " " "
604
605 frame_indx = item [ 0 ]
606 pdb = item [ 1 ]
607 parameters = item [ 2 ]
608 # pts = parameters [ ’ p t s _o r i g ’ ] . copy ( ) # th i s works
609 pts = parameters [ ’ p t s_or ig ’ ] # also works , so keep because
f a s t e r
610
611 # i f the user wants to save empty points ( points that are
removed ) , then we need a copy of the or i g ina l
612 i f parameters [ ’OutputEqualNumPointsPerFrame ’ ] == True :
613 pts_deleted = pts . copy ( )
614
615 # you may need to load i t from disk i f the user so sp e c i f i ed
616 i f parameters [ ’UseDiskNotMemory ’ ] == True : # so you need to load
i t from disk
617 pym_filename = pdb
618 pdb = pymolecule . Molecule ( )
619 pdb . f i l e i o . load_pym_into ( pym_filename )
620
621 # remove the points that are fa r from the points region anyway
622 min_pts = numpy.min( pts , 0 ) − parameters [ ’ DistanceCutoff ’ ] − 1
623 max_pts = numpy.max( pts , 0 ) + parameters [ ’ DistanceCutoff ’ ] + 1
624
625 # i d en t i f y atoms that are so fa r away from points that they can
be ignored
626 index_to_keep1 = numpy. nonzero ( ( pdb . information . coordinates [ : , 0 ]
> min_pts [ 0 ] ) ) [ 0 ] # x ’ s too small
627 index_to_keep2 = numpy. nonzero ( ( pdb . information . coordinates [ : , 0 ]
< max_pts [ 0 ] ) ) [ 0 ] # x ’ s too la rge
628 index_to_keep3 = numpy. nonzero ( ( pdb . information . coordinates [ : , 1 ]
> min_pts [ 1 ] ) ) [ 0 ] # y ’ s too small
629 index_to_keep4 = numpy. nonzero ( ( pdb . information . coordinates [ : , 1 ]
< max_pts [ 1 ] ) ) [ 0 ] # y ’ s too la rge
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630 index_to_keep5 = numpy. nonzero ( ( pdb . information . coordinates [ : , 2 ]
> min_pts [ 2 ] ) ) [ 0 ] # z ’ s too small
631 index_to_keep6 = numpy. nonzero ( ( pdb . information . coordinates [ : , 2 ]
< max_pts [ 2 ] ) ) [ 0 ] # z ’ s too la rge
632
633 index_to_keep = numpy. in tersect1d ( index_to_keep1 , index_to_keep2
, assume_unique=True )
634 index_to_keep = numpy. in tersect1d ( index_to_keep , index_to_keep3 ,
assume_unique=True )
635 index_to_keep = numpy. in tersect1d ( index_to_keep , index_to_keep4 ,
assume_unique=True )
636 index_to_keep = numpy. in tersect1d ( index_to_keep , index_to_keep5 ,
assume_unique=True )
637 index_to_keep = numpy. in tersect1d ( index_to_keep , index_to_keep6 ,
assume_unique=True )
638
639 # keep only re l evant atoms
640 i f len ( index_to_keep ) > 0 : pdb = pdb . se l ec t ions .
create_molecule_from_selection ( index_to_keep )
641
642 # get the vdw rad i i of each protein atom
643 vdw = numpy. ones ( len (pdb . information . coordinates ) ) # so the
de fau l t vdw i s 1 .0
644
645 # get vdw . . . you might want to f i l l t h i s out with addi t ional vdw
values
646 vdw [numpy. nonzero (pdb . information . atom_information [ ’
element_stripped ’ ] == "H" ) [ 0 ] ] = 1 .2
647 vdw [numpy. nonzero (pdb . information . atom_information [ ’
element_stripped ’ ] == "C" ) [ 0 ] ] = 1 .7
648 vdw [numpy. nonzero (pdb . information . atom_information [ ’
element_stripped ’ ] == "N" ) [ 0 ] ] = 1.55
649 vdw [numpy. nonzero (pdb . information . atom_information [ ’
element_stripped ’ ] == "O" ) [ 0 ] ] = 1.52
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650 vdw [numpy. nonzero (pdb . information . atom_information [ ’
element_stripped ’ ] == "F" ) [ 0 ] ] = 1.47
651 vdw [numpy. nonzero (pdb . information . atom_information [ ’
element_stripped ’ ] == "P" ) [ 0 ] ] = 1 .8
652 vdw [numpy. nonzero (pdb . information . atom_information [ ’
element_stripped ’ ] == "S" ) [ 0 ] ] = 1 .8
653 vdw = numpy. repeat (numpy. array ( [ vdw ] ) . T , len ( pts ) , ax i s=1)
654
655 # now id en t i f y the points that are c l o s e to the protein atoms
656 d i s t s = cd i s t (pdb . information . coordinates , pts )
657 close_pt_index = numpy. nonzero ( ( d i s t s < (vdw + parameters [ ’
DistanceCutoff ’ ] ) ) ) [ 1 ]
658
659 #save points ins ide protein or l igand
660 rememberedall = pts
661
662 # now keep the appropriate points
663 pts = numpy. delete ( pts , close_pt_index , ax i s=0)
664
665 # exclude points outs ide convex hul l
666 i f parameters [ ’ ConvexHullExclusion ’ ] == True :
667 convex_hull_3d = ConvexHull ( )
668
669 # get the coordinates of the non−hydrogen atoms ( f a s t e r to
discard hydrogens )
670 hydros = pdb . se l ec t ions . select_atoms ( { ’ element_stripped ’ : [ ’H’ ] } )
671 not_hydros = pdb . se l ec t ions . inve r t _ se l ec t ion ( hydros )
672 not_hydros_coors = pdb . information . coordinates [ not_hydros ]
673
674 #not_hydros = pdb . s e l e c t i on s . se lect_atoms ( { ’ name_stripped ’ : [ ’ CA
’ ] } )
675 #not_hydros_coors = pdb . information . coordinates [ not_hydros ]
676
677 # modify pts here .
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678 # note that the atoms of the pdb frame are in pdb . information .
coordinates
679 #begintime = time . time ( ) # measure execution time
680 ak l_ toussa in t_pts = convex_hull_3d . ak l_ toussa in t (
not_hydros_coors ) # quickly reduces input s i z e
681 #pr int " akl Toussaint : " , time . time ( ) − begintime
682 begintime = time . time ( ) # measure execution time
683 hu l l = convex_hull_3d . gift_wrapping_3d ( ak l_ toussa in t_pts ) #
ca l cu la t e convex hul l using g i f t wrapping algorithm
684 #pr int " gi ft_wrapping : " , time . time ( ) − begintime
685
686 old_pts = pts # we wi l l need to regenera te the pts l i s t ,
d i sregarding those outs ide the hul l
687 pts = [ ]
688 for pt in old_pts :
689 pt_outside = convex_hull_3d . outs ide_hul l ( pt , hu l l ) # check i f pt
i s outs ide hul l
690 i f not pt_outside :
691 pts . append( pt ) # i f i t s not outs ide the hull , then include i t in
the volume measurement
692 pts = numpy. array ( pts )
693
694 # Now, enforce con t i gu i t y i f needed
695 i f len ( parameters [ ’ ContiguousPocketSeedRegions ’ ] ) > 0 and len (
pts ) > 0 :
696 # f i r s t , f o r each point , determine how many neighbors i t has
697 cu to f f _d i s t = parameters [ ’ GridSpacing ’ ] ∗ 1.01 ∗ math . sqr t ( 3 ) #
to count kiddy−corner points too
698 p t s_d i s t s = squareform ( pdis t ( pts ) )
699 neighbor_counts = numpy.sum( p t s _d i s t s < cu to f f _d i s t , ax i s=0) − 1
# minus 1 because an atom shouldn ’ t be considered i t s own
neighor
700
701 # remove a l l the points that don ’ t have enough neighbors
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702 pts = pts [numpy. nonzero ( neighbor_counts >= parameters [ ’
Cont iguousPointsCri ter ia ’ ] ) [ 0 ] ]
703
704 # get a l l the points in the defined parameters [ ’ ContiguousPocket
’ ] seed reg ions
705 cont ig_pts = parameters [ ’ ContiguousPocketSeedRegions ’ ] [ 0 ] .
points_set ( parameters [ ’ GridSpacing ’ ] )
706 for Contig in parameters [ ’ ContiguousPocketSeedRegions ’ ] [ 1 : ] :
cont ig_pts = numpy. vstack ( ( contig_pts , Contig . points_set (
parameters [ ’ GridSpacing ’ ] ) ) )
707 cont ig_pts = unique_rows ( cont ig_pts )
708
709 try : # e r ro r here i f there are no points of contiguous seed
region outs ide of prote in volume .
710 # now ju s t ge t the ones that are not near the protein
711 cont ig_pts = pts [numpy. nonzero ( cd i s t ( contig_pts , pts ) < 1e−7)
[ 1 ] ]
712
713 la s t _ s i ze_o f _con t i g_p t s = 0
714 while l a s t _ s i ze_o f _con t i g_p t s != len ( cont ig_pts ) :
715 l a s t _ s i ze_o f _con t i g_p t s = len ( cont ig_pts )
716
717 # now get the indec i e s of a l l points that are c l o s e to the
cont ig_pt s
718 al l_pts_close_to_cont ig_pts_boolean = ( cd i s t ( pts , cont ig_pts ) <
cu to f f _d i s t )
719 index_a l l _p ts_c lose_ to_cont ig_pts = numpy. unique (numpy. nonzero (
a l l_pts_close_to_cont ig_pts_boolean ) [ 0 ] )
720 cont ig_pts = pts [ index_a l l _p ts_c lose_ to_cont ig_pts ]
721
722 pts = cont ig_pts
723
724 except :
725 log ( "\ tFrame " + s t r ( frame_indx ) + " : None of the points in the
contiguous−pocket seed region \n\ t \ ta re outside the volume of
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the protein ! Assuming a pocket \n\ t \ tvolume of 0 .0 A . " ,
parameters )
726 pts = numpy. array ( [ ] )
727
728 #make l i s t s from whole s e t and f i na l pts s e t
729 print ( rememberedall )
730 rememberedal l_ l is t = rememberedall . t o l i s t ( )
731 print ( rememberedal l_ l is t )
732
733 print ( pts )
734 p t s _ l i s t = pts . t o l i s t ( )
735 print ( p t s _ l i s t )
736
737 # f ind not−shared points of both l i s t s
738 res t = tuple ( x for x in rememberedal l_ l is t i f x not in p t s _ l i s t )
739 print ( r e s t )
740 res ta r ray = numpy. asarray ( re s t )
741
742 # wri te the remembered points ( ins ide protein ) to . pdb
743 i f parameters [ ’ SaveIndividualPocketVolumes ’ ] == True :
744 remem_text = " "
745 remem_text = remem_text + "REMARK Frame " + s t r ( frame_indx ) + "
\n"
746 remem_text = remem_text + numpy_to_pdb( res ta r ray , ’X ’ )
747 remem_text = remem_text + "END\n"
748
749 f l = open ( parameters [ ’ OutputFilenamePrefix ’ ] + "
inLigOrProt_frame_ " + s t r ( frame_indx ) + " . pdb" , ’w ’ )
750 f l . wri te ( remem_text )
751 f l . c lose
752
753 # now wri te the pdb and ca l cu la t e the volume
754 volume = len ( pts ) ∗ math .pow( parameters [ ’ GridSpacing ’ ] , 3 )
755
133
756 log ( "\ tFrame " + s t r ( frame_indx ) + " : " + repr ( volume) + " A^3" ,
parameters )
757 i f parameters [ ’ SaveIndividualPocketVolumes ’ ] == True :
758 frame_text = " "
759 frame_text = f rame_text + "REMARK Frame " + s t r ( frame_indx ) + "\
n"
760 frame_text = f rame_text + "REMARK Volume = " + repr ( volume) + "
Cubic Angtroms\n"
761 frame_text = f rame_text + numpy_to_pdb( pts , ’X ’ )
762
763 i f parameters [ ’OutputEqualNumPointsPerFrame ’ ] == True :
764 # you need to f ind the points that are in pt s_de l e t ed but not in
pts
765 tmp = reduce ( lambda x , y : x | numpy. a l l ( pts_deleted == y , ax i s
=−1) , pts , numpy. zeros ( pts_deleted . shape [ : 1 ] , dtype=numpy.
bool ) )
766 indices = numpy. where (tmp) [ 0 ]
767 pts_deleted = numpy. delete ( pts_deleted , indices , ax i s=0)
768
769 pts_deleted = numpy. zeros ( pts_deleted . shape ) # So extra points
w i l l always be at the or ig in . These can be ea s i l y hidden with
your v i sua l i za t i on software .
770 frame_text = f rame_text + numpy_to_pdb( pts_deleted , ’X ’ , "XXX" )
771
772 frame_text = f rame_text + "END\n"
773
774 i f parameters [ ’ CompressOutput ’ ] == True : f l = gzip . open (
parameters [ ’ OutputFilenamePrefix ’ ] + " frame_" + s t r (
frame_indx ) + " . pdb . gz" , ’wb ’ )
775 else : f l = open ( parameters [ ’ OutputFilenamePrefix ’ ] + " frame_" +
s t r ( frame_indx ) + " . pdb" , ’w ’ )
776 f l . wri te ( frame_text )
777 f l . c lose ( )
778
779 extra_data_to_add = {}
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780 i f parameters [ ’ SaveVolumetricDensityMap ’ ] == True :
extra_data_to_add [ ’ SaveVolumetricDensityMap ’ ] = pts
781
782 s e l f . r e su l t s . append ( ( frame_indx , volume , extra_data_to_add ) )
783
784 # i f len ( extra_data_to_add . keys ( ) ) != 0 :
785 # e l s e : s e l f . r e s u l t s . append ( ( frame_indx , volume ) )
786
787 c lass MultithreadingStringToMoleculeTask (
MultithreadingTaskGeneral ) :
788 ’ ’ ’ A c l a s s fo r loading PDB frames ( as s t r i n g s ) into pymolecule .
Molecule ob j e c t s . ’ ’ ’
789
790 def value_func ( se l f , item , results_queue ) :
791 " " " Convert a PDB s t r i n g into a pymolecule . Molecule ob j e c t
792
793 Arguments :
794 item −− A l i s t or tuple , the input data required fo r the
ca l cu la t ion
795 resul t s_queue −− A mult iprocess ing . Queue ( ) ob j e c t f o r s t o r ing
the ca l cu la t ion output
796
797 " " "
798
799 pdb_string = item [ 0 ]
800 index = item [ 1 ]
801 parameters = item [ 2 ]
802
803 # make the pdb ob j e c t
804 s t r_ob j = StringIO ( pdb_string )
805 tmp = pymolecule . Molecule ( )
806 tmp . f i l e i o . load_pdb_into_us ing_f i le_object ( s t r_obj , False , False
, False )
807
808 log ( "\ tFurther processing frame " + s t r ( index ) , parameters )
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809
810 i f parameters [ ’UseDiskNotMemory ’ ] == False : # so load the whole
t r a j e c t o r y into memory
811 s e l f . r e su l t s . append ( ( index , tmp) )
812 else : # save to disk , record filename
813 pym_filename = " . " + os . sep + " . povme_tmp" + os . sep + " frame_" +
s t r ( index ) + " .pym"
814 tmp . f i l e i o . save_pym( pym_filename , False , False , False , False ,
False )
815 s e l f . r e su l t s . append ( ( index , pym_filename ) )
816
817 c lass Region :
818 ’ ’ ’ A c l a s s fo r def ining reg ions that w i l l be f i l l e d with points .
’ ’ ’
819
820 def __ in i t _ _ ( s e l f ) :
821 ’ ’ ’ I n i t i a l i z e some va r iab l e s . ’ ’ ’
822
823 s e l f . center = numpy. array ( [9999 . 9 , 9999 .9 , 9999 . 9 ] )
824 s e l f . radius = 9999.9 # in case the region i s a sphere
825 s e l f . box_dimen = numpy. array ( [9999 . 9 , 9999 .9 , 9999 . 9 ] ) # in case
the region i s a box
826
827 s e l f . region_type = "SPHERE" # could also be BOX
828
829 def __s t r__ ( s e l f ) :
830 ’ ’ ’ Returns a s t r i n g representa t ion of the region . ’ ’ ’
831
832 i f s e l f . region_type == "SPHERE" : return " sphere at ( " + s t r ( s e l f
. center [ 0 ] ) + " , " + s t r ( s e l f . center [ 1 ] ) + " , " + s t r ( s e l f .
center [ 2 ] ) + " ) , radius = " + s t r ( s e l f . radius )
833 i f s e l f . region_type == "BOX" : return "box centered at ( " + s t r (
s e l f . center [ 0 ] ) + " , " + s t r ( s e l f . center [ 1 ] ) + " , " + s t r (
s e l f . center [ 2 ] ) + " ) with x , y , z dimensions of ( " + s t r ( s e l f .
box_dimen [ 0 ] ) + " , " + s t r ( s e l f . box_dimen [ 1 ] ) + " , " + s t r (
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s e l f . box_dimen [ 2 ] ) + " ) "
834 return ’ ’
835
836 def __snap ( se l f , pts , reso ) :
837 " " " Snaps a s e t of points to a f i x ed gr id .
838
839 Arguments :
840 pts −− A nx3 numpy. array represent ing 3D points .
841 r e so −− A f l oa t , the r e so lu t i on of the gr id .
842
843 Returns :
844 A nx3 numpy . array with the 3D points snapped to the neares t gr id
point .
845
846 " " "
847
848 # unfortunately , numpy . around rounds evenly , so 0 .5 rounds to
0 .0 and 1.5 rounds to 2 . 0 .
849 # very annoying , I ’ l l j u s t add a t iny amount to 0 .5 => 0.500001
850 # th i s should work , s ince user i s unl ike l y to s e l e c t region
center or radius with such
851 # pr ec i s i on
852
853 pts = pts + 1e−10
854 return numpy. around ( pts / reso ) ∗ reso
855
856 def points_set ( s e l f , reso ) :




860 r e so −− A f l oa t , the r e so lu t i on of the gr id on which the points




863 A nx3 numpy . array with the 3D points f i l l i n g the region .
864
865 " " "
866
867 to t a l _p t s = None
868
869 i f s e l f . region_type == "BOX" :
870 xs = numpy. arange ( s e l f . center [ 0 ] − s e l f . box_dimen [ 0 ] / 2 , s e l f .
center [ 0 ] + s e l f . box_dimen [ 0 ] / 2 , reso )
871 ys = numpy. arange ( s e l f . center [ 1 ] − s e l f . box_dimen [ 1 ] / 2 , s e l f .
center [ 1 ] + s e l f . box_dimen [ 1 ] / 2 , reso )
872 zs = numpy. arange ( s e l f . center [ 2 ] − s e l f . box_dimen [ 2 ] / 2 , s e l f .
center [ 2 ] + s e l f . box_dimen [ 2 ] / 2 , reso )
873
874 to t a l _p t s = numpy. empty ( ( len ( xs ) ∗ len ( ys ) ∗ len ( zs ) , 3) )
875
876 i = 0
877 for x in xs :
878 for y in ys :
879 for z in zs :
880 to t a l _p t s [ i ] [ 0 ] = x
881 to t a l _p t s [ i ] [ 1 ] = y
882 to t a l _p t s [ i ] [ 2 ] = z
883
884 i = i + 1
885
886 to t a l _p t s = s e l f . __snap ( to ta l_pts , reso )
887
888 e l i f s e l f . region_type == "SPHERE" :
889 xs = numpy. arange ( s e l f . center [ 0 ] − s e l f . radius , s e l f . center [ 0 ] +
s e l f . radius , reso )
890 ys = numpy. arange ( s e l f . center [ 1 ] − s e l f . radius , s e l f . center [ 1 ] +
s e l f . radius , reso )
891 zs = numpy. arange ( s e l f . center [ 2 ] − s e l f . radius , s e l f . center [ 2 ] +
s e l f . radius , reso )
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892
893 to t a l _p t s = numpy. empty ( ( len ( xs ) ∗ len ( ys ) ∗ len ( zs ) , 3) )
894
895 i = 0
896 for x in xs :
897 for y in ys :
898 for z in zs :
899 to t a l _p t s [ i ] [ 0 ] = x
900 to t a l _p t s [ i ] [ 1 ] = y
901 to t a l _p t s [ i ] [ 2 ] = z
902
903 i = i + 1
904
905 to t a l _p t s = s e l f . __snap ( to ta l_pts , reso )
906
907 # now remove a l l the points outs ide of t h i s sphere
908 index_inside_sphere = numpy. nonzero ( cd i s t ( to ta l_pts , numpy. array
( [ s e l f . center ] ) ) < s e l f . radius ) [ 0 ]
909 to t a l _p t s = t o t a l _p t s [ index_inside_sphere ]
910
911 return t o t a l _p t s
912
913 c lass Conf igFi le :
914 ’ ’ ’ A c l a s s fo r proces s ing the user−provided configurat ion f i l e .
’ ’ ’
915
916 en t i t i e s = [ ]
917
918 def __ in i t _ _ ( s e l f , FileName ) :




922 FileName −− A st r ing , the fi lename of the configurat ion f i l e .
923
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924 " " "
925
926 f = open ( FileName , ’ r ’ )
927 l ines = f . read l ines ( )
928 f . c lose ( )
929
930 for l i ne in l i nes :
931 # remove comments
932 l ine = l i ne . s p l i t ( "#" ,1 ) [ 0 ]
933 # l ine = l i n e . s p l i t ( " / / " , 1 ) [ 0 ] # We can ’ t have these kinds of
comments any more because of Windows fi lenames .
934
935 l ine = l i ne . s t r i p ( )
936
937 i f l i ne != " " :
938
939 # rep lace ; and , and : with space
940 # l ine = l i n e . r ep lace ( ’ , ’ , ’ ’ )
941 # l ine = l i n e . r ep lace ( ’ ; ’ , ’ ’ )
942 # l ine = l i n e . r ep lace ( ’ : ’ , ’ ’ ) # t h i s messes up Windows
fi lenames
943 l ine = l i ne . replace ( "\ t " , ’ ’ )
944
945 # now s t r i p s t r i n g
946 l ine = l i ne . s t r i p ( )
947
948 # now, rep lace double spaces with one space
949 while ’ ’ in l i ne : l ine = l i ne . replace ( ’ ’ , ’ ’ )
950
951 # Now s p l i t the thing
952 l ine = l i ne . s p l i t ( ’ ’ , 1 )
953
954 # now, make i t upper case
955 l ine [ 0 ] = l i ne [ 0 ] . upper ( )
956
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957 # I f there ’ s QUIT , EXIT , or STOP, then don ’ t continue .
958 i f l i ne [ 0 ] in [ ’QUIT ’ , ’ EXIT ’ , ’STOP ’ ] : break
959
960 s e l f . e n t i t i e s . append( l ine )
961
962 c lass run i t ( ) :
963 ’ ’ ’ The main c l a s s to run POVME. ’ ’ ’
964
965 def re ference ( se l f , parameters , before=" " ) :
966 ’ ’ ’ P r int out a message regarding terms of use . ’ ’ ’
967
968 log ( " " , parameters )
969 log ( before + " I f you use POVME in your research , please c i t e the
fo l lowing reference : " , parameters )
970 log ( before + " Durrant , J . D. , C . A . de Ol ive i ra , et a l . (2011)
. \"POVME: An algorithm" , parameters )
971 log ( before + " for measuring binding−pocket volumes . \ " J Mol
Graph Model 29(5) : 773−776." , parameters )
972
973 def load_multi_frame_pdb ( se l f , filename , parameters ) :
974 " " " Load a multi−frame PDB into memory or into separate f i l e s (
depending on user s p e c i f i c a t i on s ) .
975
976 Arguments :
977 fi lename −− A st r ing , the fi lename of the multi−frame PDB
978 parameters −− A python dict ionary , where the keys are the user−




981 I f the user has requested that the disk be used to save memory ,
t h i s function returns a l i s t of tuples , where the f i r s t item
in each tuple i s the frame index , and the second i s a
filename containing the indiv idual frame .
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982 I f memory i s to be used instead of the disk , t h i s function
returns a l i s t of tuples , where the f i r s t item in each tuple
i s the frame index , and the second i s a pymolecule . Molecule
ob j e c t r epresent ing the frame .
983
984 " " "
985
986 pdb_strings = [ ]
987 growing_string = ’ ’
988
989 log ( " " , parameters )
990 log ( "Reading frames from " + filename , parameters )
991
992 f = open ( filename , ’ rb ’ )
993 while True :
994
995 i f parameters [ ’NumFrames ’ ] != −1:
996 i f len ( pdb_strings ) >= parameters [ ’NumFrames ’ ] : break
997
998 l ine = f . readl ine ( )
999
1000 i f len ( l ine ) == 0 :
1001 pdb_strings . append( growing_string )
1002 break
1003 i f l i ne [ : 3 ] == "END" :
1004 pdb_strings . append( growing_string )
1005 growing_string = ’ ’
1006 else :
1007 growing_string = growing_string + l i ne
1008
1009 f . c lose ( )
1010
1011 while ’ ’ in pdb_strings : pdb_strings . remove ( ’ ’ )
1012
1013 # now conver t each pdb s t r i n g into a pymolecule . Molecule ob j e c t
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1014 molecules = Multithreading ( [ ( pdb_strings [ idx ] , idx + 1 ,
parameters ) for idx in range ( len ( pdb_strings ) ) ] , parameters [ ’
NumProcessors ’ ] , MultithreadingStringToMoleculeTask )




1019 def __ in i t _ _ ( s e l f , argv ) :
1020 ’ ’ ’ S t a r t POVME
1021
1022 Arguments :
1023 argv −− A l i s t of the command− l i n e arguments .
1024
1025 ’ ’ ’
1026
1027 s tar t_ t ime = time . time ( )
1028
1029 # Load the configurat ion f i l e
1030 i f len ( argv ) == 1 :
1031 print "\nPOVME " + version
1032 print "\nPlease spec i fy the input f i l e from the command l ine ! \n\
nExample : python POVME. py inpu t _ f i l e . i n i "
1033 s e l f . re ference ( { } )
1034 print
1035 sys . e x i t ( )
1036
1037 config = Conf igFi le ( argv [ 1 ] )
1038
1039 # Process the conf i g f i l e
1040 parameters = {}
1041
1042 parameters [ ’ GridSpacing ’ ] = 1 .0 # de fau l t
1043 parameters [ ’ PointsIncludeRegions ’ ] = [ ]
1044 parameters [ ’ PointsExcludeRegions ’ ] = [ ]
1045 parameters [ ’ SavePoints ’ ] = False # de fau l t
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1046 parameters [ ’ LoadPointsFilename ’ ] = ’ ’ # de fau l t
1047 parameters [ ’PDBFileName ’ ] = " " # de fau l t
1048 parameters [ ’ DistanceCutoff ’ ] = 1.09 # de fau l t i s VDW radius of
hydrogen
1049 parameters [ ’ ConvexHullExclusion ’ ] = True
1050 parameters [ ’ ContiguousPocketSeedRegions ’ ] = [ ]
1051 parameters [ ’ Cont iguousPointsCri ter ia ’ ] = 4
1052 parameters [ ’ NumProcessors ’ ] = 4
1053 parameters [ ’UseDiskNotMemory ’ ] = False
1054 parameters [ ’ OutputFilenamePrefix ’ ] = "POVME_output . " + time .
s t r f t ime ( "%m−%d−%y" ) + " . " + time . s t r f t ime ( "%H−%M−%S" ) + os .
sep
1055 parameters [ ’ SaveIndividualPocketVolumes ’ ] = False
1056 parameters [ ’ SavePocketVolumesTrajectory ’ ] = False
1057 parameters [ ’ OutputEqualNumPointsPerFrame ’ ] = False
1058 parameters [ ’ SaveTabbedVolumeFile ’ ] = False
1059 parameters [ ’ SaveVolumetricDensityMap ’ ] = False
1060 parameters [ ’ CompressOutput ’ ] = False
1061 parameters [ ’NumFrames ’ ] = −1 # This i s a parameter fo r debugging
purposes only .
1062
1063 f loat_parameters = [ "GridSpacing" , " DistanceCutoff " ]
1064 boolean_parameters = [ " SavePoints " , "ConvexHullExclusion" , "
CompressOutput" , "UseDiskNotMemory" , "
SaveVolumetricDensityMap " , "OutputEqualNumPointsPerFrame " , "
SaveIndividualPocketVolumes " , "SaveTabbedVolumeFile" , "
SavePocketVolumesTrajectory " ]
1065 int_parameters = [ "NumFrames" , " Cont iguousPointsCri ter ia" , "
NumProcessors " ]
1066 string_parameters = [ "OutputFilenamePrefix " , "PDBFileName" , "
LoadPointsFilename " ]
1067
1068 print config . e n t i t i e s
1069
1070 for en t i t y in config . e n t i t i e s :
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1071 try :
1072 index = [p . upper ( ) for p in f loat_parameters ] . index ( en t i t y [ 0 ] )
1073 parameters [ f loat_parameters [ index ] ] = f l oa t ( en t i t y [ 1 ] )
1074 except : pass
1075
1076 try :
1077 index = [p . upper ( ) for p in boolean_parameters ] . index ( en t i t y [ 0 ] )
1078 i f en t i t y [ 1 ] . upper ( ) in [ "YES" , "TRUE" ] : parameters [
boolean_parameters [ index ] ] = True
1079 else : parameters [ boolean_parameters [ index ] ] = False
1080 except : pass
1081
1082 try :
1083 index = [p . upper ( ) for p in int_parameters ] . index ( en t i t y [ 0 ] )
1084 parameters [ int_parameters [ index ] ] = int ( en t i t y [ 1 ] )
1085 except : pass
1086
1087 try :
1088 index = [p . upper ( ) for p in str ing_parameters ] . index ( en t i t y [ 0 ] )
1089 parameters [ str ing_parameters [ index ] ] = en t i t y [ 1 ] . s t r i p ( )
1090 except : pass
1091
1092 # Regions are handled sepa ra t e l y fo r each parameter . . .
1093 i f en t i t y [ 0 ] == "POINTSINCLUSIONSPHERE" :
1094 Include = Region ( )
1095 items = en t i t y [ 1 ] . s p l i t ( ’ ’ )
1096 Include . center [ 0 ] = f l oa t ( items [ 0 ] )
1097 Include . center [ 1 ] = f l oa t ( items [ 1 ] )
1098 Include . center [ 2 ] = f l oa t ( items [ 2 ] )
1099 Include . radius = f l oa t ( items [ 3 ] )
1100 Include . region_type = "SPHERE"
1101 parameters [ ’ PointsIncludeRegions ’ ] . append( Include )
1102 e l i f en t i t y [ 0 ] == "POINTSINCLUSIONBOX" :
1103 Include = Region ( )
1104 items = en t i t y [ 1 ] . s p l i t ( ’ ’ )
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1105 Include . center [ 0 ] = f l oa t ( items [ 0 ] )
1106 Include . center [ 1 ] = f l oa t ( items [ 1 ] )
1107 Include . center [ 2 ] = f l oa t ( items [ 2 ] )
1108 Include . box_dimen [ 0 ] = f l oa t ( items [ 3 ] )
1109 Include . box_dimen [ 1 ] = f l oa t ( items [ 4 ] )
1110 Include . box_dimen [ 2 ] = f l oa t ( items [ 5 ] )
1111 Include . region_type = "BOX"
1112 parameters [ ’ PointsIncludeRegions ’ ] . append( Include )
1113 i f en t i t y [ 0 ] == "CONTIGUOUSPOCKETSEEDSPHERE" :
1114 Contig = Region ( )
1115 items = en t i t y [ 1 ] . s p l i t ( ’ ’ )
1116 Contig . center [ 0 ] = f l oa t ( items [ 0 ] )
1117 Contig . center [ 1 ] = f l oa t ( items [ 1 ] )
1118 Contig . center [ 2 ] = f l oa t ( items [ 2 ] )
1119 Contig . radius = f l oa t ( items [ 3 ] )
1120 Contig . region_type = "SPHERE"
1121 parameters [ ’ ContiguousPocketSeedRegions ’ ] . append( Contig )
1122 e l i f en t i t y [ 0 ] == "CONTIGUOUSPOCKETSEEDBOX" :
1123 Contig = Region ( )
1124 items = en t i t y [ 1 ] . s p l i t ( ’ ’ )
1125 Contig . center [ 0 ] = f l oa t ( items [ 0 ] )
1126 Contig . center [ 1 ] = f l oa t ( items [ 1 ] )
1127 Contig . center [ 2 ] = f l oa t ( items [ 2 ] )
1128 Contig . box_dimen [ 0 ] = f l oa t ( items [ 3 ] )
1129 Contig . box_dimen [ 1 ] = f l oa t ( items [ 4 ] )
1130 Contig . box_dimen [ 2 ] = f l oa t ( items [ 5 ] )
1131 Contig . region_type = "BOX"
1132 parameters [ ’ ContiguousPocketSeedRegions ’ ] . append( Contig )
1133 e l i f en t i t y [ 0 ] == "POINTSEXCLUSIONSPHERE" :
1134 Exclude = Region ( )
1135 items = en t i t y [ 1 ] . s p l i t ( ’ ’ )
1136 Exclude . center [ 0 ] = f l oa t ( items [ 0 ] )
1137 Exclude . center [ 1 ] = f l oa t ( items [ 1 ] )
1138 Exclude . center [ 2 ] = f l oa t ( items [ 2 ] )
1139 Exclude . radius = f l oa t ( items [ 3 ] )
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1140 Exclude . region_type = "SPHERE"
1141 parameters [ ’ PointsExcludeRegions ’ ] . append( Exclude )
1142 e l i f en t i t y [ 0 ] == "POINTSEXCLUSIONBOX" :
1143 Exclude = Region ( )
1144 items = en t i t y [ 1 ] . s p l i t ( ’ ’ )
1145 Exclude . center [ 0 ] = f l oa t ( items [ 0 ] )
1146 Exclude . center [ 1 ] = f l oa t ( items [ 1 ] )
1147 Exclude . center [ 2 ] = f l oa t ( items [ 2 ] )
1148 Exclude . box_dimen [ 0 ] = f l oa t ( items [ 3 ] )
1149 Exclude . box_dimen [ 1 ] = f l oa t ( items [ 4 ] )
1150 Exclude . box_dimen [ 2 ] = f l oa t ( items [ 5 ] )
1151 Exclude . region_type = "BOX"
1152 parameters [ ’ PointsExcludeRegions ’ ] . append( Exclude )
1153
1154 # I f the output pr e f i x includes a di r ec tory , c r ea t e that
d i r e c t o r y i f necessary
1155 i f os . sep in parameters [ ’ OutputFilenamePrefix ’ ] :
1156 output_dirname = os . path . dirname ( parameters [ ’
OutputFilenamePrefix ’ ] )
1157 # i f os . path . e x i s t s ( output_dirname ) : shu t i l . rmtree ( output_dirname
) # So de l e t e the d i r e c t o r y i f i t already e x i s t s .
1158 try : os . mkdir ( output_dirname )
1159 except : pass
1160
1161 # pr int out the header
1162 s e l f . re ference ( parameters , " " )
1163 log ( ’ ’ , parameters )
1164
1165 # c r ea t e temp swap d i r e c t o r y i f needed
1166 i f parameters [ ’UseDiskNotMemory ’ ] == True :
1167 i f os . path . e x i s t s ( ’ . ’ + os . sep + ’ . povme_tmp ’ ) : s hu t i l . rmtree ( ’ .
’ + os . sep + ’ . povme_tmp ’ )
1168 os . mkdir ( ’ . ’ + os . sep + ’ . povme_tmp ’ )
1169
1170 # pr int out parameters
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1171 log ( "Parameters : " , parameters )
1172 for i in parameters . keys ( ) :
1173
1174 i f i == ’NumFrames ’ and parameters [ ’NumFrames ’ ] == −1: continue
# So only show th i s parameter i f i t ’ s value i s not the
de fau l t .
1175
1176 i f type ( parameters [ i ] ) i s l i s t :
1177 for i 2 in parameters [ i ] :
1178 i f i 2 != " " : log ( "\ t " + s t r ( i ) + " : " + s t r ( i2 ) , parameters )
1179 else :
1180 i f parameters [ i ] != " " : log ( "\ t " + s t r ( i ) + " : " + s t r (
parameters [ i ] ) , parameters )
1181
1182 pts = None
1183 i f len ( parameters [ ’ PointsIncludeRegions ’ ] ) > 0 : # so c r ea t e the
point f i l e
1184
1185 log ( "\nGenerating the pocket−encompassing point f i e l d " ,
parameters )
1186
1187 # get a l l the points of the inc lus ion reg ions
1188 pts = parameters [ ’ PointsIncludeRegions ’ ] [ 0 ] . points_set (
parameters [ ’ GridSpacing ’ ] )
1189 for Included in parameters [ ’ PointsIncludeRegions ’ ] [ 1 : ] : pts =
numpy. vstack ( ( pts , Included . points_set ( parameters [ ’
GridSpacing ’ ] ) ) )
1190 pts = unique_rows ( pts )
1191
1192 # get a l l the points of the exclusion reg ions
1193 i f len ( parameters [ ’ PointsExcludeRegions ’ ] ) > 0 :
1194 pts_exclus ion = parameters [ ’ PointsExcludeRegions ’ ] [ 0 ] . points_set
( parameters [ ’ GridSpacing ’ ] )
1195 for Excluded in parameters [ ’ PointsExcludeRegions ’ ] [ 1 : ] :
p ts_exclus ion = numpy. vstack ( ( pts_exclusion , Excluded .
148
points_set ( parameters [ ’ GridSpacing ’ ] ) ) )
1196 pts_exclus ion = unique_rows ( pts_exclus ion )
1197
1198 # remove the exclusion points from the inc lus ion points
1199 # I think there ought to be a se t−based way of doing th i s ,
1200 # but I ’m going to go fo r the pairwise comparison .
1201 # consider r ewr i t ing l a t e r
1202 index_to_remove = numpy. nonzero ( cd i s t ( pts , pts_exclus ion ) < 1e
−7) [ 0 ]
1203 pts = numpy. delete ( pts , index_to_remove , ax i s=0)
1204
1205 # save the points as PDB
1206 i f parameters [ ’ SavePoints ’ ] == True :
1207
1208 # F i r s t , save the point f i e l d i t s e l f
1209
1210 log ( "\nSaving the point f i e l d as a PDB and NPY f i l e " , parameters
)
1211
1212 points_f i lename = parameters [ ’ OutputFilenamePrefix ’ ] + "
po in t_ f i e ld . pdb"
1213
1214 i f parameters [ ’ CompressOutput ’ ] == True : a f i l e = gzip .open (
points_f i lename + " . gz " , ’wb ’ )
1215 else : a f i l e = open ( points_fi lename , ’w ’ )
1216
1217 a f i l e . wri te (numpy_to_pdb( pts , "X" ) )
1218 a f i l e . c lose ( )
1219
1220 # save the points as npy
1221 numpy. save ( points_f i lename + " . npy" , pts )
1222
1223 log ( "\ tPoint f i e l d saved to " + points_f i lename + " to permit
v i sua l i z a t i on " , parameters )
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1224 log ( "\ tPoint f i e l d saved to " + points_f i lename + " . npy to
opt iona l ly load for the volume ca lcu la t ion " , parameters )
1225 log ( " " , parameters )
1226
1227 # Now, save the contiguous seed points as well , i f s p e c i f i ed .
1228 i f len ( parameters [ ’ ContiguousPocketSeedRegions ’ ] ) > 0 :
1229 # get a l l the contiguous points
1230 cont ig_pts = parameters [ ’ ContiguousPocketSeedRegions ’ ] [ 0 ] .
points_set ( parameters [ ’ GridSpacing ’ ] )
1231 for Contig in parameters [ ’ ContiguousPocketSeedRegions ’ ] [ 1 : ] :
cont ig_pts = numpy. vstack ( ( contig_pts , Contig . points_set (
parameters [ ’ GridSpacing ’ ] ) ) )
1232 cont ig_pts = unique_rows ( cont ig_pts )
1233
1234 log ( "\nSaving the contiguous−pocket seed points as a PDB f i l e " ,
parameters )
1235
1236 points_f i lename = parameters [ ’ OutputFilenamePrefix ’ ] + "
contiguous_pocket_seed_points . pdb"
1237
1238 i f parameters [ ’ CompressOutput ’ ] == True : a f i l e = gzip .open (
points_f i lename + " . gz " , ’wb ’ )
1239 else : a f i l e = open ( points_fi lename , ’w ’ )
1240
1241 a f i l e . wri te (numpy_to_pdb( contig_pts , "X" ) )
1242 a f i l e . c lose ( )
1243
1244 log ( "\ tContiguous−pocket seed points saved to " +
points_f i lename + " to permit v i sua l i z a t i on " , parameters )
1245 log ( " " , parameters )
1246
1247 i f parameters [ ’PDBFileName ’ ] != ’ ’ : # so there ’ s a PDB point
sp e c i f i ed fo r ca l cu la t ing the volume .
1248
1249 # load the points in they aren ’ t already present
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1250 i f pts i s None :
1251 log ( "\nLoading the point− f i e l d NPY f i l e . . . " , parameters )
1252 parameters [ ’ p t s_or ig ’ ] = numpy. load ( parameters [ ’
LoadPointsFilename ’ ] )
1253 else : parameters [ ’ p t s_or ig ’ ] = pts
1254
1255 # load the PDB frames
1256 index_and_pdbs = s e l f . load_multi_frame_pdb ( parameters [ ’
PDBFileName ’ ] , parameters )
1257
1258 # ca l cu la t e a l l the volumes
1259 log ( " " , parameters )
1260 log ( " Calculat ing the pocket volume of each frame" , parameters )
1261 tmp = Multithreading ( [ ( index , pdb_object , parameters ) for index ,
pdb_object in index_and_pdbs ] , parameters [ ’NumProcessors ’ ] ,
MultithreadingCalcVolumeTask )
1262
1263 # de l e t e the temp swap d i r e c t o r y i f necessary
1264 i f parameters [ ’UseDiskNotMemory ’ ] == True :
1265 i f os . path . e x i s t s ( ’ . ’ + os . sep + ’ . povme_tmp ’ ) : s hu t i l . rmtree ( ’ .
’ + os . sep + ’ . povme_tmp ’ )
1266
1267 # display the r e s u l t s
1268 resu l t s _d i c = {}
1269 for r e su l t in tmp . r e su l t s : r e su l t s _d i c [ r e su l t [ 0 ] ] = r e su l t [ 1 ]
1270 log ( " " , parameters )
1271 log ( "FRAME | VOLUME (A^3) " , parameters )
1272 log ( "−−−−−−−−−−−−−+−−−−−−−−−−−−−" , parameters )
1273 for i in sorted ( r e su l t s _d i c . keys ( ) ) : log ( s t r ( i ) . l j u s t (13 ) + " | "
+ s t r ( r e su l t s _d i c [ i ] ) , parameters )
1274
1275 log ( " " , parameters )
1276 log ( "Execution time = " + s t r ( time . time ( )−s ta r t_ t ime ) + " sec " ,
parameters )
1277 log ( " " , parameters )
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1278
1279 # i f the user requested a separate volume f i l e , save that as
wel l
1280 i f parameters [ ’ SaveTabbedVolumeFile ’ ] == True :
1281 i f parameters [ ’ CompressOutput ’ ] == True : f = gzip .open (
parameters [ ’ OutputFilenamePrefix ’ ] + "volumes . tabbed . t x t . gz " ,
’wb ’ )
1282 else : f = open ( parameters [ ’ OutputFilenamePrefix ’ ] + "volumes .
tabbed . t x t " , ’w ’ )
1283
1284 for i in sorted ( r e su l t s _d i c . keys ( ) ) : f . wr i te ( s t r ( i ) + "\ t " + s t r
( r e su l t s _d i c [ i ] ) + "\n" )
1285 f . c lose ( )
1286
1287 # i f the user wanted a s i n g l e t r a j e c t o r y containing a l l the
volumes , generate that here .
1288 i f parameters [ ’ SavePocketVolumesTrajectory ’ ] == True :
1289 i f parameters [ ’ CompressOutput ’ ] == True : t r a j _ f i l e = gzip .open (
parameters [ ’ OutputFilenamePrefix ’ ] + " volume_trajectory . pdb .
gz" , ’wb ’ )
1290 else : t r a j _ f i l e = open ( parameters [ ’ OutputFilenamePrefix ’ ] + "
volume_trajectory . pdb" , ’w ’ )
1291
1292 for frame_index in range (1 , len ( r e su l t s _d i c . keys ( ) )+1) :
1293 i f parameters [ ’ CompressOutput ’ ] == True : f rame_f i l e = gzip .open (
parameters [ ’ OutputFilenamePrefix ’ ] + " frame_" + s t r (
frame_index ) + " . pdb . gz" , ’ rb ’ )
1294 else : f rame_f i l e = open ( parameters [ ’ OutputFilenamePrefix ’ ] + "
frame_" + s t r ( frame_index ) + " . pdb" , ’ r ’ )
1295
1296 t r a j _ f i l e . wri te ( f rame_f i l e . read ( ) )
1297 f rame_f i l e . c lose ( )
1298
1299 t r a j _ f i l e . c lose ( )
1300
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1301 # i f the user requested a volumetric dens i t y map, then generate
i t here
1302 i f parameters [ ’ SaveVolumetricDensityMap ’ ] == True :
1303 unique_points = {}
1304
1305 overall_min = numpy. ones (3 ) ∗ 1e100
1306 overall_max = numpy. ones (3 ) ∗ −1e100
1307
1308 for r e su l t in tmp . r e su l t s :
1309 pts = r e su l t [ 2 ] [ ’ SaveVolumetricDensityMap ’ ]
1310
1311 i f len ( pts ) > 0 :
1312 amin = numpy.min( pts , ax i s=0)
1313 amax = numpy.max( pts , ax i s=0)
1314
1315 overall_min = numpy.min(numpy. vstack ( ( overall_min , amin) ) , ax i s
=0)
1316 overall_max = numpy.max(numpy. vstack ( ( overall_max , amax) ) , ax i s
=0)
1317
1318 for pt in pts :
1319 pt_key = s t r ( pt [ 0 ] ) + " ; " + s t r ( pt [ 1 ] ) + " ; " + s t r ( pt [ 2 ] )
1320 try : unique_points [ pt_key ] = unique_points [ pt_key ] + 1
1321 except : unique_points [ pt_key ] = 1
1322 i f overall_min [ 0 ] == 1e100 :
1323 log ( "ERROR ! Cannont save volumetric density f i l e because no
volumes present in any frame . " , parameters )
1324 else :
1325 xpts = numpy. arange ( overall_min [ 0 ] , overall_max [ 0 ] + parameters [
’ GridSpacing ’ ] , parameters [ ’ GridSpacing ’ ] )
1326 ypts = numpy. arange ( overall_min [ 1 ] , overall_max [ 1 ] + parameters [
’ GridSpacing ’ ] , parameters [ ’ GridSpacing ’ ] )
1327 zpts = numpy. arange ( overall_min [ 2 ] , overall_max [ 2 ] + parameters [
’ GridSpacing ’ ] , parameters [ ’ GridSpacing ’ ] )
1328
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1329 a l l _p t s = numpy. zeros ( ( len ( xpts ) ∗ len ( ypts ) ∗ len ( zpts ) , 4) )
1330
1331 i = 0
1332 for x in xpts :
1333 for y in ypts :
1334 for z in zpts :
1335 key = s t r ( x ) + " ; " + s t r ( y ) + " ; " + s t r ( z )
1336 a l l _p t s [ i ] [ 0 ] = x
1337 a l l _p t s [ i ] [ 1 ] = y
1338 a l l _p t s [ i ] [ 2 ] = z
1339
1340 try : a l l _p t s [ i ] [ 3 ] = unique_points [ key ]
1341 except : pass
1342
1343 i = i + 1
1344
1345 # conver t the counts in the fourth column into f r equenc i e s
1346 a l l _p t s [ : , 3 ] = a l l _p t s [ : , 3 ] / len ( tmp . r e su l t s )
1347 dx_freq ( a l l _p t s , parameters ) # save the dx f i l e
1348
1349 #pr int "To turn into a DX f i l e : "
1350 #pr int a l l _p t s
1351 #import cP i ck l e as p i ck l e
1352 # p i ck l e .dump( a l l _p t s , open ( ’ d i l l . p i ck l e ’ , ’w ’ ) )
1353
1354 i f __name__ == "__main__" : dorun = run i t ( sys . argv )
A.2. Shape Complementarity R Script
1 ###whole t r a j e c t o r y al igned on f i r s t frame , l igand and protein
coordinates ex t rac t ed sepe ra t e l y
2 ###POVME maps created as descr ibed in the Experimental Sect ion
3 ### fo r l a t e r pair ing with other frame parameters , make sure





6 workingDirectory <− " /some/working / di rectory "
7 setwd ( workingDirectory )
8
9 ### sp e c i f i c a t i on of input f i l e s
10
11 ligandPDB <− " pdbf i l e_of _ l igandconfs /over_MD/without_headline .
pdb"
12 s ta r t ingPo in t s <− " f i l e _of _ s t a r t i n g _point_map/ as_ created_by_
POVME.pdb"
13 povmeOutputDir <− " d i rec tory /of /povme/output_ f i l e s / "
14 f i l ePa t t e rnP ro t e in <− " pattern / according / to /povmeoutput" #
something l i k e " t r j p r o t e i npa r t .+ inLigOrProt .+\\ . pdb" to
s p e c i f i y the POVME output f i l e s of the points ins ide the
protein
15 f i l ePa t t e rnL ig inner <− #something l i k e " t r j l i gandpar t [0−9 ] [0−9 ]
inner059frame\\_ [0−9 ]+\\ .pdb" to s p e c i f i y the POVME output
f i l e s of the points surrounding the l igand with dis tance to
heavy atoms of at l e a s t 0 .59 Angstrom
16 f i l ePa t t e rnL igou t e r <− #something l i k e " t r j l i gandpar t
[0−9 ] [0−9 ] innerframe \\_ [0−9 ]+\\ .pdb" to s p e c i f i y the POVME
output f i l e s of the points surrounding the l igand with
dis tance to heavy atoms of at l e a s t 1 .59 Angstrom
17
18 ### load required packages
19
20 l ibrary (doSNOW)
21 l ibrary (R . u t i l s )
22 l ibrary ( gdata )
23 l ibrary (RANN)
24
25
26 ### load the ordering of atoms fo r the l igand
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27
28 l i ga tomf i l e l eng th <− countLines ( ligandPDB )
29 l igatomlength <− ( grep ( "END" , readLines ( ligandPDB ) ) [ [1 ] ] −1 )
30 numberofframes <− ( l i g a tomf i l e l eng th ) / ( l igatomlength+1)
31 l i g a toml i s t <− l i s t ( )
32 for ( i in 1 : numberofframes ) { l i g a t oml i s t [ [ i ] ] <− read . fwf (
ligandPDB , widths = c (−8 ,3 ,5 ,−14 ,8 ,8 ,8 ,−23 ,1) , skip =(( i −1)∗ (
l igatomlength+1) ) , nrow = l igatomlength ) }
33 saveRDS ( l i ga toml i s t , " l i g a toml i s t . rds " )
34
35 ###load s t a r t i n g point map
36
37 f i l e l e n g t h <− countLines ( s t a r t ingPo in t s )
38 pointMaplist <− read . fwf ( s ta r t ingPoints , widths = c
(−30 ,8 ,8 ,8 ,−24) , nrow = f i l e l e n g t h )
39 pointMapmatrix <− do . ca l l ( cbind , pointMaplist )
40 saveRDS ( pointMapmatrix , "pointMapmatrix . rds " )
41
42 ###load point maps of the protein in the binding area
43
44 f i l e l i s t P r o t <− l i s t . f i l e s (path = povmeOutputDir , pattern =
f i l ePa t t e rnP ro t e in )
45 f i l e p a t h l i s t P r o t <− paste ( povmeOutputDir , f i l e l i s t P r o t , sep=" " )
46
47 da t a l i s t P ro t <− l i s t ( )
48 s izeProt <− l i s t ( )
49 for ( i in 1 : length ( f i l e p a t h l i s t P r o t ) ) { s izeProt [ [ i ] ] <−
countLines ( f i l e p a t h l i s t P r o t [ [ i ] ] ) }
50
51 c lu s te r <− makeCluster ( 3 )
52 registerDoSNOW( c lus te r )
53
54 da t a l i s t P ro t <− foreach ( x=1: length ( f i l e p a t h l i s t P r o t ) , .
errorhandling="remove" ) %dopar% read . fwf ( f i l e p a t h l i s t P r o t [ [ x
] ] , skip=1 , widths=c (−30 ,8 ,8 ,8 ,−24) , nrow=s izeProt [ [ x ] ] −2)
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55
56 stopCluster ( c lu s te r )
57
58 saveRDS ( da ta l i s tP ro t , " da t a l i s t P ro t . rds " )
59
60 da ta l i s tno t0Pro t <− l i s t ( )
61 for ( i in 1 : length ( da t a l i s t P ro t ) ) { da ta l i s tno t0Pro t [ [ i ] ] <−
da t a l i s t P ro t [ [ i ] ] [ apply ( da t a l i s t P ro t [ [ i ] ] , MARGIN=1 , function (
x ) ! a l l ( x==0) ) , ] }
62 saveRDS ( data l i s tnot0Prot , " da ta l i s tno t0Pro t . rds " )
63
64
65 ### load ligand surrounding point maps with at l e a s t 1 .59
Angstrom distance to the l igand
66
67 f i l e l i s t I n v l i g <− l i s t . f i l e s (path = povmeOutputDir , pattern =
f i l ePa t t e rnL igou t e r )
68 f i l e p a t h l i s t I n v l i g <− paste ( povmeOutputDir , f i l e l i s t I n v l i g , sep=
" " )
69
70 d a t a l i s t I n v l i g <− l i s t ( )
71 s i z e I n v l i g <− l i s t ( )
72 for ( i in 1 : length ( f i l e p a t h l i s t I n v l i g ) ) { s i z e I n v l i g [ [ i ] ] <−
countLines ( f i l e p a t h l i s t I n v l i g [ [ i ] ] ) }
73
74 c lu s te r <− makeCluster ( 3 )
75 registerDoSNOW( c lus te r )
76
77 d a t a l i s t I n v l i g <− foreach ( x=1: length ( f i l e p a t h l i s t I n v l i g ) , .
errorhandling="remove" ) %dopar% read . fwf ( f i l e p a t h l i s t I n v l i g [ [
x ] ] , skip=2 , widths=c (−30 ,8 ,8 ,8 ,−24) , nrow=s i z e I n v l i g [ [ x ] ] −3)
78
79 stopCluster ( c lu s te r )
80
81 saveRDS ( d a t a l i s t I n v l i g , " d a t a l i s t I n v l i g . rds " )
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83 da t a l i s tno t 0 Inv l i g <− l i s t ( )
84 for ( i in 1 : length ( d a t a l i s t I n v l i g ) ) { da t a l i s tno t 0 Inv l i g [ [ i ] ] <−
d a t a l i s t I n v l i g [ [ i ] ] [ apply ( d a t a l i s t I n v l i g [ [ i ] ] , MARGIN=1 ,
function ( x ) ! a l l ( x==0) ) , ] }
85 saveRDS ( da ta l i s tno t0 Inv l i g , " da t a l i s tno t 0 Inv l i g . rds " )
86
87
88 ###load ligand surrounding point maps with at l e a s t 0 .59
Angstrom distance to the l igand
89
90 f i l e l i s t I n v l i g i n n e r <− l i s t . f i l e s (path = povmeOutputDir , pattern
= f i l ePa t t e rnL i g inne r )
91 f i l e p a t h l i s t I n v l i g i nn e r <− paste ( povmeOutputDir ,
f i l e l i s t I n v l i g i n n e r , sep=" " )
92
93 da t a l i s t I n v l i g inne r <− l i s t ( )
94 s i ze Inv l i g inner <− l i s t ( )
95 for ( i in 1 : length ( f i l e p a t h l i s t I n v l i g i nn e r ) ) { s i ze Inv l i g inner [ [ i
] ] <− countLines ( f i l e p a t h l i s t I n v l i g i n n e r [ [ i ] ] ) }
96
97 c lu s te r <− makeCluster ( 3 )
98 registerDoSNOW( c lus te r )
99
100 da t a l i s t I n v l i g inne r <− foreach ( x=1: length (
f i l e p a t h l i s t I n v l i g i n n e r ) , . errorhandling="remove" ) %dopar%
read . fwf ( f i l e p a t h l i s t I n v l i g i nn e r [ [ x ] ] , skip=2 , widths=c
(−30 ,8 ,8 ,8 ,−24) , nrow=s i ze Inv l i g inner [ [ x ] ] −3)
101
102 stopCluster ( c lu s te r )
103
104 saveRDS ( da t a l i s t I n v l i g inne r , " da t a l i s t I n v l i g inne r . rds " )
105
106 da ta l i s tno t0 Inv l i g inne r <− l i s t ( )
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107 for ( i in 1 : length ( da t a l i s t I n v l i g i nne r ) ) {
da ta l i s tno t0 Inv l i g inner [ [ i ] ] <− da t a l i s t I n v l i g inne r [ [ i ] ] [
apply ( da t a l i s t I n v l i g inne r [ [ i ] ] , MARGIN=1 , function ( x ) ! a l l ( x
==0) ) , ] }
108 saveRDS ( da ta l i s tno t0 Inv l i g inner , " da ta l i s tno t0 Inv l i g inner . rds " )
109
110 ###from both ligand surrounding maps ca l cu la t e the l igand
surrounding sur face map points ( overlap )
111
112 notduplicatedPoints <− l i s t ( )
113 da ta l i s tL i g IDs <− l i s t ( )
114 da t a l i s t L i g <− l i s t ( )
115 for ( t in 1 : length ( da ta l i s tno t0 Inv l i g inne r ) ) { notduplicatedPoints
[ [ t ] ] <− ! duplicated ( rbind ( da t a l i s tno t 0 Inv l i g [ [ t ] ] ,
da ta l i s tno t0 Inv l i g inner [ [ t ] ] ) )
116 mapStart <− dim ( da t a l i s tno t 0 Inv l i g [ [ t ] ] )
[1 ]+1
117 mapEnd <− dim( rbind ( da t a l i s tno t 0 Inv l i g [ [ t
] ] , da ta l i s tno t0 Inv l i g inne r [ [ t ] ] ) ) [ 1 ]
118 da ta l i s tL i g IDs [ [ t ] ] <− notduplicatedPoints
[ [ t ] ] [ mapStart :mapEnd ]
119 da t a l i s t L i g [ [ t ] ] <− da ta l i s tno t0 Inv l i g inne r
[ [ t ] ] [ da ta l i s tL i g IDs [ [ t ] ] , ] }
120
121
122 saveRDS ( da t a l i s t L i g , " d a t a l i s t L i g . rds " )
123
124 ### ass ign l igand atoms to near parts of the l igand surrounding
point map
125
126 l igatomlistnoHs <− l i s t ( )
127
128 for ( l in 1 : length ( l i g a toml i s t ) ) { l igatomlistnoHs [ [ l ] ] <−




131 nnresult<− l i s t ( )
132
133 for ( l in 1 : length ( l i g a toml i s t ) ) {
134 nnresult [ [ l ] ] <− nn2( l igatomlistnoHs [ [ l ] ] [ , 3 : 5 ] ,
d a t a l i s t L i g [ [ l ] ] [ , 1 : 3 ] , k=1 , t reetype="kd" )
135 }
136
137 r e s u l t l i s t <− l i s t ( )
138
139 for ( l in 1 : length ( l i g a toml i s t ) ) {
140 re su l t s <− l i s t ( )
141 for (n in 1 : length ( nnresult [ [ l ] ] [ [ 1 ] ] ) ) {
142 re su l t s [ [ n ] ] <− l igatomlistnoHs [ [ 1 ] ] [ nnresult [ [ l
] ] [ [ 1 ] ] [ n ] , 2 ]
143 }
144 r e s u l t l i s t [ [ l ] ] <− unl i s t ( r e su l t s )
145 }
146
147 for ( l in 1 : length ( l i g a toml i s t ) ) {
148 da t a l i s t L i g [ [ l ] ] [ "atom" ] <− r e s u l t l i s t [ [ l ] ]
149 }
150
151 saveRDS ( da t a l i s t L i g , " data l is tL igAtom . rds " )
152
153 ### f ind overlap of l igand surrounding and protein surrounding
maps
154
155 duplicatedPoints <− l i s t ( )
156 overlapMapIDs <− l i s t ( )
157 overlapMap <− l i s t ( )
158 for ( t in 1 : length ( da ta l i s tno t0Pro t ) ) { duplicatedPoints [ [ t ] ] <−
duplicated ( rbind ( da ta l i s tno t0Pro t [ [ t ] ] , d a t a l i s t L i g [ [ t
] ] [ 1 : 3 ] ) )
160
159 mapStart <− dim ( da ta l i s tno t0Pro t [ [ t ] ] )
[ [ 1 ] ] + 1
160 mapEnd <− length ( duplicatedPoints [ [ t ] ] )
161 overlapMapIDs [ [ t ] ] <− duplicatedPoints [ [ t
] ] [ mapStart :mapEnd ]
162 overlapMap [ [ t ] ] <− da t a l i s t L i g [ [ t ] ] [
overlapMapIDs [ [ t ] ] , ] }
163
164
165 saveRDS ( overlapMap , "overlapMap . rds " )
166
167 overlapLength <− l i s t ( )
168 for ( i in 1 : length ( overlapMap ) ) { overlapLength [ [ i ] ] <− (dim (
overlapMap [ [ i ] ] ) [ [ 1 ] ] ) }
169 saveRDS ( overlapLength , " overlapLength . rds " )
170
171 write . fwf ( ( as . data . frame ( unl i s t ( overlapLength ) ) ) , f i l e="
overlapLength . dat " ,rownames=FALSE , colnames=FALSE , quote=
FALSE , j u s t i f y=" r i gh t " , width=10)
172
173 overlapRatio <− l i s t ( )
174 for ( i in 1 : length ( overlapLength ) ) { overlapRatio [ [ i ] ] <− (
overlapLength [ [ i ] ] / (dim( d a t a l i s t L i g [ [ i ] ] ) [ 1 ] ) ) }
175 saveRDS ( overlapRatio , " overlapRatio . rds " )
176
177 write . fwf ( ( as . data . frame ( unl i s t ( overlapRatio ) ) ) , f i l e="
overlapRatio . dat " ,rownames=FALSE , colnames=FALSE , quote=FALSE
, j u s t i f y=" r i gh t " , width=12)
178
179 ratiobyatom <− l i s t ( )
180 for ( l in 1 : length ( l i g a toml i s t ) ) {
181 ratiobyatom [ [ l ] ] <− table ( overlapMap [ [ l ] ] $atom) / table (
d a t a l i s t L i g [ [ l ] ] $atom)
182 }




186 df <− lapply ( ratiobyatom , as . data . frame )
187 td f <− lapply ( df , t )
188 tdf2 <− l i s t ( )
189 for ( l in 1 : length ( td f ) ) {
190 tdf2 [ [ l ] ] <− as . numeric( td f [ [ l ] ] [ 2 , ] ) }
191 exp <− do . ca l l ( rbind , td f2 )
192 saveRDS (exp , " plotdata . rds " )
193 names <− unl i s t ( df [ [ 1 ] ] [ 1 ] )
194
195 write . fwf (exp , f i l e="overlapRatiobyatom . dat " ,rownames=FALSE ,
colnames=FALSE , quote=FALSE , j u s t i f y=" r i gh t " , width=12)
196 write . fwf ( t ( df [ [ 1 ] ] [ 1 ] ) , f i l e="colnamesOverlapRatiobyatom . dat " ,
rownames=FALSE , colnames=FALSE , quote=FALSE , j u s t i f y=" r i gh t " ,
width=12)
A.3. Cluster Step Selection R Script
1 ###whole t r a j e c t o r y al igned on f i r s t frame , only protein
coordinates ex t rac t ed
2 ###POVME maps created as descr ibed in the Experimental Sect ion
3 ### fo r l a t e r pair ing with other frame parameters , make sure
ordering of the input data according to the MD timel ine i s
maintained
4 ### input i s a datamatrix containing fo r each frame binary data
on whether a gr id point i s present ( part of the binding s i t e )
or not
5
6 workingDirectory <− " /some/working / di rectory "




11 l ibrary ( ade4 )
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12 l ibrary ( gdata )
13
14 ### input data
15
16 matrix_bothprots_ a l l _names <− readRDS ( "matrix_bothprots_ a l l _
names . rds " )
17
18 ###data from equ i l i b ra t i on and bootstrapping
19
20 matrix_allfromeq <− matrix_bothprots_ a l l _names[−c (1 :3125 ,
10420:13545 , 20838:23963 , 31256:34381 , 41675:44800 ,
52093:55218) , ]
21
22 saveRDS (matrix_allfromeq , "matrix_allfromeq . rds " )
23
24 rm(matrix_bothprots_ a l l _names)
25
26 set . seed (19 )
27 sampledata<−matrix_allfromeq [ sample (nrow (matrix_allfromeq ) ,
14598) , ]
28 saveRDS ( sampledata , " sampledata_ 19 . rds " )
29 rm(matrix_allfromeq )
30
31 ###distance matrix simple matching
32
33 matchingdist<−d i s t . binary ( sampledata , method=2 , diag=FALSE ,
upper=FALSE )
34
35 rm( sampledata )
36 ###ward ’ s c l u s t e r i n g
37
38 wardsresul ts<−hclust ( matchingdist , method="ward .D" , )
39 saveRDS ( wardsresults , " wardsresul ts_sample19fromeq . rds " )
40
41 ### ana ly s i s of l e v e l s 1 :50 of c l u s t e r i n g r e su l t s
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42 ### get c l u s t e r s
43
44 t rees<−cutree ( wardsresults , k=1:50)
45
46 t r e e l i s t<− l i s t ( )
47 for ( i in 1 :50 )
48 {
49 t r e e l i s t [ [ i ] ]<−sort ( t r ee s [ , i ] )
50 }
51
52 c l u s t e r l i s t<− l i s t ( l i s t ( ) )
53 for ( i in 1 :50 )
54 {
55 c lu s te r<− l i s t ( )
56 for (n in 1 : i )
57 {
58 c lu s te r [ [ n ] ]<−rownames ( subset ( as . data . frame (
t r e e l i s t [ [ i ] ] ) , as . data . frame ( t r e e l i s t [ [ i ] ] )
[ ,1 ]==n) )
59 }
60 c l u s t e r l i s t [ [ i ] ]<−c lu s te r
61 }
62
63 saveRDS ( c l u s t e r l i s t , "WardsClusters . rds " )
64
65 c l u s t e r r a t i o l i s t<− l i s t ( l i s t ( ) )
66 c l u s t e r r a t i o on l y l i s t<− l i s t ( l i s t ( ) )
67
68 ### f ind out how many frames are in each c l u s t e r and which ra t i o
of i t belongs to PTP1B (named "1PTY . . . . " ) frames
69
70 for ( i in 1 :50 )
71 {
72 c lu s t e r r a t i o<− l i s t ( )
73 c lu s te r ra t ioon ly<− l i s t ( )
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78 for ( y in 1 : length ( c l u s t e r l i s t [ [ i ] ] [ [ n ] ] ) )
79 {
80 i f ( grepl ( "1P" , c l u s t e r l i s t [ [ i ] ] [ [ n ] ] [ [ y ] ] )==TRUE
)
81 {count<−count+1} else {count<−count }
82 }
83 c lu s t e r r a t i o [ [ n ] ]<−paste ( count/ length (
c l u s t e r l i s t [ [ i ] ] [ [ n ] ] ) , length ( c l u s t e r l i s t [ [ i
] ] [ [ n ] ] ) , sep="−" )
84 c lu s te r ra t ioon l y [ [ n ] ]<− count/ length ( c l u s t e r l i s t
[ [ i ] ] [ [ n ] ] )
85 }
86 c l u s t e r r a t i o l i s t [ [ i ] ]<−c lu s t e r r a t i o
87 c l u s t e r r a t i o on l y l i s t [ [ i ] ]<−c lu s te r ra t ioon l y
88 i<− i+1
89 }
90 saveRDS ( c l u s t e r r a t i o l i s t , "WardsClusterRatios . rds " )
91 saveRDS ( c l u s t e r r a t i o on l y l i s t , "WardsClusterRatiosOnly . rds " )
92
93 ###determine fo r each c l u s t e r i n g s t ep which c l u s t e r s belong to 1
B and which to TC ( contain more than 92.5% or l e s s than 7.5%
PTP1B frames )
94
95 nbro fc lus ters teps<−length ( c l u s t e r r a t i o on l y l i s t )
96
97 nbrs1Bl i s t<− l i s t ( )
98 nbrsTCl is t<− l i s t ( )
99 for ( step in 2 : nbro fc lus ters teps )
100 {
101 nbrs1Bl i s t [ [ step ] ]<−which ( c l u s t e r r a t i o on l y l i s t [ [ step
] ] >0 .925 )
165
102 nbrsTCl is t [ [ step ] ]<−which ( c l u s t e r r a t i o on l y l i s t [ [ step
] ] <0 .075 )
103 }
104
105 ### get names of frames fo r both the 1B and TC l i s t s
106
107 names1Blist<− l i s t ( l i s t ( ) )
108 for ( step in 3 : nbro fc lus ters teps )
109 {
110 names1B<− l i s t ( )
111 for ( l in 1 : length ( nbrs1Bl i s t [ [ step ] ] ) )
112 {
113 names1B [ [ l ] ]<− c l u s t e r l i s t [ [ step ] ] [ [ nbrs1Bl i s t [ [
step ] ] [ l ] ] ]
114 }
115
116 names1Blist [ [ step ] ]<−names1B
117 }
118
119 namesTClist<− l i s t ( l i s t ( ) )
120 for ( step in 3 : nbro fc lus ters teps )
121 {
122 namesTC<− l i s t ( )
123 for ( l in 1 : length ( nbrsTCl is t [ [ step ] ] ) )
124 {
125 namesTC [ [ l ] ]<− c l u s t e r l i s t [ [ step ] ] [ [ nbrsTCl is t [ [
step ] ] [ l ] ] ]
126 }
127







134 rm( c l u s t e r r a t i o on l y l i s t )
135 rm( c l u s t e r l i s t )
136 rm( nbrs1Bl i s t )
137 rm( nbrsTCl is t )
138
139 ### get point map data corresponding to the framenames from
or i g ina l matrix
140
141 matrix_bothprots<−readRDS ( " . . /matrix_allfromeq . rds " )
142
143
144 for ( step in 3 : nbro fc lus ters teps )
145 {
146 data1B<− l i s t ( )
147 for ( z in 1 : length ( names1Blist [ [ step ] ] ) )
148 {
149 data1B [ [ z ] ]<−matrix_bothprots [ names1Blist [ [ step
] ] [ [ z ] ] , ]
150 }
151 filename<−paste ( "data1B_ step " , step , " . rds " , sep=" " )
152 saveRDS ( data1B , fi lename )
153 }
154
155 for ( step in 3 : nbro fc lus ters teps )
156 {
157 dataTC<− l i s t ( )
158 for ( z in 1 : length ( namesTClist [ [ step ] ] ) )
159 {
160 dataTC [ [ z ] ]<−matrix_bothprots [ namesTClist [ [ step
] ] [ [ z ] ] , ]
161 }
162 filename<−paste ( "dataTC_ step " , step , " . rds " , sep=" " )





167 ### ca l cu la t e occupancy fo r each TC or 1B assigned c l u s t e r (how
often i s a point of the s t a r t i n g map part of the binding s i t e
throughout th i s c l u s t e r ) f o r l e v e l s 3 :50 ( not much
c lu s t e r i n g has happened in l e v e l 1 and 2 the r e fo r e omitted )
168
169 for ( step in 3 :50 )
170 {
171 filename<−paste ( "dataTC_ step " , step , " . rds " , sep=" " )
172 dataTC<−readRDS ( filename )
173 rm( f i lename )
174
175 for ( subcl in 1 : length ( dataTC ) )
176 {
177 name <− paste ( "MDSumsCl_" , step , "_TCSubcl_" ,
subcl , sep=" " )
178 subcluster<−assign (name, dataTC [ [ subcl ] ] )
179 MDSums<− colSums ( subcluster )
180 ca l cu l a t e r a t i o<−function (MDSums, s i ze=s i ze<−dim (
subcluster ) [ 1 ] )
181 { r a t i o<− ( (MDSums/ s i ze ) ∗100)
182 return ( r a t i o ) }
183 occupancy<−lapply (MDSums, ca l cu l a t e r a t i o )
184 occupancyround<−lapply ( occupancy , round , d i g i t s
=2)
185 occ<−unl i s t ( occupancyround )
186 filename<−paste ( " /home/ alex /Desktop/
Rworkspacewards_allfromeq / seed19fromeq/
Occupancy_Cl_" , step , "_TCSubcl_" , subcl , " .
dat " , sep=" " )
187 write . fwf ( ( as . data . frame ( occ ) ) , f i l e=filename ,
rownames=FALSE , colnames=FALSE , quote=FALSE ,
j u s t i f y=" r i gh t " , width=6)
188 rdsname<−paste ( "Occupancy_Cl_" , step , "_TCSubcl_
" , subcl , " . rds " , sep=" " )
168
189 saveRDS ( occ , rdsname )
190
191 rm(name)
192 rm( subcluster )
193 rm(MDSums)
194 rm( c a l cu l a t e r a t i o )
195 rm( occupancy )
196 rm( occupancyround )
197 rm( occ )
198 rm( f i lename )
199 rm( rdsname )
200 }
201




206 for ( step in 3 :50 )
207 {
208
209 filename<−paste ( "data1B_ step " , step , " . rds " , sep=" " )
210 data1B<−readRDS ( filename )
211 rm( f i lename )
212
213 for ( subcl in 1 : length ( data1B ) )
214 {
215 name <− paste ( "MDSumsCl_" , step , "_1BSubcl_" ,
subcl , sep=" " )
216 subcluster<−assign (name, data1B [ [ subcl ] ] )
217 MDSums<− colSums ( subcluster )
218 ca l cu l a t e r a t i o<−function (MDSums, s i ze=s i ze<−dim (
subcluster ) [ 1 ] )
219 { r a t i o<− ( (MDSums/ s i ze ) ∗100)
220 return ( r a t i o ) }
221 occupancy<−lapply (MDSums, ca l cu l a t e r a t i o )
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222 occupancyround<−lapply ( occupancy , round , d i g i t s
=2)
223 occ<−unl i s t ( occupancyround )
224 filename<−paste ( " /home/ alex /Desktop/
Rworkspacewards_allfromeq / seed19fromeq/
Occupancy_Cl_" , step , "_1BSubcl_" , subcl , " .
dat " , sep=" " )
225 write . fwf ( ( as . data . frame ( occ ) ) , f i l e=filename ,
rownames=FALSE , colnames=FALSE , quote=FALSE ,
j u s t i f y=" r i gh t " , width=6)
226 rdsname<−paste ( "Occupancy_Cl_" , step , "_1BSubcl_
" , subcl , " . rds " , sep=" " )
227 saveRDS ( occ , rdsname )
228
229 rm(name)
230 rm( subcluster )
231 rm(MDSums)
232 rm( c a l cu l a t e r a t i o )
233 rm( occupancy )
234 rm( occupancyround )
235 rm( occ )
236 rm( f i lename )
237 rm( rdsname )
238 }
239
240 rm( data1B )
241 }
242
243 occupancyvar1Blist<− l i s t ( )
244
245 ### fo r the same l e v e l s i n v e s t i g a t e a l l 1B and TC assigned
c l u s t e r s : count how many points are present in more than 95%
or l e s s than 5% of the contained frames
246
247 for ( step in 3 :50 )
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248 {
249 cat ( " step " , step )
250 occupancyvars1B<− l i s t ( )
251 filename<−paste ( " /home/ alex /Desktop/Rworkspacewards_allfromeq /
seed19fromeq/data1B_ step " , step , " . rds " , sep=" " )
252 data1B<−readRDS ( filename )
253 subcl _ length<−length ( data1B )
254 rm( data1B )
255
256 for ( subcl in 1 : subcl_ length )
257 {
258 cat ( " subcl " , subcl )
259 rdsname<−paste ( " /home/ alex /Desktop/Rworkspacewards_
allfromeq /seed19fromeq/Occupancy_Cl_" , step , "_1
BSubcl_" , subcl , " . rds " , sep=" " )




264 while ( l < ( length ( occupancy )+1) )
265 {
266 cat ( " step " , step , " subcl " , subcl , " l " , l )
267 i f ( occupancy [ [ l ] ] >95 | | occupancy [ [ l ] ] <5) {nbr<−
nbr+1




272 occupancyvars1B [ [ subcl ] ]<−nbr
273 }
274
275 occupancyvar1Blist [ [ step ] ]<−occupancyvars1B
276 savename<−paste ( "OccVar1B_Cl_" , step , " . rds " , sep=" " )




280 saveRDS ( occupancyvar1Blist , " occupancyvar1Blist . rds " )
281
282 rm( l i s t= l s ( a l l=TRUE) )
283
284 occupancyvarTClist<− l i s t ( )
285
286 for ( step in 3 :50 )
287 {
288
289 occupancyvarsTC<− l i s t ( )
290 filename<−paste ( " /home/ alex /Desktop/Rworkspacewards_allfromeq /
seed19fromeq/dataTC_ step " , step , " . rds " , sep=" " )
291 dataTC<−readRDS ( filename )
292 subcl _ length<−length ( dataTC )
293 rm( dataTC )
294
295 for ( subcl in 1 : subcl_ length )
296 {
297 rdsname<−paste ( "Occupancy_Cl_" , step , "_TCSubcl_" , subcl
, " . rds " , sep=" " )




302 while ( l < ( length ( occupancy )+1) )
303 {
304 i f ( occupancy [ [ l ] ] >95 | | occupancy [ [ l








311 occupancyvarTClist [ [ step ] ]<−occupancyvarsTC
312 savename<−paste ( "OccVarTC_Cl_" , step , " . rds " , sep=" " )
313 saveRDS ( occupancyvarsTC , savename)
314 }
315




320 x<−c ( )
321 y<−c ( )
322
323 for ( step in 3 : length ( occupancyvar1Blist ) )
324 {
325 for ( s c l in 1 : length ( occupancyvar1Blist [ [ step ] ] ) )
326 {
327 x<−append ( x , step )






334 for ( step in 3 : length ( occupancyvarTClist ) )
335 {
336 for ( s c l in 1 : length ( occupancyvarTClist [ [ step ] ] ) )
337 {
338 x<−append ( x , step )




343 saveRDS ( x , " c lus terdec i s ion _x_n . rds " )





348 table<−cbind ( x , y )
349 sor tedtab le<−table [ order ( x ) , ]
350 d_ f<−as . data . frame ( sor tedtab le )
351
352 ymean<−c ( )
353 xstep<−c ( )
354 ysd<−c ( )
355
356 for ( step in 3 :50 )
357 {
358 ymean_n<−mean(d_ f [which (d_ f$x==step ) , ] $y )
359 ymean<−append (ymean , ymean_n)
360 ysd_n<−sd (d_ f [which (d_ f$x==step ) , ] $y )
361 ysd<−append ( ysd , ysd_n)
362 xstep<−append ( xstep , step )
363 }
364
365 d_ f _mean<−data . frame ( xstep , ymean)
366
367 l ibrary ( ggplot2 )
368 step_plot<−ggplot ( ) + theme_bw( ) + geom_point ( aes ( y = y , x = x ) ,
data = d_ f , s ta t=" iden t i t y " , s i z e =0.1) +geom_ l i ne ( aes ( y=ymean
, x=xstep ) , data = d_ f _mean, s ta t=" iden t i t y " , colour = "#
fc0cc1 " , s i z e=1) + geom_ ribbon ( aes ( ymin = ymean − ysd [ xstep
−2 ] , ymax = ymean + ysd [ xstep −2 ] , x=xstep ) , data = d_ f _mean,
f i l l = "# fc0cc1 " , alpha=0.2) + labs ( x=" c lu s te r ing step " , y="
intra−c lu s te r uniformness" )+ theme( tex t = element_ text ( s i z e =
12) )+ ylim (0 . 7 , 0 .87 )+ xlim (0 , 50) + scale _x_continuous (
breaks=seq (0 ,50 ,2 ) )
369
370 postscript ( " step _plot19 . eps" , width=10 , height=4.5)
371 print ( step_plot )
372 dev . of f ( )
174
373 pdf ( " step _plot19 . pdf " , width=10 , height=4.5)
374 print ( step_plot )
375 dev . of f ( )
A.4. Pose Consistency R Script
1 #
#####################################################################
2 # s c r i p t fo r ca l cu la t ing and ex t ra c t ing cons i s t en t pose
r ep r e s en t a t i v e s
3 #from protein−l igand docking output
4 #
#####################################################################
5 # th i s vers ion works on a sp l i t t e d input f i l e with a l l docking
poses fo r a l igand




8 #working d i r e c t r y and number of poses per l igand have to be





12 #−−>sp e c i f y fo lde r were input f i l e s l i e
13 setwd ( " / . . . / . . . / . . . " )
14
15 #load packages
16 l ibrary ( readr )
17 l ibrary ( bio3d )
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18 l ibrary ( dbscan )
19 l ibrary ( gdata )
20
21 #−−>sp e c i f y number of poses per l igand ( has to be constant )
22 posesper l ig<−25
23
24 # c o l l e c t input f i l e s
25 f i l e l i s t <− l i s t . f i l e s ( pattern=" part " )
26 moleculenumber<−length ( f i l e l i s t ) / posesper l ig
27
28 tokeep<−c ( )
29
30 for (m in 1 :moleculenumber)
31 {
32 #read input f i l e s
33 s ta r t<− ( (m−1)∗posesper l ig )+1
34 end<−m∗25
35 filename<− f i l e l i s t [ [ s ta r t ] ]
36 con<− f i l e ( filename , open=" r " )
37 l ine<−readLines ( con )
38 atomnumber<−as . numeric ( substr ( l ine [ [ 4 ] ] , 0 , 3 ) )
39 close ( con )
40 rm( l ine )
41
42 da t a l i s t<− l i s t ( )
43 count<−1
44 for ( f in s ta r t : end )
45 {
46 da t a l i s t [ [ count ] ]<−read_ fwf ( f i l e l i s t [ [ f ] ] , fwf _





50 #conver t heavy atom coordinates into matrix
176
51 coordinate _ l i s t<− l i s t ( )
52 coordinates<− l i s t ( )
53 for ( s in 1 : posesper l ig )
54
55 {
56 withoutHs<−da t a l i s t [ [ s ] ] [ ! ( d a t a l i s t [ [ s ] ] [ "X4" ]
== "H" ) , ]
57 coordinate _ l i s t [ [ s ] ]<−withoutHs [ c ( "X1" , "X2" , "X3"
) ]
58 coordinates [ [ s ] ]<−c (do . ca l l ( rbind , coordinate _




62 matrix<−do . ca l l ( rbind , coordinates )
63
64 # c r ea t e rmsd matrix from a l l pose coordinates of each
ligand
65 rmsdmatrix<−rmsd (matrix , ncore=3)




70 #parameters fo r c l u s t e r i n g can be changed here
71 re su l t s<−dbscan ( rmsddistmatrix , 1 . 5 , minPts=8)
72
73 index<−seq ( 1 : 2 5 )
74 table<−as . data . frame ( cbind ( index , r e su l t s $ c lu s te r ) )
75
76 #ass ign value 9 to a l l values in the l i n e s ( poses ) that
do not belong to a c l u s t e r ( f o r each c l u s t e r number
s epe ra t e l y )
77 reducedmatrix<− l i s t ( )
78 i f (max( r e su l t s $ c lu s te r ) >0)
79 {
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80 for ( r in 1 :max( r e su l t s $ c lu s te r ) )
81 {
82 reducedmatrix [ [ r ] ]<−rmsdmatrix








90 # fo r each row of a reduced matrix ca l cu la t e the pose ,
which i s the one with the lowest rmsd sum ( s imi la r to
medioid pose )
91 repres<− l i s t ( )
92 i f (max( r e su l t s $ c lu s te r )>0)
93 { for ( r in 1 : length ( reducedmatrix ) )
94 {
95 repres [ [ r ] ]<−which ( apply ( reducedmatrix [ [ r ] ] , 1 , sum)==




99 zeros<−rep (0 , posesper l ig )
100
101 i f (max( r e su l t s $ c lu s te r )>0)
102 {
103 repres<−unl i s t ( repres )
104 zeros [ repres ]<−1
105 }
106





111 #save a l l con s i s t en t pose r ep r e s en t a t i v e s to f i l e ( can be merged
with . sd f of docking poses fo r exmaple with MOE)
112 saveRDS ( tokeep , " tokeep . rds " )
113
114 index<−seq ( 1 : length ( tokeep ) )
115 table<−as . data . frame ( cbind ( index , tokeep ) )
116
117 write . fwf ( table , f i l e=" tokeeptable . t x t " , rownames=FALSE ,
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